{
    "1": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A 61-year-old man with ESRD due to membranous nephropathy presents for evaluation of HD access options. He previously received a living related kidney transplant that failed because of antibody-mediated rejection. His panel reactive antibody (PRA) titer remains high. He was treated with PD for 7 years but transitioned to HD because of encapsulating sclerosing peritonitis. He has received maintenance HD for the past 6 months using a tunneled HD catheter, because a previously placed arteriovenous fistula (AVF) failed to mature. In the last 6 months, he was diagnosed with catheter-associated <em>Staphylococcus aureus</em> bacteremia that required catheter removal, as well as catheter-associated brachiocephalic vein thrombosis, for which he is now prescribed warfarin. </p>\n<p dir=\"”ltr”\" style=\"margin-top: 30px; margin-bottom: 20px;\"><strong>Which of the following would be the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Placement of a percutaneous, endovascular AVF"
            },
            {
                "label": "B.",
                "text": "Placement of an arteriovenous graft (AVG) designed for early cannulation"
            },
            {
                "label": "C.",
                "text": "Placement of a Hemodialysis Reliable Outflow (HeRO) hybrid catheter-graft device"
            },
            {
                "label": "D.",
                "text": "Placement of a heparin-bonded AVG"
            },
            {
                "label": "E.",
                "text": "Balloon-assisted maturation of the immature AVF"
            }
        ],
        "correct_answer": "Placement of an arteriovenous graft (AVG) designed for early cannulation",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management for this patient with a failed transplant, forced transition from PD, and infectious and thrombotic complications from his HD catheter is to establish non–catheter-based HD access as soon as possible. This goal would be best achieved by placement of an AVG designed for early cannulation (an early cannulation or early access AVG).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Reliable arteriovenous access for HD is often difficult to achieve. AVFs have a high primary failure rate and long maturation times (weeks to months). Access of polytetrafluoroethylene (PTFE) grafts is usually delayed for at least 2 weeks to allow the graft to be incorporated into subcutaneous tissue and for endothelialization to occur, both of which are thought to be associated with a lower risk of hemorrhage or hematoma formation. This practice is considered necessary for safe cannulation. Limited data suggest that very carefully created and managed PTFE grafts can be used for dialysis within 72 hours of creation without adverse consequences, but this is not standard practice. Catheters provide instant access for HD but are complicated by infections, thrombosis, and venous stenosis. Placement of a percutaneous, endovascular AVF or balloon angioplasty of the existing, immature AVF would still require weeks to months for maturation. The HeRO hybrid catheter-graft device is indicated for a patient with central venous stenosis, which this patient does not have. In addition, because this device has a catheter component, it is subject to the complications already experienced by this patient: infection, thrombosis, and stenosis. Early access of heparin-bonded PTFE grafts has not been studied. Current practice is to allow time for incorporation and endothelialization, similar to standard PTFE grafts.</p>\n<p>Early access AVGs (eAVGs) have a three-layer design that incorporates an elastomeric, self-sealing membrane to allow cannulation soon (or immediately) after implantation of the AVG. Different commercially available eAVGs for HD access have demonstrated efficacy in obviating the need for catheters. A review of 15 studies using eAVGs for HD showed that early cannulation within 72 hours was possible, with no significant difference in patency or complication rates compared with conventional delayed access of standard PTFE grafts. Thus, an AVG designed specifically for early access is the best choice for this patient.</p>\n</div>",
        "references": []
    },
    "2": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 17-year-old boy is brought by his parents to the emergency department for evaluation of confusion and a 2-week history of progressively severe thirst, frequent urination, malaise, and a 4-kg weight loss.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On presentation, his BP is 90/60 mm Hg and heart rate 110/min. He has sunken eyes and poor skin turgor, absent jugular venous pulsations, and no edema. The heart and lungs are normal except for tachycardia and tachypnea. The abdomen is soft and\n    nontender.\n</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory investigations include the following:</span></p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                130 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                3.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                90 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                11 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                56 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                2.15 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                900 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                70–99 , fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                9.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                2.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Ketones\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                Positive\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                Lactic acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                6–19\n            </td>\n</tr>\n<tr>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<strong>Arterial Blood Gas</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                pCO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                25 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                38–42\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">\n                pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                7.25\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n                7.38–7.44\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"”ltr”\" style=\"margin-top: 30px; margin-bottom: 20px;\"><strong>\n        Along with fluid resuscitation, which of the following is the NEXT most appropriate treatment?\n\n    </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Insulin with dextrose"
            },
            {
                "label": "B.",
                "text": "Potassium supplementation"
            },
            {
                "label": "C.",
                "text": "Insulin"
            },
            {
                "label": "D.",
                "text": "Sodium bicarbonate"
            },
            {
                "label": "E.",
                "text": "Phosphate supplementation"
            }
        ],
        "correct_answer": "Potassium supplementation",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with diabetic ketoacidosis (DKA), hypokalemia, and hypophosphatemia would benefit most from potassium supplementation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with DKA are prone to dyskalemias due to cellular shift and total body potassium depletion. Insulin stimulates the Na-K-ATPase and promotes potassium influx into cells. Insulin deficiency results in reduced Na-K-ATPase activity and tends to promote hyperkalemia. Hyperglycemia itself, independent of insulin sufficiency, also promotes hyperkalemia by solvent drag. Conversely, osmotic diuresis from glycosuria, as well as renin-angiotensin-aldosterone system activation from hypovolemia, will lead to enhanced renal potassium excretion. Thus, patients with DKA may have low, normal, or high potassium levels depending on the relative influence of these mechanisms and concomitant intake. Those who present with hypokalemia despite the shifting of intracellular potassium to the extracellular compartment are profoundly potassium depleted.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients such as this one are at risk for worsening hypokalemia and cardiac arrhythmias when insulin is administered. For this reason, insulin administration should be delayed until serum potassium is normalized. Insulin is a cornerstone of DKA management; once potassium and glucose are corrected, infusion of dextrose with ongoing insulin therapy is necessary until the anion gap normalizes.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The role of sodium bicarbonate in the treatment of DKA is controversial but is usually reserved for patients with profound acidemia and severe depression of pH. In this case, the patient’s anion gap acidosis from DKA would mandate treatment of the underlying etiology before administration of bicarbonate. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypophosphatemia is common in patients with DKA, but it is usually unnecessary to prioritize phosphate administration above potassium, glucose, and acid-base management. In this patient, the initial phosphorus level is near normal, so potassium supplementation should come first. Nevertheless, the need for phosphate supplementation should be anticipated and initiated before severe hypophosphatemia occurs. Potassium phosphate can be useful in these circumstances but may not be as readily available as potassium chloride for initial management.</p>\n</div>",
        "references": []
    },
    "3": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man with AKI requiring HD is evaluated in the ICU for acute onset headache, dyspnea, and back pain 2 hours into the dialysis session. The dialysis nurse notes a pink discoloration of the dialysis filtrate. A non-reuse high-flux polysulfone dialyzer was used for the treatment, and no obvious kinking of the dialysis blood tubing is noted.</p>\n<p>On physical examination, he is in mild distress. His BP is 110/78 mm Hg, pulse is 102/min, respiratory rate is 24/min, and temperature is 37°C.</p>\n<p>Dialysis is discontinued without returning the blood to the patient, and laboratory studies are obtained. </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6,700/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7 g/dL (10 yesterday)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                289,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                103 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                32 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Aspartate aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Total bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Indirect bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.2–0.7\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Lactate dehydrogenase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                600 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80–225\n            </td>\n</tr>\n</tbody>\n</table>\n<p>A peripheral blood smear shows “bite cells” and Heinz bodies.</p>\n<p><strong>Dysfunction of which ONE of the following elements is MOST likely responsible for this patient’s findings?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Dialysis blood tubing"
            },
            {
                "label": "B.",
                "text": "Polysulfone dialyzer"
            },
            {
                "label": "C.",
                "text": "Carbon filter"
            },
            {
                "label": "D.",
                "text": "Dialysate proportioning system"
            },
            {
                "label": "E.",
                "text": "Reverse osmosis membrane"
            }
        ],
        "correct_answer": "Carbon filter",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p>Chloramine toxicity, most likely due to dysfunction of the carbon filtration system, is most likely responsible for this patient’s hemolytic anemia.</p>\n<p>This patient has an acute onset of hemolytic anemia during HD, and the presence of bite cells and Heinz bodies is most consistent with chloramine breakthrough related to dysfunction of the carbon filtration system. Inadequate rinsing of reprocessed dialyzers cleansed with bleach can also cause a similar clinical presentation, but this patient was dialyzed with a non-reuse membrane. Hemolysis during HD may be due to breakthrough of chloramine, bleach, copper, nitrates, or formaldehyde; improper mixing of the dialysate; increased dialysate temperature; or mechanical trauma from kinking or narrowing of the dialysis blood tubing. The features of each of these forms of dialysis-related hemolysis are summarized in the table below.</p>\n<p>When there is suspicion of hemolysis, such as with an acute drop in hemoglobin, acute onset of back or chest pain, or pink discoloration of the dialysis filtrate, the tubing should be clamped with immediate cessation of dialysis. Blood should not be returned to the patient because there is a high risk of hyperkalemia in this setting. The tubing should be saved for further analysis because defective tubing with narrowing or kinks may cause extravascular hemolysis. The composition of the dialysate should also be analyzed. When there is suspicion of a contaminated water product based on the findings in a single patient at a unit with shared water products, strong consideration should be given to discontinuing dialysis for the entire unit until water safety can be confirmed.</p>\n<p>The process of water purification for HD involves multiple steps in series to create a water that is free of contaminants. </p>\n<ol start=\"1\" type=\"1\">\n<li>Depth filters remove particulate matter from municipal water.</li>\n<li>Carbon filters remove chlorine, chloramines, and other dissolved organic contaminants. This step is essential and generally includes two carbon beds to ensure complete removal of chloramine.</li>\n<li>Water softeners exchange calcium and magnesium for sodium. Although these ions are also removed by reverse osmosis, water softeners in regions with “hard water” reduce accumulation of calcium and magnesium salts, thereby prolonging the life of the reverse osmosis (RO) membrane.</li>\n<li>RO is the mainstay of dialysis water purification. Hydrostatic pressure drives water across a semipermeable membrane and excludes &gt;90% of the contaminants. This strategy removes ionic contaminants, bacteria, and endotoxin.</li>\n<li>Deionization (DI) removes ionic contaminants by exchanging cations for H<sup>+</sup> and anions for OH<sup>-</sup>. DI is usually used for water purification when the RO membrane fails. Water processing through DI requires bacterial control filters after DI purification because DI systems promote bacterial growth. Finally, the DI membrane is saturable and requires continuous monitoring of conductivity with mechanisms for diverting RO water when conductivity exceeds 1 µS/cm to avoid breakthrough of fatal contaminants such as fluoride.</li>\n<li>Bacteria- and endotoxin-retentive filters bind and remove bacteria and endotoxin.</li>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td colspan=\"4\" style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\"><strong>Mechanisms of hemolysis in patients undergoing HD</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 25%;\"><strong>Etiology</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 25%;\"><strong>Mechanism of hemolysis</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 25%;\"><strong>Location of defect</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 25%;\"><strong>Clinical consequence</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Sodium hypochlorite (bleach)</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Oxidant red blood cell (RBC) injury</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Inadequate rinsing during dialyzer reprocessing</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Hemolytic anemia Heinz bodies Methemoglobinemia</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Chloramine</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Oxidant RBC injury</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Activated charcoal filter (minimally removed by DI, but NOT by RO)</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Hemolytic anemia Heinz bodies Methemoglobinemia</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Copper</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Oxidant RBC injury</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">DI</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Greenish hue to serum or plasma</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Nitrate (common in contaminated well water)</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Oxidant RBC injury</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Water source</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Black venous blood</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Formaldehyde (seen with reused dialyzers)</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Inhibition of RBC glycolysis</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Use of formaldehyde during sterilization of dialyzers</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Anti–N-like cold agglutinins</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Dialysate temperature &gt;42°C</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Thermal RBC injury</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Temperature-sensing monitors</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Dialysate osmolality</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Osmolal trauma</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Mixing error</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Tubing</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Mechanical trauma</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Kinked tubing</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">Schistocytes</td>\n</tr>\n</tbody>\n</table>\n</ol>\n</div>",
        "references": []
    },
    "4": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A 69-year-old woman with ESRD presents to the emergency department with weakness following passage of a dark, tarry bowel movement. Her ESRD has been attributed to type 2 diabetes mellitus and hypertension, and she has received maintenance HD\n    for 5 years. She last received dialysis 2 days ago and has not missed any HD treatments. Her medical history is significant for recurrent episodes of melena, for which she has undergone both upper and lower endoscopy within the past 6 months without\n    establishing a diagnosis.\n</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Her BP is 114/56 mm Hg and heart rate 102/min. Physical exam reveals a pale, weak-appearing woman with a functioning left arm arteriovenous fistula. There is no edema.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 30%;\">\n<strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                7.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                Platelet counts</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                245,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                5.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                18 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                89 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                4.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                Prothrombin time\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                11 s\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                11–13\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                Activated partial thromboplastin time\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                31 s\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                25–35\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                Transferrin saturation\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                5%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                20–50\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                Ferritin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                26 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                11–307\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"”ltr”\" style=\"margin-top: 30px; margin-bottom: 15px;\">The most recent hemoglobin on record, drawn last week for routine monthly ESRD management, was 9.7 g/dL. An EKG is normal.</p>\n<p></p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 20px;\">While the patient is being evaluated in the emergency department, she has another large, melenic bowel movement.\n\n</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px; \"><strong>Which one of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hemodialysis"
            },
            {
                "label": "B.",
                "text": "Packed RBC transfusion"
            },
            {
                "label": "C.",
                "text": "Conjugated estrogen IV"
            },
            {
                "label": "D.",
                "text": "Desmopressin IV"
            },
            {
                "label": "E.",
                "text": "Cryoprecipitate transfusion"
            }
        ],
        "correct_answer": "Packed RBC transfusion",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with acute anemia due to ongoing gastrointestinal (GI) bleeding should receive a transfusion of packed RBCs (PRBCs) as initial management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although many clinicians use a Hb value of 7 g/dL as a threshold for PRBC transfusion, there is no evidence for this practice, especially in the absence of coronary ischemia. This patient’s Hb exceeds 7 g/dL, but she has experienced an acute decrease\n        and may be actively bleeding. Thus, she should receive an urgent transfusion of PRBCs as the next step in management. Correction of anemia with either PRBC transfusion or erythropoietin is associated with improvement in uremic platelet dysfunction.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">She will require ongoing HD to manage potassium, acidosis, azotemia, and volume status, but none of these problems is as urgent as the acute anemia with ongoing GI bleeding. If feasible, PRBC transfusion may be done during HD to minimize\n        the risk of volume overload, although this patient is likely hypovolemic from blood loss, based on vital signs and physical exam. Dialysis improves uremic platelet dysfunction, but this patient is essentially current with her maintenance dialysis\n        regimen.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Both desmopressin and cryoprecipitate have been used to treat uremic bleeding, which is characterized by platelet dysfunction in the setting of normal platelet count. These agents either stimulate release of von Willebrand factor from the endothelium\n        (desmopressin) or deliver it directly to the circulation (cryoprecipitate) to ameliorate uremic platelet dysfunction. An additional consideration for this patient with recurrent GI bleeding is estrogen therapy, which may help decrease bleeding\n        in cases of angiodysplasia or colonic polyps. It is usually prescribed as IV conjugated estrogen 0.6 mg/kg per day for 5 days, but oral and transdermal preparations have also been effective. Estrogen therapy can provoke thrombotic events. In this\n        case, it would be premature to add either desmopressin, cryoprecipitate, or IV estrogen. If bleeding persisted despite correction of anemia and provision of dialysis, and could not be addressed anatomically, these measures would be reasonable\n        approaches.</p>\n</div>",
        "references": []
    },
    "5": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 68-year-old man presents to the office for follow-up of CKD stage G5/A1 attributed to ischemic nephropathy. He also has a past medical history of chronic obstructive pulmonary disease (COPD), hypertension, and dyslipidemia. He feels well without any uremic symptoms. Medications include ramipril, tiotropium, albuterol, atorvastatin, and furosemide.\n\n</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, his BP is 123/65 mm Hg, heart rate 94/min, respiratory rate 18/min, temperature 37.2°C, and oxygen saturation 92% while receiving 2 L/min of inspired oxygen. Heart sounds are normal, respiratory examination reveals expanded chest dimensions and\n    distant breath sounds, abdominal examination is unremarkable, and there is no edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 70%;\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 30%;\">\n<strong>Result</strong></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\"><span><strong>Serum</strong></span></td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">Sodium</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">139 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">Potassium</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">4.8 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">Chloride</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">99 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">23 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">BUN</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">72 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">Creatinine</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">6.25 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">Albumin</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">3.5 g/dL</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\"><strong>Arterial blood gas</strong></td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">pH</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">7.27</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">7.38–7.44</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">pO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">59 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">75–100</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">pCO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">50 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">38–42</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 15px;\">Bicarbonate (HCO<sub>3</sub>)</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">22 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">23–26</td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 20px;\"><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Metabolic acidosis, metabolic alkalosis, and respiratory acidosis"
            },
            {
                "label": "B.",
                "text": "Respiratory acidosis"
            },
            {
                "label": "C.",
                "text": "Metabolic acidosis and respiratory acidosis"
            },
            {
                "label": "D.",
                "text": "Metabolic acidosis, respiratory acidosis,\n and respiratory alkalosis"
            },
            {
                "label": "E.",
                "text": "Metabolic alkalosis and respiratory acidosis"
            }
        ],
        "correct_answer": "Metabolic acidosis, metabolic alkalosis, and respiratory acidosis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p>This patient presents with a metabolic acidosis, metabolic alkalosis, and respiratory acidosis.</p>\n<p>The first step in the evaluation of an acid-base disorder is to examine the arterial pH. In this case, pH 7.27 indicates acidemia. Next, the HCO<sub>3</sub> (total CO<sub>2</sub>) and pCO<sub>2</sub> are examined to ascertain the cause of acidemia. High pCO<sub>2</sub> indicates a primary respiratory acidosis, which should be accompanied by an increase in serum HCO<sub>3</sub> as a “compensatory” response. Correction factors vary, but the expected metabolic compensation (HCO<sub>3</sub> retention) for a respiratory acidosis is an increase in HCO<sub>3</sub><sup> </sup>of 0.1–0.3 mEq/L per 1 mm Hg increase in pCO<sub>2</sub>, depending on chronicity. In this case, with pCO<sub>2</sub> increased by (50 – 40) 10 mm Hg, the HCO<sub>3</sub> should have increased by (10 × [0.1 to 0.3] =) 1–3 mEq/L, for a final expected value of (24 + 1–3 =) 25–28 mEq/L. Because the HCO<sub>3</sub> of 23 mEq/L is less than expected, there is also a concurrent metabolic acidosis.</p>\n<p>A parallel approach is to calculate the anion gap (AG), which in this case is [Na] – [Cl] – [HCO<sub>3</sub>], or 139 – 99 – 23 = 17 mEq/L. The ABIM defines a normal AG range of 7–13 mEq/L. Current understanding of the AG is that it should be individualized to patient and lab circumstances and corrected if the albumin level is less than normal. In this case, the AG is above the normal range, indicating the presence of an anion gap metabolic acidosis. </p>\n<p>When an AG metabolic acidosis is present, it is important to evaluate the change in anion gap compared with the change in bicarbonate (DAG/DHCO<sub>3</sub>) to uncover any additional underlying acid-base disorders. To perform this part of the analysis, it is necessary to choose a specific value as the normal AG so that a change (DAG) may be calculated. In this case, choosing 8 mEq/L as the normal AG, DAG = 17 – 8 = 9 mEq/L and DHCO<sub>3</sub> = 24 – 23 = 1 mEq/L, so DAG/DHCO<sub>3</sub> = 9/1 = 9. The expected DAG/DHCO<sub>3</sub> is approximately 1 (reference range, 0.7–1.7), so this increased value of 9 may be interpreted as an excess of 8 mEq/L of HCO<sub>3</sub>. As previously calculated, part of this total excess of 8 mEq/L (1–3 mEq/L) is related to the respiratory acidosis, so the remaining part of this total (5–7 mEq/L) is attributable to metabolic alkalosis.</p>\n<p>The most likely etiology of this triple acid-base disorder is COPD (respiratory acidosis), advanced CKD (metabolic acidosis), and diuresis (metabolic alkalosis).</p>\n</div>",
        "references": []
    },
    "6": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 65-year-old man with CKD stage G3a/A1, hypertension, and type 2 diabetes is seen in clinic for BP management. He has no current concerns and reports no recent hospitalizations. His anti-hypertensive regimen consists of amlodipine 10 mg daily, lisinopril 40 mg daily, and carvedilol 6.25 mg twice daily. He also takes aspirin, atorvastatin, and insulin. His social history is significant for daily cocaine use. He has not been monitoring his BP at home.</p><p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP is 120/80 mm Hg and heart rate 80/min. On exam, he is in no acute distress and appears his stated age. The fundi are not well visualized. There is no cardiac murmur, rub, or gallop. He has no peripheral edema. No rashes or skin lesions are noted.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">His serum creatinine is 2.2 mg/dL, which is at his baseline (reference range, 0.7–1.3). His hemoglobin is stable at 11 g/dL (reference range, 14–18) and platelet count is normal. His urinalysis is bland with a urine protein-to-creatinine ratio of 0.5 mg/mg (reference range, &lt;0.2). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>In addition to counseling the patient about cocaine cessation, which of the following is the MOST appropriate change to his current anti-hypertensive regimen?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discontinue amlodipine"
            },
            {
                "label": "B.",
                "text": "Change lisinopril to losartan"
            },
            {
                "label": "C.",
                "text": "Discontinue carvedilol"
            },
            {
                "label": "D.",
                "text": "Prescribe furosemide"
            },
            {
                "label": "E.",
                "text": "No change"
            }
        ],
        "correct_answer": "No change",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">No change is required to this patient’s current anti-hypertensive regimen. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the patient’s active cocaine use raises the concern for cardiovascular toxicity, which can manifest with tachycardia, hypertensive emergency, and myocardial ischemia. Historically, the use of β-blockers in this setting has been avoided because of the concern that β-adrenergic blockade would result in unopposed α-adrenergic stimulation and lead to worsening of hypertension and coronary vasoconstriction. However, several studies have demonstrated the safe and effective use of β-blockers for cocaine-associated chest pain without adverse outcomes. One systematic review of 1744 patients described only 7 reported adverse events, none of which was associated with the use of mixed α/β blockers (i.e., labetalol, carvedilol). The American College of Cardiology/American Heart Association guidelines list the use of mixed α- and β-blockers as a class IIb recommendation (may be considered), provided the patient has been treated with a vasodilator. In this case, the patient is receiving the vasodilator amlodipine. Dihydropyridine calcium channel blockers are routinely used in the treatment of cocaine-related toxicity, so his amlodipine can be continued. In the absence of medication intolerance, there is no indication for switching an ACEI to an ARB. This patient has no evidence of fluid overload, so furosemide is not indicated. Although an office BP measurement is inadequate to establish the level of control, there is no evidence in this case to justify an increase or decrease in the intensity of the regimen.</p>\n</div>",
        "references": []
    },
    "7": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">An 83-year-old man with CKD stage 3 and a history of myocardial infarction and ischemic cardiomyopathy presents to the emergency department with fatigue, dyspnea on exertion, cough, nausea, anorexia, and lightheadedness. Five days prior to presentation,\n    he began taking clarithromycin 500 mg twice daily to treat symptoms of bronchitis and sinusitis. Other medications include spironolactone 25 mg daily, digoxin 0.125 mg daily, lisinopril 20 mg daily, pravastatin 40 mg daily, and aspirin 81 mg daily.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">He appears unwell. His BP is 124/50 mm Hg, heart rate 48/min, respiratory rate 16/min, and oxygen saturation 92% while breathing ambient air. The rhythm is regular. Bibasilar crackles are present. His abdomen is soft and nontender. There is mild pretibial\n    edema.\n</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The EKG shows sinus bradycardia and Q waves in leads I, II, aVL, and V1–V4, which are unchanged from prior EKGs. The chest x-ray shows faint opacities in both lung bases.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>His laboratory investigations include the following:</span></p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 40%;\">\n                     \n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 30%;\">\n<strong>Reference</strong> <strong>Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    WBC count\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    13,600/µL\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    4000–11,000\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    Hemoglobin\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    16 g/dL\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    14–18\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    Platelet counts</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    263,000/µL\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    150,000–450,000\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                     \n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                     \n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px;\">\n                    Sodium\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    136 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    136–145\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px;\">\n                    Potassium\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    4.8 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    3.5–5.0\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px;\">\n                    Chloride\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    105 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    98–106\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px;\">Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    19 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    23–28\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px;\">\n                    Creatinine\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    1.5 mg/dL\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    0.7–1.3\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px;\">\n                    Digoxin\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    3.6 ng/mL\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">\n                    1.0–2.0\n                </td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Besides discontinuing digoxin, which of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Administer albuterol"
            },
            {
                "label": "B.",
                "text": "Discontinue clarithromycin"
            },
            {
                "label": "C.",
                "text": "Initiate hemodialysis"
            },
            {
                "label": "D.",
                "text": "Administer digoxin-specific antibody fragments"
            },
            {
                "label": "E.",
                "text": "Administer sodium bicarbonate"
            }
        ],
        "correct_answer": "Discontinue clarithromycin",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with nonemergent digoxin toxicity should have digoxin and clarithromycin discontinued.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient has symptoms consistent with digoxin toxicity. The most likely cause in this scenario is a drug interaction with clarithromycin. Clarithromycin has been shown to increase the half-life of digoxin by up to 82% by inhibiting P-glycoprotein-mediated\n        digoxin efflux from cells. Digoxin concentration has also been found to increase by 70% after a dose of clarithromycin 400 mg daily in a cohort of Japanese patients. Any macrolide antibiotic is thought to act similarly. In this case, as there\n        are no signs of severe or life-threatening digoxin toxicity (see below) and the level is &lt;4 ng/mL, observation is appropriate after discontinuing digoxin and clarithromycin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In the absence of hyperkalemia, administration of albuterol or bicarbonate to shift potassium intracellularly is unnecessary. HD is not indicated in cases of digoxin toxicity because digoxin has a large volume of distribution and is\n        not effectively removed by dialysis. Administration of digoxin-specific antibody fragments (FAB) is indicated in the presence of elevated digoxin concentration and life-threatening or unstable arrhythmias, hyperkalemia, and end-organ dysfunction,\n        including AKI or altered mental status. In the absence of these features, administration of digoxin FAB is unnecessary.</p>\n</div>",
        "references": []
    },
    "8": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 23-year-old woman with SLE is seen in clinic for management of lupus nephritis (LN). SLE was diagnosed 5 years ago based on rash, arthralgias, fever, and serologic studies. Kidney function and UA were normal until 3 years ago, when symptoms flared and AKI was identified. The urine sediment was active and proteinuria was present. A kidney biopsy (see image) demonstrated diffuse proliferative LN with segmental and active lesions. Induction immunosuppression with cyclophosphamide IV and corticosteroids resulted in a rapid, stable remission. On completing induction, her kidney function improved and proteinuria resolved. Maintenance therapy with mycophenolate mofetil (MMF) 1000 mg twice daily was begun at that time. She remains on hydroxychloroquine. She now presents at 36 months in sustained remission (see table). She is using contraception and does not plan on pregnancy in the foreseeable future.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The biopsy report indicates Class IV-S(A) LN with features of hypercellularity, hyaline thrombi, double contours, and wire loops. </p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q8-ksapv7m1.png\" width=\"60%\"/>\n<figcaption>Image courtesy of <em>J Am Soc Nephrol</em> 15(2): 241–250, 2004 </figcaption>\n</figure>\n<div style=\"margin-top: 20px; margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 85%; vertical-align: top;\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px; width: 30%;\"> </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px; width: 12.5%;\">\n<div style=\"text-align: center;\"><strong>Baseline</strong></div>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px; width: 12.5%;\">\n<div style=\"text-align: center;\"><strong>Pre-induction</strong></div>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px; width: 12.5%;\">\n<div style=\"text-align: center;\"><strong>6 Months</strong></div>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px; width: 12.5%;\">\n<div style=\"text-align: center;\"><strong>24 Months</strong></div>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px; width: 12.5%;\">\n<div style=\"text-align: center;\"><strong>36 Months</strong></div>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px; width: 12.5%;\">\n<div style=\"text-align: center;\"><strong>Reference Range</strong></div>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">Creatinine</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">0.8 mg/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">1.3</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">1.0</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">1.0</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">.9</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">Urine protein-to-creatinine ratio</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\"><br/></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">2.5 mg/mg</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">0.2</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">0.2</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">0.2 </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">&lt;0.2 </td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which ONE of the following options is the MOST appropriate regimen for continued maintenance therapy for this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Change MMF to azathioprine"
            },
            {
                "label": "B.",
                "text": "Change MMF to methotrexate"
            },
            {
                "label": "C.",
                "text": "Change MMF to rituximab"
            },
            {
                "label": "D.",
                "text": "Decrease dose of MMF"
            },
            {
                "label": "E.",
                "text": "Discontinue MMF"
            }
        ],
        "correct_answer": "Decrease dose of MMF",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate plan for this patient after 3 years of complete remission of SLE nephritis is to gradually decrease the MMF dose and closely monitor kidney function, proteinuria, and lupus serologic activity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MMF has become the preferred agent for maintenance therapy in proliferative LN. The 2021 KDIGO guidelines state, “The total duration of initial immunosuppression plus combination maintenance immunosuppression for proliferative LN should not be &lt;36 months.” There are several reports of successful withdrawal of MMF in patients with clinically quiescent LN. In one study, 52 of 73 patients were able to completely taper off MMF, with only 15 of these patients experiencing at least one renal flare during the follow-up period (median time 37 months). A separate retrospective study demonstrated that MMF dose reduction after 18 months in patients in sustained remission was not associated with an increased rate of relapse. More recently, a repeat biopsy to help guide maintenance therapy has evolved as another potential tool to aid in the decision to withdraw maintenance immunosuppression. Thus, for this patient, who has been in clinical remission for 3 years, it is reasonable to slowly taper the MMF dose while closely monitoring symptoms and kidney function, urinalysis, and serologic studies. Abrupt withdrawal of MMF is not recommended.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Azathioprine can be used for maintenance therapy in LN based on the results of the MAINTAIN Nephritis Trial. Because, unlike MMF, azathioprine can be used in pregnancy, conversion to this drug would be appropriate if pregnancy were desired. However, there is no role for this conversion in this case. Similarly, changing to methotrexate or rituximab would not confer any advantage in this scenario.</p>\n</div>",
        "references": []
    },
    "9": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 24-year-old woman with ESRD secondary to IgA nephropathy who received a deceased donor kidney transplant 7 months ago presents with myalgia, fever, profuse watery diarrhea, and decreased urination for 5 days.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The donor was seropositive for previous exposure to CMV, but the recipient was not (D+/R-). Induction therapy consisted of thymoglobulin and maintenance therapy consists of tacrolimus, mycophenolate mofetil, and prednisone. Her post-transplant course\n    has been uncomplicated until now; her serum creatinine decreased from 10 mg/dL to a nadir of 1.2 mg/dL within 10 days of transplant and remained stable at that level. Trimethoprim-sulfamethoxazole and valganciclovir prophylaxis were provided for the\n    first 6 months post-transplant, after which they were discontinued.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient appears ill. Her BP is 90/60 mm Hg, heart rate 117/min, and temperature 39.4°C. Physical exam is significant for postural decrease in BP, dry mucous membranes, and a regular tachycardia. Bowel sounds are hyperactive, but the abdomen\n    is soft, nontender, and nondistended.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;width: 30%;\">\n<strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                2400/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                147 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                3.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                115 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                16 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                100 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                4.4 mg/dL (baseline, 1.2)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Tacrolimus, trough\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                11 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                5.0–10.0, &gt;3 months post-transplant\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                CMV PCR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                47,500 IU/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">IV fluids are initiated, and the next day, the patient’s creatinine improves to 2.2 mg/dL. She had four loose bowel movements overnight.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>In addition to decreasing the dose of immunosuppression, which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Valganciclovir PO"
            },
            {
                "label": "B.",
                "text": "Colonoscopy"
            },
            {
                "label": "C.",
                "text": "Ganciclovir IV"
            },
            {
                "label": "D.",
                "text": "CMV genotype"
            },
            {
                "label": "E.",
                "text": "Kidney biopsy"
            }
        ],
        "correct_answer": "Ganciclovir IV",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with CMV colitis complicated by AKI should receive ganciclovir IV.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Life-threatening, CMV-associated conditions, including pneumonitis, meningoencephalitis, and moderate to severe gastrointestinal disease should be treated with ganciclovir, 5 mg/kg IV every 12 hours (adjusted for kidney function). This therapy has been shown to be effective against tissue-invasive CMV disease in randomized trials.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Oral valganciclovir is effective prophylaxis against CMV infection. CMV disease often arises once prophylaxis has been discontinued, typically 6 months after transplant. In this case, CMV colitis was diagnosed 1 month after discontinuing prophylaxis. Oral valganciclovir is readily bioavailable and avoids the risks and expense of central venous access; however, the drug’s absorption requires enterocyte metabolism of the prodrug, which may be unreliable in patients with gastrointestinal disease. Thus, valganciclovir PO would not be the best choice for this patient, although it could be reconsidered once symptoms improve.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Colonoscopy may be considered for patients who do not respond to therapy, or if the diagnosis is in question, but would not be the next best step in the management of this patient, in whom CMV colitis is highly likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CMV genotyping may be done to assess resistance patterns and predict response to therapy but is not usually required unless CMV viral load remains elevated, rebounds after an initial decrease, or continues to increase or symptoms fail to improve with adequate dose and time (≥2 weeks) on empiric therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CMV infection is associated with increased risk of allograft loss. However, in this case, the serum creatinine is improving with hydration, suggesting prerenal AKI. Kidney biopsy may be indicated if function does not return to baseline but would not be the next best step in management at this time.</p>\n</div>",
        "references": []
    },
    "10": {
        "question": "<div class=\"qtext\"><p>A 35-year-old Japanese man is brought to the emergency department complaining of severe weakness. Earlier that day, he had gone jogging and then eaten a breakfast consisting of pancakes and fruit. One hour later, he experienced difficulty rising from a chair and was unable to walk. Additional recent symptoms include difficulty sleeping, heat intolerance, sweating, and frequent bowel movements. He has no significant medical history and does not take medications, herbal products, or nonprescription drugs.</p>\n<p>His BP is 140/90 mm Hg and heart rate is 105/min and regular. On physical examination, he has mild proptosis and a fine resting tremor. Strength is graded 2 out of 5 in his lower extremities. Patellar reflexes are trace and ankle reflexes are absent. Sensation and proprioception are intact.</p>\n<p>His serum potassium level is 1.7 mEq/L (reference range, 3.5–5.0). Remaining serum chemistry values are within normal limits.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>After his hypokalemia is corrected, which ADDITIONAL treatment will reduce his risk of recurrent attacks?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Spironolactone"
            },
            {
                "label": "B.",
                "text": "Acetazolamide"
            },
            {
                "label": "C.",
                "text": "Methimazole"
            },
            {
                "label": "D.",
                "text": "Loperamide"
            },
            {
                "label": "E.",
                "text": "Potassium"
            }
        ],
        "correct_answer": "Methimazole",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with presumed thyrotoxic periodic paralysis should be treated with methimazole.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has paralysis associated with hypokalemia. The differential diagnosis includes autosomal dominant inherited disorders of muscle calcium or sodium channels, Andersen syndrome (inherited hypokalemic periodic paralysis, ventricular arrhythmias, and dysmorphic features), and thyrotoxic periodic paralysis. Because this patient has evidence of thyrotoxicosis (resting tachycardia, fine tremor, proptosis, heat intolerance, increased sweating, and frequent bowel movements) and because his first episode occurred at age 35 years, the most likely diagnosis is thyrotoxic periodic paralysis. This disorder is more common in Asian men. The diagnosis could be confirmed by measuring thyroid-stimulating hormone and free thyroxine. Graves disease is a common cause of thyrotoxicosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The increased levels of thyroid hormone lead to increased responsiveness to β-adrenergic stimulation, overstimulation of the sodium-potassium-ATPase, and intracellular internalization of potassium. Exercise, stress, and high-carbohydrate meals can trigger attacks. Treatment consists of acute potassium supplementation to relieve the acute symptoms followed by treatment of hyperthyroidism, such as with methimazole or propylthiouracil. Treatment with maintenance potassium supplementation alone or antimotility agents such as loperamide would not address the cause of hypokalemia. Potassium-sparing diuretics and carbonic anhydrase inhibitors have been used to treat inherited forms of hypokalemic periodic paralysis but would be inappropriate in this case. Nonselective β-blockers such as propranolol can prevent recurrence of attacks until hyperthyroidism is corrected.</p>\n</div>",
        "references": []
    },
    "11": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 20-year-old man presents to clinic for evaluation of nephrocalcinosis that was incidentally discovered during recent abdominal imaging. His past medical history is notable for premature birth, failure to thrive during infancy, and growth retardation and chronic\n    weakness during childhood. Review of systems is positive for polyuria and fatigue.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP is 112/72 mm Hg and heart rate 98/min. On examination, he is a small, thin young man in no distress. Physical examination is otherwise unrevealing. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 33.3%\">\n                     \n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 33.3%\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 33.3%\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     \n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     \n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                    Potassium\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    3.0 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    3.5–5.0\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    34 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    23–28\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                    Creatinine\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    0.7 mg/dL\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    0.7–1.3\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                    Calcium\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    9.2 mg/dL\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    8.6–10.2\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                    Magnesium\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    1.9 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    1.6–2.6\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine (random)</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     \n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     \n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                    Sodium\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    65 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    Varies with intake\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                    Potassium \n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    50 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    Varies with intake\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                    Chloride\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    70 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    Varies with intake\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                    Calcium-to-creatinine ratio\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    0.25\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    &lt;0.14\n                </td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney ultrasound reveals a 9.2-cm left kidney, an 8.6-cm right kidney, no evidence of hydronephrosis, and symmetric, bilateral nephrocalcinosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following renal transporters or channels is MOST LIKELY abnormal in this patient</strong>?</p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Thiazide-sensitive Na+/Cl-(NCC)"
            },
            {
                "label": "B.",
                "text": "Amiloride-sensitive epithelial Na+(ENaC)"
            },
            {
                "label": "C.",
                "text": "Vacuolar H+-ATPase (V-ATPase)"
            },
            {
                "label": "D.",
                "text": "Loop diuretic-sensitive Na+/K+/2Cl-(NKCC2)"
            },
            {
                "label": "E.",
                "text": "Na+-K+-ATPase"
            }
        ],
        "correct_answer": "Loop diuretic-sensitive Na+/K+/2Cl-(NKCC2)",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with Bartter syndrome (BS) most likely has a defect in the loop diuretic-sensitive Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> (NKCC2) cotransporter.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nephrocalcinosis, high urine calcium, hypokalemia, and metabolic alkalosis are all features of Bartter syndrome (BS). BS refers to a family of genetic disorders all characterized by impaired sodium and chloride transport in the thick ascending limb of the loop of Henle (TALH). At least 5 types have been described, with different phenotypes attributed to the precise gene defect. Most presentations are antenatal or perinatal, but occasionally patients are identified during childhood or even as adults. Type 1 BS is an autosomal recessive disorder caused by a defect in the loop diuretic-sensitive Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> (NKCC2) cotransporter. The defect in NaCl reabsorption (evidenced by the relatively high urine Na<sup>+</sup> and Cl<sup>-</sup> concentrations) leads to volume depletion and secondary hyperaldosteronism, which together with increased distal delivery of Na<sup>+</sup> leads to excessive K<sup>+</sup> and H<sup>+</sup> excretion, resulting in hypokalemia and metabolic alkalosis. Clinical features include prematurity, failure to thrive, growth retardation, and polyuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Similar abnormalities in NaCl reabsorption leading to secondary hyperaldosteronism and abnormal K<sup>+</sup> and H<sup>+</sup> handling are present in Gitelman syndrome (GS), which is caused by mutations in the thiazide-sensitive Na<sup>+</sup>/Cl<sup>-</sup> (NCC) cotransporter. The key to differentiating these disorders is the urine calcium value. Hypercalciuria is found in BS, whereas hypocalciuria is found in GS. Paracellular Ca<sup>2+</sup> reabsorption in the TALH relies on the electrochemical gradient created by NaCl reabsorption via the NKCC2 cotransporter, with subsequent K<sup>+</sup> recycling into the lumen. Disruption of this gradient in BS leads to inability to reabsorb calcium, resulting in hypercalciuria. In contrast, the distal tubule NCC cotransporter defect in GS results in low urine Ca<sup>2+</sup>, possibly because the volume depletion caused by distal NaCl excretion leads to increased proximal Ca<sup>2+</sup> reabsorption. The urine calcium-to-creatinine ratio varies by age, but this patient’s ratio of 0.25 is well above any age-adjusted normal. The presence of hypercalciuria and nephrocalcinosis in this patient is not consistent with the NCC defect in GS. Patients with GS often display hypomagnesemia, but this overlaps with some forms of BS. Genetic testing and response to diuretic challenges are additional methods available to distinguish BS from GS if not apparent based on phenotypic differences.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Activating mutations in ENaC cause Liddle syndrome, which is characterized by hypertension, hypokalemia, and metabolic alkalosis, but not hypercalciuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Autosomal recessive mutations in the V-ATPase cause distal renal tubular acidosis, with hypokalemia, hypercalciuria, and kidney stones, as well as sensorineural deafness, but not metabolic alkalosis as seen in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The Na<sup>+</sup>-K<sup>+</sup>-ATPase is present in all cells, and pharmacologic inhibition targeted to cardiac myocytes with digoxin is used therapeutically. Mutations in the α-isoform of this exchanger and decreased expression of the ATPase are associated with neurologic disorders.</p>\n</div>",
        "references": []
    },
    "12": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 25-year-old man presents for evaluation of kidney cysts that were discovered incidentally during abdominal ultrasound done 1 month ago after a motor vehicle collision. He currently feels well and reports no medical problems. He has never experienced\n    urinary tract infection or gross hematuria. Family history is negative for kidney disease. He does not smoke, drink alcohol, or use illicit drugs, and he takes no prescription or over-the-counter medications. He is married and has one child. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vital signs are normal, with BP 115/75 mm Hg. Physical examination reveals a thin young man with no abnormal findings. Routine laboratory data are unremarkable, including serum creatinine 0.8 mg/dL (reference range, 0.7–1.3) and normal urinalysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">A representative image from a kidney ultrasound is shown below (right kidney):</p>\n<figure><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q12-v7m1.png\" width=\"60%\"/>\n<figcaption><em>Image courtesy of Neera Dahl, MD, Yale University</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">The radiology report notes 5 small (&lt;1.5 cm) cortical cysts in each kidney. Kidney size is 9.8 cm on the left and 10.1 cm on the right. The previous ultrasound disclosed no hepatic cysts.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe tolvaptan"
            },
            {
                "label": "B.",
                "text": "MRI of the abdomen with kidney volume measurement"
            },
            {
                "label": "C.",
                "text": "Genetic testing forPKD1andPKD2mutations"
            },
            {
                "label": "D.",
                "text": "MRI/magnetic resonance angiography (MRA) of the brain"
            },
            {
                "label": "E.",
                "text": "24-Hour urine collection to calculate creatinine clearance"
            }
        ],
        "correct_answer": "Genetic testing forPKD1andPKD2mutations",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This young patient with an unusually high number of cysts in both kidneys should undergo genetic testing for <em>PKD1</em> and <em>PKD2</em> mutations to evaluate for ADPKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The diagnosis of ADPKD relies on age-based ultrasound criteria in individuals with a family history of ADPKD. Ultrasound criteria for individuals without a family history are less well established, but most experts consider the presence of &gt;10 cysts per kidney combined with bilateral enlarged kidneys to be diagnostic. In equivocal cases (≥3 cysts total in patients aged 18–49 years, ≥5 cysts total in patients aged &gt;50 years), further testing is necessary, typically with genetic mutation analysis, which would provide both diagnostic and prognostic information.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Not every asymptomatic person wants to know if they have ADPKD, because treatment is limited and the course can be highly variable. It would not be unreasonable to discuss expectant management with the patient and defer further diagnostic testing if that were preferred. However, because the progression of ADPKD may be amenable to intervention such as aggressive control of BP, and knowledge of the condition could affect surveillance and management of both renal and extrarenal manifestations, the best option for many patients is to pursue a definitive diagnosis through mutation analysis. Employment-related public safety concerns and family planning are additional reasons that a patient may choose to pursue a definitive diagnosis. However, if such testing is unavailable, then surveillance with periodic re-imaging may be appropriate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Volumetric kidney measurements are helpful to determine prognosis and to follow treatment in patients with a confirmed diagnosis of ADPKD but are not used for diagnosis. Similarly, MRI/MRA of the brain to screen for aneurysms is done for patients with a confirmed diagnosis and a family history of intracranial aneurysms, for those with high-risk occupations, and for patients scheduled to undergo high-risk procedures. Both CT and MRI have a higher sensitivity than ultrasound for small kidney cysts and can be used in cases in which ultrasound findings are indeterminate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The diagnosis of ADPKD does not require assessment of kidney function by eGFR or creatinine clearance, so a 24-hour urine collection for this purpose would be unnecessary.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tolvaptan has been shown in randomized, controlled trials to slow the decrease in kidney function and the increase in kidney volume in patients with ADPKD who are candidates for treatment. In this patient, in whom the diagnosis of ADPKD has not been established, treatment with tolvaptan would not be appropriate. </p>\n</div>",
        "references": []
    },
    "13": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 61-year-old man with CKD stage 5 due to ADPKD and congestive heart failure is admitted to the hospital with anorexia, nausea, emesis, and weight loss. He underwent left forearm arteriovenous fistula placement in preparation for HD 6 months ago. His current medications include lisinopril, furosemide, and atorvastatin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, his BP is 145/90 mm Hg, heart rate 90/min, respiratory rate 20/min, temperature 37°C, and oxygen saturation 94% while breathing room air. His lungs demonstrate bibasilar crackles, and cardiovascular examination reveals regular rate and rhythm. Extremities demonstrate 3+ pretibial edema. Asterixis is present.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HD is initiated for uremia. In preparation for placing the patient with outpatient in-center HD, hepatitis B serologies and tuberculin skin testing (TST) are ordered. The patient declines TST, stating that he was raised in Morocco and that previous testing has yielded positive results since childhood because of vaccination.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Interferon-γ release assay (IGRA)"
            },
            {
                "label": "B.",
                "text": "Chest radiograph"
            },
            {
                "label": "C.",
                "text": "Tuberculin skin testing (TST)"
            },
            {
                "label": "D.",
                "text": "Sputum testing for acid-fast bacilli (AFB)"
            },
            {
                "label": "E.",
                "text": "Rifampin 600 mg once daily"
            }
        ],
        "correct_answer": "Interferon-γ release assay (IGRA)",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This high-risk patient who has undergone previous bacille Calmette-Guérin (BCG) vaccination should now undergo IGRA testing to screen for latent tuberculosis infection (LTBI).</p>\n<p>Individuals at increased risk for the development of active tuberculosis (TB), and those at higher likelihood for reactivation, should undergo screening for LTBI. The prevalence of LTBI is elevated among patients with ESRD, and these patients also have a significantly higher risk for progression to active TB compared with the general population. In addition, the diagnosis is often difficult and delayed because of atypical clinical presentations with a predominance of extrapulmonary involvement. Therefore, screening for LTBI is recommended in this population; the goal is to decrease the likelihood of progression to TB and to prevent transmission to other patients and healthcare professionals.</p>\n<p>Both the TST and IGRA are used to evaluate cell-mediated immunity to mycobacterial protein antigens, which may occur after exposure to and infection by mycobacteria. Either the TST or the IGRA may be used as the initial step in the diagnosis of LTBI in patients with CKD, but testing with IGRA is preferred for this patient because of his history of BCG vaccination. BCG vaccination is administered at birth in most TB-endemic countries, including Morocco, which has a high prevalence of LTBI, with a 1% annual risk of infection. The TST may contain antigens also present in the BCG vaccine; therefore, individuals vaccinated with BCG but not infected with <em>Mycobacterium tuberculosis</em> may have false-positive results. The TST also has a lower sensitivity than the IGRA. Conversely, there is also a significantly higher prevalence of anergy to the TST in patients with ESRD compared with the general population; therefore, a negative TST result may not eliminate the possibility of latent or active TB (false negative). Of note, a positive TST correlates poorly with a history of BCG vaccination, and many guidelines discount the possibility of a false-positive result due to BCG. Nevertheless, the superior sensitivity and specificity of IGRA make it the preferred screening test for LTBI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although a chest x-ray is often performed to help distinguish between active disease and LTBI, it is insensitive for LTBI. Therefore, it is prudent to first establish evidence of infection with <em>M. tuberculosis</em> with IGRA testing.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Once a positive TB test result has been established, chest x-ray should be performed to identify those who may have active disease. Individuals with clinical manifestations, an abnormal chest radiograph, or concerns for extrapulmonary disease must undergo evaluation to exclude active TB. Three sputum specimens must be tested for acid-fast bacillus microscopy, culture, and diagnostic nucleic acid amplification testing. However, this test would be premature before establishing exposure to <em>M. tuberculosis</em>.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">An individual diagnosed with LTBI should be offered treatment to prevent progression to active TB. Among patients with ESRD, mortality from active TB in the dialysis population is 17–75%. The options for LTBI treatment include taking rifampin daily for 4 months. In this patient for whom LTBI has neither been established nor active TB excluded, rifampin would not be appropriate.</p>\n</div>",
        "references": []
    },
    "14": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 23-year-old woman is referred by her urologist for evaluation of CKD. She has a history of spina bifida with a lumbar myelomeningocele and has undergone numerous surgeries related to these congenital abnormalities, including ventriculoperitoneal shunt placement, bladder augmentation, and tethered cord release. She has had recurrent urinary tract infections (UTIs) requiring hospitalization throughout childhood. Her current bladder hygiene regimen includes intermittent straight catheterization (ISC) four times daily, for which she wakes once nightly. ISC yields approximately 400 mL of urine, although the amount varies considerably. Currently, she feels well and reports no difficulties with ISC. Medications include oxybutynin, baclofen, and bisacodyl. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 130/85 mm Hg. Physical examination reveals a thin woman with lower extremity sarcopenia who uses a wheelchair. There is no peripheral edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Serum creatinine is 1.4 mg/dL (reference range, 0.5–1.1), which has been stable for the past 2 years. UA shows a specific gravity of 1.010, trace albumin, trace blood, and 10–20 WBC/HPF (specific gravity reference range, 1.002–1.030; others negative). Urine culture reveals &gt;100,000 colony-forming units/mL of <em>Escherichia coli</em> that is sensitive to all antibiotics tested.</p>\n<p>Kidney ultrasound images, shown below, reveal hydronephrosis, hydroureter, and a distended bladder.</p>\n<div style=\"margin-bottom: 15px; max-width: 960px; width: 75%;\">\n<figure style=\"display: inline-block; align: left; vertical-align: top;\">\n<figcaption><br/></figcaption><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q14-v7m1-figa.png\" width=\"60%\"/>\n</figure>\n<figure style=\"display: inline-block; vertical-align: top;\"><br/><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q14-v7m1-figb.png\" width=\"60%\"/>\n<figcaption><em>Images courtesy of Cybele Ghossein, MD, Northwestern University School of Medicine</em></figcaption>\n</figure><em>\n</em></div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px; \"><strong>Which of the following is the NEXT BEST STEP to prevent progression of CKD?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Place bilateral percutaneous nephrostomy tubes"
            },
            {
                "label": "B.",
                "text": "Place suprapubic catheter"
            },
            {
                "label": "C.",
                "text": "Prescribe ciprofloxacin"
            },
            {
                "label": "D.",
                "text": "Increase frequency of ISC"
            },
            {
                "label": "E.",
                "text": "Prescribe lisinopril"
            }
        ],
        "correct_answer": "Increase frequency of ISC",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient, with CKD attributable to hydronephrosis due to vesicoureteral reflux (VUR), should increase the frequency of ISC to prevent CKD progression. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Spina bifida (SB) is the most common congenital neural tube defect, affecting nearly 160,000 adult patients in the United States. Of the 4 subtypes of SB, myelomeningocele is the most severe, with incomplete formation of the spine leading to external protrusion of the spinal cord and meninges. Neurologic manifestations are determined by the level of the cord defect, but bladder dysfunction is almost always present. With improved medical and surgical interventions, the survival of patients born with SB has improved over the past several decades, leading to a growing population of adults with SB.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney disease from SB is caused by VUR, repeated UTIs, and kidney stones. VUR is caused by a poorly compliant neurogenic bladder, resulting in high bladder pressures. The most important management strategy is to maintain low bladder pressures. Although an indwelling urethral or suprapubic catheter would accomplish this goal, these devices may increase infection risk; ISC (also termed clean intermittent catheterization, or CIC) is usually preferred for patients or families capable of applying this technique. Frequent ISC improves continence and prevents urine stasis. There are little data to guide the prescription for ISC, and the frequency may be determined by a compromise between a desire to keep bladder pressures low and what is practical for the patient and family. In this case, there is both hydronephrosis and a decline in kidney function, indicating that ISC frequency should be increased to keep bladder volume and pressure lower and thereby reduce reflux. Although without urodynamic studies there is no way to recommend a precise acceptable bladder volume, it would be reasonable to advise this patient to perform ISC often enough to keep bladder volumes &lt;300 mL. Imaging and kidney function could then be reassessed for improvement. Importantly, CKD in patients with spina bifida may be masked by low serum creatinine caused by sarcopenia. Kidney function may be more accurately assessed by measuring cystatin C or by collecting a 24-hour urine sample.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Percutaneous nephrostomy tubes are not required in this case, because hydronephrosis is caused by chronic VUR rather than obstruction. For cases in which the cause of hydronephrosis is unclear, renal nuclear scintigraphy may be done to refine the diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A suprapubic catheter will effectively drain the collecting system and maintain low bladder pressures, but is unnecessarily invasive at this stage and would not be the next best step. Suprapubic catheters may be appropriate for some patients who are unable or unwilling to perform ISC.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient performs regular ISC and would be expected to have urinary bacterial colonization. However, she has no symptoms of UTI, so ciprofloxacin is not indicated for treatment of UTI at this time. The role for continuous antibiotic prophylaxis (CAP) in patients reliant on ISC who have recurrent UTIs is an area of controversy. For children with high-grade VUR, CAP is recommended to preserve kidney function and reduce symptomatic UTI. For adults, CAP can reduce symptomatic UTI, but there is no evidence that this results in better preservation of kidney function. Because of the concern that CAP will increase the prevalence of resistant organisms, it is not widely used in adults. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with CKD associated with proteinuria may benefit from taking an ACEI. However, this patient is non-proteinuric, and a diagnosis of hypertension has not been established, so lisinopril would not be the next best step in management.</p>\n</div>",
        "references": []
    },
    "15": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 55-year-old man with advanced CKD due to diabetic nephropathy presents for follow-up. He reports no major changes in his health. Symptoms include moderate swelling of his legs. He does not have chest pain or shortness of breath. He lives with two cats and is currently unemployed. He uses marijuana recreationally once or twice weekly. His eGFR last month was 17 mL/min/1.73 m<sup>2</sup> and is 14 mL/min/1.73 m<sup>2</sup> today. He has learned about dialysis options and would prefer PD when dialysis is necessary. His current medications include sodium bicarbonate, calcitriol, amlodipine, furosemide, lisinopril, and ferrous sulfate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, his BP is 150/90 mm Hg and body mass index 35 kg/m<sup>2</sup>. Cardiovascular and pulmonary examinations are within normal limits. There is +2 edema to the mid-shin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span> Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.7 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Intact PTH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                299 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–65\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Transferrin saturation\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20–50\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ferritin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                400 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24–336\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Place PD catheter and initiate PD"
            },
            {
                "label": "B.",
                "text": "Place HD catheter and initiate HD"
            },
            {
                "label": "C.",
                "text": "Prescribe sodium zirconium cyclosilicate"
            },
            {
                "label": "D.",
                "text": "Prescribe erythropoietin"
            },
            {
                "label": "E.",
                "text": "Refer for kidney transplant evaluation"
            }
        ],
        "correct_answer": "Refer for kidney transplant evaluation",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with CKD stage 5, few symptoms, and no apparent absolute contraindications to kidney transplantation should be evaluated for preemptive kidney transplantation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients who receive a kidney transplant prior to initiating dialysis have superior long-term outcomes compared with those receiving PD or HD or a kidney transplant after dialysis initiation. Thus, timely referral for kidney transplant evaluation is crucial to allow for the possibility of preemptive transplant. Even if a living donor is not identified, early referral is advantageous because patients with eGFR &lt;20 mL/min/1.73 m<sup>2</sup> can begin to accrue time on the kidney transplant waiting list after completing the evaluation process. For patients referred after dialysis initiation, wait time can be dated to the initiation of dialysis once evaluation has been completed and candidacy established.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has CKD stage 5, he does not yet have indications to initiate renal replacement therapy, such as symptoms of uremia or evidence of pulmonary edema. Although laboratory studies reveal anemia, hyperkalemia, metabolic acidosis, and secondary hyperparathyroidism, these conditions are mild and manageable with medications. Thus, placement of a PD or HD catheter with dialysis initiation would be premature.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potassium binders may help maintain normokalemia as CKD advances and may facilitate the use of renin-angiotensin-aldosterone blocking medications that would otherwise result in hyperkalemia. This patient has only mild hyperkalemia that may be addressed by increasing the dose of diuretic and decreasing dietary intake. It would be premature to add a potassium binder at this juncture.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The need for erythropoietin or an alternative erythropoiesis-stimulating agent (ESA) can be anticipated in this patient, but neither the degree of anemia nor any symptoms indicate that initiation of an ESA is necessary at this time. Other reasonable considerations would include titrating antihypertensive therapy, as well as early referral for creation of an arteriovenous fistula or graft, even if the patient favors PD. None of these interventions would obviate the need for timely referral for transplant evaluation, but can be performed concurrently.</p>\n</div>",
        "references": []
    },
    "16": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 75-year-old man is evaluated in the HD unit during dialysis rounds. HD was initiated 2 months ago for AKI following left ventricular assist device (LVAD) implantation. Past medical history is significant for ischemic cardiomyopathy and CKD stage 3 attributed to cardiorenal syndrome with ischemic nephropathy. LVAD implantation was done as destination therapy, as the patient is not a candidate for heart transplantation. He frequently feels fatigued after receiving HD, and he is prone to hypotensive episodes during treatment. Medications include carvedilol, lisinopril, and warfarin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His vital signs are notable for mean arterial pressure (MAP) of 72 mm Hg and weight 70 kg. Examination is significant for a right internal jugular HD catheter and an abdominal LVAD drive line, which exits from the right upper abdomen. There is no edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following: </span></p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: padding: 5px; width: 40%;\">\n                     \n                </td>\n<td style=\"border: 1px solid black; padding: padding: 5px; width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: padding: 5px; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: padding: 5px;\">\n                    Potassium\n                </td>\n<td style=\"border: 1px solid black; padding: padding: 5px;\">\n                    5.0 mEq/L\n                </td>\n<td style=\"border: 1px solid black; padding: padding: 5px;\">\n                    3.5–5.0\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: padding: 5px;\">\n                    BUN\n                </td>\n<td style=\"border: 1px solid black; padding: padding: 5px;\">\n<p>54 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: padding: 5px;\">\n                    8–20\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: padding: 5px;\">\n                    Albumin\n                </td>\n<td style=\"border: 1px solid black; padding: padding: 5px;\">\n                    3.8 g/dL\n                </td>\n<td style=\"border: 1px solid black; padding: padding: 5px;\">\n                    3.5–5.5\n                </td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">The patient is interested in transitioning to PD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Review specifics of LVAD drive line placement"
            },
            {
                "label": "B.",
                "text": "Refer for arteriovenous access placement"
            },
            {
                "label": "C.",
                "text": "Obtain echocardiogram"
            },
            {
                "label": "D.",
                "text": "No change in management"
            },
            {
                "label": "E.",
                "text": "Schedule a home visit with PD nurses"
            }
        ],
        "correct_answer": "Review specifics of LVAD drive line placement",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The first step for this patient with dialysis-dependent AKI who is interested in PD should be to review the details of the LVAD insertion with attention to the location of the drive line. This would likely include review of the operative report and also discussion with the cardiologist and surgeons caring for the patient. PD catheter placement and subsequent dialysis would require that the drive line connecting the LVAD to the battery does not violate the peritoneum.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">LVADs are used as both bridges to heart transplant as well as destination therapy for those who are not transplant candidates. The device augments heart function by diverting some blood from the left ventricle into a pump reservoir and then into the aorta. The system is powered by a battery pack, attached via a drive line (see figure). The drive line, in turn, is typically tunneled through subcutaneous tissue above the fascia and out to the skin. In early LVAD models, the peritoneum was routinely violated by LVAD hardware, but current LVAD models typically leave the peritoneum intact. The drive line must be located before PD catheter placement to avoid accidental peritoneal compromise.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">PD is an acceptable option for patients with LVADs and may be relatively advantageous because of its continuous nature and hemodynamic tolerability. Performance of PD may decrease the likelihood of LVAD alarms, which are triggered by acute hypovolemia, which may be more likely during HD. In addition, the likelihood of bloodstream and subsequent LVAD infection is decreased in PD compared with HD. Thus, referral for arteriovenous access placement or using the tunneled dialysis catheter to continue HD long-term would be inappropriate until PD candidacy has been determined.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Echocardiogram for assessment of LV function and LVAD position would not affect candidacy for PD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The natural history of patients with AKI from cardiorenal syndrome undergoing LVAD implantation is a 50% improvement in kidney function within 1 month. Patients who do not improve after 1 month of LVAD implantation are unlikely to recover kidney function. Even those who improve within 1 month may be left with CKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Scheduling a home visit is advisable to assess this patient’s candidacy for PD after determining that PD catheter placement is possible but would be premature at this time.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients who develop AKI requiring dialysis in association with LVAD placement have a high mortality. Moreover, patients with ESRD and LVAD have a &gt;70% risk of death within 1 year. Therefore, another option that should be explored with this patient is maximal conservative management with a focus on palliative care.</p>\n<figure><img height=\"365\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q16-ksapv7m1.jpg\" width=\"295\"/>\n<figcaption>Image courtesy of <em>Clin J Am Soc Nephrol</em> 13(2): 348–55, 2018</figcaption>\n</figure>\n</div>",
        "references": []
    },
    "17": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 55-year-old man presents to the emergency department with several days of worsening, bilateral flank pain that radiates to the groin. He does not report dysuria, hematuria, fever, or weight loss. He has a past medical history of hypertension and prolactinoma. His medications include carvedilol, hydralazine, and bromocriptine.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">BP is 155/92 mm Hg. His physical examination is unremarkable. Urine output over the past 24 hours has been 1.8 L.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the followin<span>g:</span></span></p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\"><br/></td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<strong>1 Year Ago</strong>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0); width: 18.9072%;\">\n<strong>Today</strong>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0); width: 31.4073%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">Hemoglobin</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">13.5 g/dL\n                </td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0); width: 18.9072%;\">\n                    12.0</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0); width: 31.4073%;\">14–18</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n                    BUN\n                </td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n                    9 mg/dL\n                </td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0); width: 18.9072%;\">\n                    28\n                </td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0); width: 31.4073%;\">\n                    8–20\n                </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">Creatinine<br/></td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">0.8 mg/dL\n                </td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0); width: 18.9072%;\">\n                    1.4</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0); width: 31.4073%;\">0.7–1.3</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urinalysis is negative for blood and protein.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A kidney and bladder ultrasound demonstrates mild fullness of the collecting system. The bladder is non-distended, and a post-void residual is 10 mL.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT most appropriate step in diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Kidney Biopsy"
            },
            {
                "label": "B.",
                "text": "Serum IgG4 levels"
            },
            {
                "label": "C.",
                "text": "MRI of the abdomen"
            },
            {
                "label": "D.",
                "text": "Cystoscopy"
            },
            {
                "label": "E.",
                "text": "Serum prostate-specific antigen (PSA)"
            }
        ],
        "correct_answer": "MRI of the abdomen",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p>MRI (or CT with IV contrast) would be the next diagnostic step for this patient, whose presentation with flank pain, decreased kidney function, and suspicion for collecting system obstruction without bladder distention should raise concern for retroperitoneal fibrosis (RPF). </p>\n<p>RPF is a rare fibroinflammatory disorder characterized by peri-aortic inflammation. RPF may be idiopathic, but a variety of associated conditions and causes have been described, including drugs, autoimmune disease, IgG4 disease, infection, and malignancy. This patient’s medications, including bromocriptine, hydralazine, and a β-blocker, are among those that have been linked to RPF. Before searching for a specific etiology, the most appropriate next step would be to establish the diagnosis by MRI or CT with IV contrast, which would typically demonstrate peri-aortic fibrosis with encasement of local blood vessels and, in this case, both ureters.</p>\n<p>CT without contrast would be less helpful in this case, because IV contrast is needed to characterize fibrosis, masses, or lymphadenopathy, which can also be seen with RPF. CT without contrast is preferred when there is concern for symptoms or obstruction related to nephrolithiasis, but in this patient with subacute, bilateral symptom onset and normal urinalysis, the likelihood of kidney stones is relatively low.</p>\n<p>A kidney biopsy may be useful in patients with hematuria or proteinuria who are suspected to have glomerular disease. In this patient with new-onset back and flank pain, fullness of the collecting system, and normal urinalysis, definitive imaging of the abdomen would be the next best step in diagnosis.</p>\n<p>IgG4-related disease is an increasingly recognized autoimmune condition with protean clinical manifestations such as autoimmune pancreatitis, interstitial nephritis, thyroiditis, and RPF, among others. Serum IgG4 levels would be consistent with a diagnosis of IgG4-related disease in the presence of consistent imaging and tissue pathology, but would not obviate the need for diagnostic imaging at this stage of evaluation.</p>\n<p>Cystoscopy is an invasive test to assess for bladder malignancy and is not indicated at this time, particularly before performing noninvasive imaging.</p>\n<p>This patient’s imaging does not demonstrate obstruction (distended bladder, increased post-void residual) at the level of the prostate gland. Moreover, although a PSA test may be useful to detect prostate cancer, it is less useful to diagnose benign prostatic hypertrophy, a more common cause of urinary outlet obstruction.</p>\n</div>",
        "references": []
    },
    "18": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 78-year-old man is evaluated for hypernatremia. One week ago, he underwent an elective inguinal hernia repair. The surgery was uncomplicated, and he was discharged on the day of the surgery with an oxycodone prescription for pain control. Two days ago, he presented to the emergency department with worsening abdominal pain and distention that began soon after surgery. He also reports constipation and reduced urine output.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In the ED, he was diagnosed with AKI, with an increase in serum creatinine to 5.0 mg/dL compared with a baseline of 1.0 mg/dL. Kidney ultrasound revealed bilateral hydronephrosis and bladder distention. A urinary catheter was placed with initial drainage of 1.5 L. Isotonic saline was administered, and the patient was admitted to the hospital. Over the next 2 days, his creatinine improved, but he developed polyuria (8 L/day) and hypernatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Currently, his BP is 118/76 mm Hg, heart rate 92/min, and weight 100 kg. He appears euvolemic. Except for a healing inguinal hernia repair incision, the physical examination is unremarkable.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Value</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                160 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                56 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                123 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                17 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Assuming negligible insensible water loss, which of the following MOST CLOSELY represents the volume of water required to fully correct this patient’s serum sodium over the next 24 hours?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "7 L"
            },
            {
                "label": "B.",
                "text": "8 L"
            },
            {
                "label": "C.",
                "text": "15 L"
            },
            {
                "label": "D.",
                "text": "1 L"
            },
            {
                "label": "E.",
                "text": "14 L"
            }
        ],
        "correct_answer": "8 L",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hypernatremia (dehydration) from post-obstructive diuresis would require 8 L over the next 24 hours to correct his serum sodium and his ongoing renal water losses, assuming no insensible water losses.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Free water deficit (FWD) may be calculated using the following equation: </p>\n<p>FWD = total body water (TBW) x ([serum Na/140] – 1)</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this elderly, dehydrated patient, TBW may be estimated as 50% of his weight, or 50 kg. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FWD = 50 L x (160/140 – 1) = 7.1 L</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ongoing renal water losses, or electrolyte-free water clearance (C<sup>e</sup><sub>H2O</sub>), must also be calculated. The concept of C<sup>e</sup><sub>H2O</sub> was originally developed to determine renal water clearance by conceptually separating the urine into two quantities: isosmotic urine and water. C<sup>e</sup><sub>H2O</sub> may be calculated using the following equation:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">C<sup>e</sup><sub>H2O</sub> = urine volume (V) x (1 – [urine Na + urine K]/serum Na)</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">C<sup>e</sup><sub>H2O</sub> = 8 L/day x (1 – [123 + 17]/160) = 1 L/day</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thus, this patient would require (7.1 + 1=) 8.1 L to fully correct his serum sodium over the next 24 hours. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Many clinicians would also add an allowance for insensible water loss, estimated at 10 mL/kg per day (in this case, 1 L/day), to estimate water replacement targets. However, insensible losses are dependent on variables such as temperature, respiration, body composition, and skin integrity, and even if these details are known, precise estimation of insensible loss is not practical. In addition, there is water generation from the metabolism of ingested carbohydrate that may balance out insensible loss, at least in part. In the absence of extremes, it is reasonable to exclude insensible losses from the calculation. However, in all cases, serum sodium should be followed regularly to confirm appropriate correction.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Note that the optimal rate of correction of hypernatremia remains an area of controversy. Traditionally, based on observations in children, a rate of correction of not greater than 0.5 mEq/L per hour was advised to avoid cerebral edema. However, little data exist for adults, and a 2019 investigation did not find any evidence to support the contention that rapid correction is associated with increased mortality or neurologic consequences.</p>\n</div>",
        "references": []
    },
    "19": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 30-year-old woman with sepsis complicating treatment for acute myeloid leukemia (AML) is evaluated for metabolic acidosis. The patient was recently diagnosed with AML and presented with neutropenic fever after induction chemotherapy with idarubicin and cytarabine. Her symptoms included fever and rigors. Blood cultures were drawn, and she was initially treated with IV fluid, cefepime, and vancomycin, as well as acetaminophen, which were all continued. Over the next 7 days, fever persisted, and blood cultures grew <em>Candida albicans</em>. Micafungin was then added, but she remained febrile and hypotensive. Abdominal pain and distension due to ileus were addressed with nasogastric (NG) suction. Her plasma creatinine concentration gradually increased from a normal baseline, although she remained nonoliguric.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">She currently appears ill and has bitemporal wasting. BP is 90/42 mm Hg and pulse 120/min. Respiratory rate is 30/min with oxygen saturation 96% while receiving 2 L/min oxygen by nasal cannula. Weight is 45 kg, decreased from 55 kg over the past month. Cardiac examination reveals regular tachycardia with no murmurs, and lungs are clear to auscultation bilaterally. Abdominal examination reveals mild distension and tenderness to palpation without guarding or rebound. The NG tube continues to drain more than 1 L/day.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are shown below:</span></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"60%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>148 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>4.0 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  Chloride</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>100 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>10 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>42 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>1.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  Glucose</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>80 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  Lactic acid</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>3 mmol/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>0.7–2.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p><strong>Arterial blood gas</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  pH</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>7.20</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>7.38–7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  pCO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>16 mm Hg</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>38–42</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"35.483870967741936%\">\n<p>  pO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>88 mm Hg</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"32.25806451612903%\">\n<p>75–100</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY cause of metabolic acidosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "ʟ-Lactic acidosis"
            },
            {
                "label": "B.",
                "text": "ᴅ-Lactic acidosis"
            },
            {
                "label": "C.",
                "text": "Ketoacidosis"
            },
            {
                "label": "D.",
                "text": "Acute Kidney Injury"
            },
            {
                "label": "E.",
                "text": "Pyroglutamic acidosis"
            }
        ],
        "correct_answer": "Pyroglutamic acidosis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of anion gap metabolic acidosis in this septic, malnourished patient receiving acetaminophen is pyroglutamic acidosis, or 5-oxoproline accumulation.</p>\n<p>Glutathione is a tripeptide antioxidant composed of glutamate, glycine, and cysteine that protects the liver from oxidative stress and allows detoxification of reactive oxygen species. Risk factors for glutathione depletion include female sex, advanced age, chronic acetaminophen use, poor nutrition, and cirrhosis. With chronic glutathione depletion, especially that caused by acetaminophen, glutamate is unable to be used for synthesis into glutathione and auto-cyclizes in an ATP-depleting futile cycle to 5-oxoproline. Pyroglutamic acidosis can result in profound elevation of the anion gap and may be more common than recognized as awareness and investigation of this condition may be lacking. Treatment usually consists of withdrawal of acetaminophen combined with nutritional support. Most cases describe chronic (weeks) of acetaminophen exposure in undernourished patients, but pyroglutamic acidosis has also been observed with acute exposure.</p>\n<p>This patient has sepsis with fungemia, but the slightly elevated l-lactic acid level (3 mmol/L) would not account for the profound (38 mmol/L) anion gap. Malignancies such as leukemia, lymphoma, and solid organ malignancies can cause a type B lactic acidosis due to anaerobic glycolysis by tumor cells, but would be expected to show an elevated lactate level.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ᴅ-Lactic acidosis occurs in gastrointestinal bacterial overgrowth syndromes, as well as in patients receiving propylene glycol (a vehicle for IV sedatives) and in some cases of diabetic ketoacidosis. ᴅ-Lactic acid would not be detected by conventional serum lactic acid tests, which only measure the ʟ-enantiomer. This patient has no risk factors for ᴅ-Lactic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Euglycemic ketoacidosis is referred to as starvation ketosis when it occurs in the setting of nutritional depletion and poor intake. Although this patient has evidence of nutritional depletion and poor intake, and may have a component of starvation ketoacidosis, this condition typically results in only a mild depression of serum bicarbonate and would be unlikely to account for the large anion gap seen here. It can be identified by the presence of ketones in blood or urine and managed with carbohydrates and, if needed, insulin. Thiamine should be provided if there is any concern for deficiency of this vitamin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Severe AKI is a well-recognized cause of high anion gap metabolic acidosis, but the moderate degree of AKI seen in this case would be unlikely to explain the anion gap of 38 mmol/L.</p>\n</div>",
        "references": []
    },
    "20": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 69-year-old woman with ESRD receiving PD presents with right shoulder pain, edema, shortness of breath, and weight gain over the past week. The patient has underlying hypertension and has been treated with PD for 3 years. Her dialysis prescription\n    calls for four 2.5-L exchanges over 9 hours overnight via a cycler, with a 2-L final fill and mid-day exchange, all 2.5% dextrose. Her most recent standard weekly Kt/V was 1.9, and urine output is reported unchanged. Medications include lisinopril\n    20 mg daily, furosemide 80 mg twice daily, calcitriol 0.25 µg daily, and calcium acetate 667 mg with meals. There have been no recent changes to the patient’s dialysis prescription or medications, although because of a recent move, she has had to\n    place the cycler farther from her bed, which necessitated extension tubing. She has noted more frequent alarms from the cycler and increased drain times. She has not had fever or abdominal pain, and her effluent has been clear.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, BP is 168/110 mm Hg, heart rate 88/min, temperature 37.4°C, and oxygen saturation 88% while breathing room air. Other significant findings include bibasilar rales and 3+ lower extremity edema. Her abdomen is distended but without tenderness,\n    guarding, or rebound, and the catheter exit site and tunnel are normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Peritoneal dialysate fluid cell count includes is 5 WBC/mm<sup>3</sup>, and Gram stain is negative. Serum lactic acid is normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Abdominal x-ray is shown below.</p>\n<figure><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q20-ksapv7m1.jpg\" width=\"50%\"/>\n<figcaption><em>Image courtesy of Jason Kidd, MD, Virginia Commonwealth University School</em></figcaption>\n<p dir=\"ltr\" style=\"margin-bottom: 15px; margin-top: 20px;\"><strong>Which of the following is the MOST likely cause of volume overload and shoulder pain?</strong></p>\n</figure></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Peritonitis"
            },
            {
                "label": "B.",
                "text": "Loss of residual renal function"
            },
            {
                "label": "C.",
                "text": "Cycler connection technique"
            },
            {
                "label": "D.",
                "text": "Retroperitoneal fluid leak"
            },
            {
                "label": "E.",
                "text": "Perforated abdominal viscus"
            }
        ],
        "correct_answer": "Cycler connection technique",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has pneumoperitoneum most likely attributable to cycler connection technique.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has developed pneumoperitoneum and volume overload due to the use of extension tubing to make her connection for APD. When longer extension tubing is added, the prime volume must be increased to ensure all the air is flushed from the longer tubing. If the prime volume is not increased, air can be introduced. Pneumoperitoneum is common in patients undergoing peritoneal dialysis (incidence 21–34%) and is sometimes attributable to changes in technique. Although often asymptomatic if related to technique, irritation of the phrenic nerve can lead to referred pain in either shoulder and impairment of dialysate drainage, causing volume overload; inadequate dialysis can also occur. All of these features are present in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Perforation of a hollow viscus also results in pneumoperitoneum but would also be accompanied by cloudy peritoneal effluent, abdominal pain, and features of sepsis. In this case, features of peritonitis and sepsis are absent. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Common causes of volume overload in a patient receiving PD include nonadherence to the dialysis prescription, inappropriate prescription, nonadherence to a salt-restricted diet, loss of residual renal function, and peritoneal membrane failure. None of these etiologies would account for the pneumoperitoneum present in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Loss of residual renal function would not be suspected as a cause of volume overload in this patient, who has an adequate standard weekly Kt/V and is adherent to furosemide with unchanged urine output.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Retroperitoneal dialysate leak may occur in cases of retroperitoneal trauma or nephrectomy but typically presents as a loculated abdominal fluid collection or edema of the extraperitoneal tissues rather than pneumoperitoneum. Right shoulder pain would not be expected.</p>\n</div>",
        "references": []
    },
    "21": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 60-year-old man with a 25-year history of type 2 diabetes presents for evaluation of CKD. His past medical history includes diabetic retinopathy, hypertension, coronary artery disease, and CKD stage G3b/A3. Currently he feels well, and his review of systems is unremarkable. His medications include losartan 100 mg daily, atorvastatin 40 mg daily, aspirin 81 mg daily, clopidogrel 75 mg daily, metformin 500 mg twice daily, and glipizide 5 mg daily. He reports that his fasting glucose averages 130 mg/dL by fingerstick, but postprandial values often exceed 200 mg/dL.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Physical examination reveals BP 128/65 mm Hg and heart rate 75/min. The heart, lungs, and abdomen are normal. Dorsalis pedis and posterior tibial pulses are intact, and there are no areas of ulceration. Light touch sensation is mildly impaired to the level of the mid-shin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; 30%;\">\n<strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                2.1 mg/dL (baseline)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                38 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                ≥60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Hemoglobin A<sub>1c</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                7.5%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                4.0–5.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Glucose, fasting\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                150 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                70–99\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Urine albumin-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                650 mg/g\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                &lt;30\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the most appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase glipizide"
            },
            {
                "label": "B.",
                "text": "Discontinue metformin"
            },
            {
                "label": "C.",
                "text": "Initiate canagliflozin"
            },
            {
                "label": "D.",
                "text": "Initiate insulin"
            },
            {
                "label": "E.",
                "text": "Initiate repaglinide"
            }
        ],
        "correct_answer": "Initiate canagliflozin",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with suboptimally controlled type 2 diabetes mellitus and CKD stage G3b/A3 should be treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor such as canagliflozin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The optimal HbA<sub>1c</sub> target for patients with CKD has not been established, but a reasonable target is 7% if hypoglycemia can be avoided. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Trials such as the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) and others have shown that patients with type 2 diabetes mellitus and CKD with albuminuria who are treated with SGLT2 inhibitors benefit from improved cardiovascular outcomes and decreased risk of progressing to ESRD. The SGLT2 inhibitor clinical trials have included patients with eGFR as low as 25 mL/min/1.73 m<sup>2</sup>. It is not yet clear if safety and benefit extend to patients with eGFR &lt;25 mL/min/1.73 m<sup>2</sup>, although patients in the CREDENCE trial did not discontinue canagliflozin once their eGFR decreased below this threshold. Renin-angiotensin-aldosterone system blockade should continue when SGLT2 inhibitors are started. Because of their mechanism of action, SGLT2 inhibitors may increase the risk of hypovolemia. The dose of diuretics should be assessed and potentially decreased before initiating an SGLT2 inhibitor, although evidence to support this practice is limited. Caution is advised in patients with peripheral vascular disease or ulceration that would place them at higher risk for amputation, which has been reported in one trial and a meta-analysis. Another consideration regarding the use of SGLT2 inhibitors is their association with euglycemic diabetic ketoacidosis. These agents should be stopped during episodes of prolonged fasting or during episodes of critical illness to reduce this risk.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Glipizide is a relatively long-acting sulfonylurea that can provoke hypoglycemia as kidney function declines. Although it can be used for patients with moderately advanced CKD, dose reduction is required. In addition, this class of drugs does not have as much evidence for improving long-term cardiovascular and renal outcomes. Increasing the dose of glipizide for this patient would not be the best option.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Repaglinide is an oral hypoglycemic agent that enhances insulin sensitivity. These agents are shorter acting than sulfonylureas but have a similar mechanism of action and are not usually used in combination.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Metformin is renally cleared, and prior guidelines have suggested that the drug be discontinued in patients with creatinine levels over 1.4 mg/dL (women) and 1.5 mg/dL (men). However, a systemic review showed that in patients with mild-to-moderate CKD (eGFR 30–60 mL/min per 1.73 m<sup>2</sup>), the incidence of lactic acidosis was indistinguishable from the background rate. The package insert for metformin states the drug should not be used in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>. Thus, there is no indication to discontinue metformin if kidney function remains stable, and doing so would likely worsen his glycemic control.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Insulin therapy is often needed to achieve optimal control of diabetes but has drawbacks, including the need for injections, weight gain, and risk of hypoglycemia. In this patient whose HbA<sub>1c</sub> is relatively near target, insulin initiation would not be the next best step in management.</p>\n</div>",
        "references": []
    },
    "22": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 36-year-old woman with ESRD presents to the emergency department with dyspnea and orthopnea. Other symptoms include low-grade fever, nonproductive cough, and intermittent substernal chest pain that began 1 week prior to presentation and does not radiate. Her ESRD was attributed to FSGS and she initiated HD 1 year ago, although she has been nonadherent to her treatment schedule. Her last HD session was 10 days ago. Other medical history includes depression. She dialyzes via a left brachiocephalic arteriovenous fistula (AVF). Her target weight is 68 kg.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her current weight is 73 kg. BP is 164/104 mm Hg, heart rate 101/min, temperature 38.2°C, and O<sub>2</sub> saturation 93% while receiving 2L/min oxygen via nasal cannula. Jugular venous distention is present. S1 and S2 are faint, and no murmurs, rubs, or gallops are detected. Bibasilar crackles are present. The legs are moderately edematous, and the left arm AVF is well developed with a thrill and bruit and no overlying inflammation. </p><p dir=\"ltr\" style=\"margin-bottom: 15px;\">Initial laboratory results are as follows:</p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"60%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>9000/µL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>9.8 g/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Platelet count</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>189,000/µL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>131 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>5.7 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Chloride</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>100 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>15 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>130 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Troponin I</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.15 ng/mL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>≤0.04</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">EKG reveals sinus tachycardia, low voltage, and nonspecific T-wave changes. Chest x-ray shows new cardiomegaly with pulmonary vascular congestion and small bibasilar effusions. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Dialysis is initiated with an ultrafiltration rate of 1 L/h. Thirty minutes into treatment, the patient’s BP decreases to 100/60 mm Hg, and she reports feeling unwell.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acute myocardial infarction"
            },
            {
                "label": "B.",
                "text": "Dialysis-associated pericarditis"
            },
            {
                "label": "C.",
                "text": "Acute bacterial pneumonia"
            },
            {
                "label": "D.",
                "text": "Excessive ultrafiltration"
            },
            {
                "label": "E.",
                "text": "Pulmonary embolism"
            }
        ],
        "correct_answer": "Dialysis-associated pericarditis",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis in this patient experiencing hypotension during dialysis in the context of azotemia, new cardiomegaly, and poor adherence to her treatment regimen is dialysis-associated pericarditis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Intradialytic hypotension is reported in up to 20–30% of treatments and has a broad differential diagnosis. In this patient with marked azotemia, dialysis nonadherence, chest pain, and fever, dialysis-associated pericarditis should be considered.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In the absence of other explanations (such as viral infection, autoimmunity, or malignancy), pericarditis and pericardial effusions in advanced CKD and ESRD are arbitrarily divided into uremic pericarditis (occurring before or within 8 weeks of starting dialysis) and dialysis-associated pericarditis (occurring after 8 weeks of dialysis). The underlying etiology is unknown but has been attributed to accumulation of uremic toxins in the pericardium. Inadequate dialysis and fluid overload appear to be risk factors. In addition to pleuritic, substernal chest pain, patients may present with constitutional symptoms, including fever, cough, and fatigue. The onset of symptoms may be more insidious than acute. A pericardial rub is often present but is typically transient and may be missed, so the absence of a rub does not rule out pericarditis. Of note, the classic EKG findings of diffuse ST segment elevation are only found in 1–10% of patients with dialysis-associated pericarditis; most have nonspecific ST segment or T-wave changes only, and some will show low voltage. Pericardial effusion may appear as cardiomegaly on chest x-ray. Intensification of dialysis, with associated amelioration of azotemia, often resolves associated signs and symptoms, although the friction rub may persist for weeks after appropriate treatment. Pericardiocentesis or pericardial window creation may be necessary if there is evidence of worsening or recurrent effusion, cardiac tamponade, or constrictive pericarditis. A reduction in right-sided filling pressure related to the extracorporeal circuit, ultrafiltration, and transcellular fluid shift may unmask hemodynamic instability, as in this case. Demonstration of a pulsus paradoxus may increase suspicion for this diagnosis, which can be confirmed with echocardiography.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute myocardial infarction cannot be excluded without serial investigation of cardiac biomarkers but is a less likely explanation in this young patient with nonspecific EKG findings and a mildly elevated troponin. Small increases in both troponin T and I are common in patients with ESRD, related to both increased myocardial leakage and reduced clearance. Moreover, troponin elevation is common in pericarditis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Infection cannot be excluded without further investigation and observation but is not the most likely diagnosis. The chest x-ray does not suggest pneumonia, and the fever and cough are consistent with dialysis-associated pericarditis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Excessive ultrafiltration relating to either an inaccurate assessment of target weight or too rapid a rate is a common explanation for intradialytic hypotension. This patient is undergoing ultrafiltration at a rate of approximately 13 mL/kg per hour, which is at the upper aspect of the recommended range. Even if her target weight is inaccurate, this rate of fluid removal would be unlikely to result in severe hypotension after 30 minutes.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"> </p><p>Despite platelet dysfunction and exposure to anticoagulants, dialysis patients experience pulmonary emboli more frequently than the general population. Due to nonspecific presentations, the diagnosis may be missed, leading to morbidity or mortality. Such symptoms as chest pain, dyspnea, fever, cough, and even abnormal troponin levels may overlap with those of other diagnoses. In this case, the history of nonadherence, azotemia, low voltage, and new cardiomegaly favor a diagnosis of pericarditis.</p>\n</div>",
        "references": []
    },
    "23": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 32-year-old woman with a history of CKD stage 3 attributed to hypertension returns to clinic for routine follow-up. She feels well and has no symptoms. Current medications include lisinopril/hydrochlorothiazide 20/25 mg daily. She is a nonsmoker. She is currently using barrier contraception but is dissatisfied and interested in changing to an alternative strategy. She has discussed a change with her primary provider but is concerned about potential adverse effects.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 135/85 mm Hg and heart rate 76/min. She appears well. Heart and lung exams are normal, and there is no lower extremity edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following would be the BEST CHOICE for contraception for this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Estrogen only"
            },
            {
                "label": "B.",
                "text": "Progestin only"
            },
            {
                "label": "C.",
                "text": "Estrogen-progestin combination"
            },
            {
                "label": "D.",
                "text": "Barrier methods"
            },
            {
                "label": "E.",
                "text": "Drospirenone"
            }
        ],
        "correct_answer": "Progestin only",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best contraceptive choice among these options for this patient with CKD and hypertension is a progestin-only drug, which can be delivered as a pill or as a component of an intrauterine device (IUD).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although the choice of a contraceptive strategy may be nuanced, nephrologists may prescribe ACEIs or other agents that can adversely pregnancy outcomes. In addition, hormone-containing contraceptive agents may affect BP and thrombotic risk. Therefore, nephrologists should be familiar with strategies for contraception and their potential consequences.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Oral contraceptive pills containing estrogen may cause or exacerbate hypertension. Older studies have shown that combinations of estrogen and progestin containing higher doses of estrogen (&gt;50 µg/day) carried a 5% risk of hypertension. This risk was reduced with lower doses of estrogen, but the age-adjusted relative risk for developing hypertension remained 1.5. For most women, the absolute risk of persistent hypertension and resulting cardiovascular complications is low, but those patients with preexisting risk factors for cardiovascular disease should avoid combination estrogen-progestin oral contraceptives. These risk factors include preexisting hypertension (even if controlled), ischemic heart disease, age &gt;35 years, current smoking, and history of deep venous thrombosis or pulmonary embolism. In contrast, progestin-only therapy, including oral and intrauterine formulations, does not confer an increased risk of cardiovascular disease and is an acceptable strategy for contraception in patients with preexisting hypertension. A non-hormonal intrauterine approach such as a copper intra-uterine device is also a valid option.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because progestin-only forms are safe in patients with preexisting hypertension and CKD, there is no compelling reason to continue to rely on barrier methods, and in this case, the patient has expressed dissatisfaction with this approach.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Drospirenone is a progestin with weak anti-mineralocorticoid effects that have been shown to mildly lower BP. However, these anti-mineralocorticoid effects may increase the risk of hyperkalemia in CKD, so drospirenone is contraindicated in patients with CKD. In this patient who is already taking lisinopril, the risk of hyperkalemia could be further increased.</p>\n</div>",
        "references": []
    },
    "24": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 73-year-old man with ESRD receiving HD, diabetes mellitus, hypertension, coronary artery disease, and a chronic right heel ulcer complicated by osteomyelitis presents to the emergency department with severe back pain and right leg weakness. These symptoms have progressed over the past 2 weeks and are refractory to oral analgesics. One month ago, he completed 6 weeks of vancomycin and cefepime treatment for the heel ulcer, which improved clinically and radiographically. He began dialysis 6 months ago via a tunneled, cuffed catheter (TCC), which remains in place. Daily urine output is approximately 1 L.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, his BP is 146/77 mm Hg, heart rate 65/min, temperature 37.1°C, respiratory rate 20/min, and oxygen saturation 94% while breathing room air. He appears chronically ill. Palpation and percussion of the mid-thoracic spine (T7) elicit severe pain. Right leg strength is 3/5 from hip to ankle, and knee and ankle reflexes are diminished on the left. His lungs are clear. The cardiac rhythm is regular, and no murmur is present. The left heel ulcer demonstrates a granulating base without exudate, fluctuance, or tenderness. The TCC site is clean and dry without signs of infection.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His laboratory results are as follows: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4100/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                28 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  C-reactive protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤0.8\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Erythrocyte sedimentation rate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                58 mm/h\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–15\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Spine radiographs demonstrate disc space narrowing and irregularity of the vertebral endplates involving the 7th and 8th thoracic intervertebral spaces.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which one of the following is the MOST APPROPRIATE next step in diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "MRI without contrast"
            },
            {
                "label": "B.",
                "text": "CT myelogram"
            },
            {
                "label": "C.",
                "text": "MRI with gadobutrol"
            },
            {
                "label": "D.",
                "text": "CT without contrast"
            },
            {
                "label": "E.",
                "text": "Positron emission tomography"
            }
        ],
        "correct_answer": "MRI with gadobutrol",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient should undergo an MRI with gadobutrol to evaluate for epidural abscess.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient’s history of recently treated osteomyelitis and clinical presentation should prompt an evaluation for an epidural abscess. The absence of fever is not unusual in this diagnosis and should not discourage evaluation. The presence of neurologic impairment adds urgency. A plain film can suggest discitis and potentially detect osteomyelitis but is not diagnostic for spinal epidural abscess. Imaging with MRI using contrast is the optimal imaging test given its ability to detect abscess early in the disease course, allowing for prompt surgical intervention. Previously, there was concern about the association between gadolinium and the development of nephrogenic systemic fibrosis (NSF). However, there are few reported cases of NSF with newer, group II agents (gadobenate dimeglumine, gadoterate meglumine, gadobutrol, and gadoteridol).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">NSF is characterized by severe, progressive, irreversible fibrosis of the skin and can involve internal organs with fatal consequences. It was initially described in 1998 and linked to gadolinium administration by 2006. Subsequently, an FDA black box warning was issued for gadolinium-based contrast agents in patients with severe AKI or CKD. These restrictions and a heightened awareness by radiologists and nephrologists have resulted in a significant decrease in incidence of NSF. Research on the risks of different gadolinium-based contrast agents has led to classification of agents into 3 groups based on their vintage and association with NSF. Group 1 agents, which include gadopentetate, have the strongest link to NSF. These agents are contraindicated for patients with CKD and ESRD. Group 2 agents have been associated with few, if any, unconfounded instances of NSF. Group 3 agents lack sufficient data to draw conclusions. A joint statement from the American College of Radiology and the National Kidney Foundation states that the benefit of withholding contrast-enhanced MRI when warranted outweighs the relatively unsubstantiated risk of harm. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MRI without contrast would not be the preferred imaging test to diagnose epidural abscess.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CT without contrast may be diagnostic but has lower sensitivity than MRI and often is not sufficient for surgical planning. Although a CT myelogram has a high sensitivity for detecting epidural abscess, it is relatively invasive, and may confer a risk of iodinated contrast-associated AKI in patients with CKD. Positron emission tomography would not provide the structural information needed to guide therapy.</p>\n</div>",
        "references": []
    },
    "25": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 50-year-old man develops severe pain in his buttocks on post-operative day 2 after laparoscopic gastric bypass surgery. The operative notes indicate that the procedure time was 6 hours, with an estimated blood loss of 150 mL and a nadir BP of 100/70 mm Hg. The patient received 2 L of isotonic IV fluids during the procedure.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP is 160/80 mm Hg, heart rate 95/min, temperature 37.8°C, and body mass index 58 kg/m<sup>2</sup>. Physical examination is significant for hyperactive bowel sounds, a mildly tender abdomen with normal-appearing port incisions, no rebound tenderness, and no suprapubic masses or pain. His buttocks are without rashes, ecchymosis, or other skin changes but are exquisitely tender to touch or pressure. Urine output has been 700 mL over the past 24 hours via urinary catheter.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>His laboratory data are noted below:</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"60%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"24.124513618677042%\">\n<p><strong> </strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"25.291828793774318%\">\n<p><strong>1 Month Ago</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"18.8715953307393%\">\n<p><strong>Current</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"31.71206225680934%\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"24.124513618677042%\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"25.291828793774318%\">\n<p>4.3 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"18.8715953307393%\">\n<p>5</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"31.71206225680934%\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"24.124513618677042%\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"25.291828793774318%\">\n<p>24 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"18.8715953307393%\">\n<p>22</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"31.71206225680934%\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"24.124513618677042%\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"25.291828793774318%\">\n<p>18 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"18.8715953307393%\">\n<p>45</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"31.71206225680934%\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"24.124513618677042%\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"25.291828793774318%\">\n<p>1.3 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"18.8715953307393%\">\n<p>2.9</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"31.71206225680934%\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urinalysis yields a specific gravity of 1.012, 2+ protein, and 3+ blood. Urine microscopy reveals 0–1 RBC/HPF, 5–10 WBC/HPF, and abundant amorphous debris. A low-power view of a representative urine sediment is shown below.</p>\n<figure><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q25-ksapv7m1.png\n\" width=\"50%\"/>\n<figcaption>Image courtesy of <em>Kidney360</em> 1(8): 819–823, 2020 </figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST TEST to help diagnose the cause of AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Serum creatine kinase"
            },
            {
                "label": "B.",
                "text": "Fractional excretion of sodium"
            },
            {
                "label": "C.",
                "text": "CT of abdomen and pelvis"
            },
            {
                "label": "D.",
                "text": "Kidney ultrasound"
            },
            {
                "label": "E.",
                "text": "Blood and urine cultures"
            }
        ],
        "correct_answer": "Serum creatine kinase",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A serum creatine kinase (CK) should be checked in this patient with AKI and suspected rhabdomyolysis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CK is usually dramatically elevated in cases of AKI due to rhabdomyolysis and should be measured in this patient with AKI and severe muscle pain after surgery. Other clues to the diagnosis include a dark red or brown appearance of the urine and a strongly positive urine dipstick for blood in the absence of significant microscopic hematuria. Note that there may be some RBCs, WBCs, or both related to urinary catheter placement or other causes, as in this case. The urine sediment often contains an abundance of “muddy brown” granular debris and coarsely granular casts as depicted in the image.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Rhabdomyolysis occurs when there is skeletal muscle necrosis and subsequent release of myoglobin (and other debris) into the systemic circulation. Muscle pain is a typical symptom of rhabdomyolysis, although there may be no visible changes to the affected region. Weakness may also be a prominent feature. Myoglobin is nephrotoxic, especially when other risk factors for AKI are present, such as hypotension or inflammation. Rhabdomyolysis-related AKI can result from multiple mechanisms, including tubular obstruction from pigment casts, toxic and ischemic tubular injury, and intrarenal vasoconstriction. Risk factors for non-traumatic rhabdomyolysis include certain medications, infections, and toxins. Surgical patients may have multiple risk factors for rhabdomyolysis, including prolonged positioning (especially in non-supine positions), exposure to certain anesthetics (such as propofol), prolonged operative time (&gt;7 hours), and body mass index &gt;50 kg/m<sup>2</sup>. Post-operative rhabdomyolysis has been reported to develop in 1.4–12.9% of patients undergoing bariatric surgery despite operative times &lt;7 hours and supine positioning. A large, prospective study found that procedure time was the only factor significantly correlated with rhabdomyolysis, with risk increasing after 230 minutes, and that initiating IV fluids within 24 hours may prevent AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The urinary fractional excretion of sodium (FENa) has long been used to assist in differentiating prerenal from intrarenal causes of AKI, but studies have shown a wide range of sensitivity and specificity for the test, and it often does not provide a definitive diagnosis. Suspicion for prerenal AKI would be low in this patient without hypotension or history to suggest volume depletion. Furthermore, despite tubular damage and the frequent presence of granular casts in the urine sediment in patients with rhabdomyolysis, the FENa is often low. This might relate to true intravascular volume depletion due to sequestration of fluid in the hyperosmotic environment of necrotic muscle, or to intense renal vasoconstriction, or to a combination of mechanisms. Volume expansion with crystalloids is a mainstay of therapy for rhabdomyolysis, and observations suggest that IV fluids may prevent or ameliorate AKI if delivered early in the course, but fluid administration should not be guided by the FENa.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Muscle injury may be apparent by CT, but measurement of CK is still needed to establish a rapid diagnosis. Kidney ultrasound is not indicated in this patient whose urine is being collected via urinary catheter; moreover, the incidence of in-hospital obstructive AKI is low, and ultrasound is not commonly cost-effective in this setting. Although sepsis can be associated with rhabdomyolysis, this patient has no signs or symptoms of systemic infection.</p>\n</div>",
        "references": []
    },
    "26": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 25-year-old man presents to the nephrology clinic complaining of 2 weeks of urinary frequency. He urinates 8–10 times per day, including multiple times overnight, producing a large amount of urine each time. He has no relevant medical history and notes no changes in weight, vision, or thirst. He takes no medications. He has no urinary symptoms other than the amount and frequency of urination. He reports that his kitchen has been under renovation for 3 weeks; he has been buying most of his meals at convenience stores and fast-food restaurants.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vital signs are unremarkable, with weight 73 kg. Physical exam is normal, with moist oral mucosa and no peripheral edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory studies, including a 24-hour urine collection, are noted below:</span></p>\n<table style=\"font-size: 0.9375rem; border: 1px solid black; width: 75%;\"><tbody><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                 \n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\"><strong>Result</strong></td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\"><strong>Reference Range</strong>\n</td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\"><strong>Serum</strong>\n</td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                 \n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                 \n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Sodium\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                141 mEq/L\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                136–145\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Potassium\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                4.3 mEq/L\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  BUN\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                8–20\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Creatinine\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                1.3 mg/dL\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Glucose\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                110 mg/dL\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Osmolality\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                280 mOsm/kg H<sub>2</sub>O\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                275–295\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\"><strong>Urine</strong>\n</td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                 \n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                 \n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Sodium\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                124 mEq/L\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Potassium\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                22 mEq/L\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Chloride\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                90 mEq/L\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Glucose\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                0 mg/dL\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                0\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Osmolality\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                318 mOsm/kg H<sub>2</sub>O\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                38–1400\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Creatinine, 24-hour\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                1400 mg\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                15–25 mg/kg body weight </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Protein, 24-hour\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                45 mg\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                &lt;100\n            </td></tr><tr><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                  Volume, 24-hour\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                4.2 L\n            </td><td style=\"border-style: solid; border-color: black; padding: 1px 5px; vertical-align: top;\">\n                ≤3             </td></tr></tbody></table><br/><strong>Which of the following is the MOST APPROPRIATE treatment for this patient's polyuria?</strong><br/><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Protein restriction"
            },
            {
                "label": "B.",
                "text": "Fluid restriction"
            },
            {
                "label": "C.",
                "text": "Hydrochlorothiazide"
            },
            {
                "label": "D.",
                "text": "Desmopressin"
            },
            {
                "label": "E.",
                "text": "Sodium restriction"
            }
        ],
        "correct_answer": "Sodium restriction",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with polyuria caused by solute diuresis, the most appropriate treatment is a sodium-restricted diet.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Polyuria is generally defined as &gt;3 L urine output per 24 hours. Polyuria can arise from a water, mixed, or solute diuresis. To distinguish among these possibilities, the first step is to examine the urine osmolality. A water diuresis is suggested by urine osmolality (Uosm) &lt;150 mOsm/kg H<sub>2</sub>O, a mixed diuresis by Uosm 150–300 mOsm/kg H<sub>2</sub>O, and a solute diuresis by Uosm &gt;300 mOsm/kg H<sub>2</sub>O. In this case, the Uosm of 318 mOsm/kg H<sub>2</sub>O suggests a solute diuresis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In addition, 24-hour urinary osmolal excretion &gt;1000 mOsm/day is consistent with a solute diuresis. In this case:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">318 mOsm/kg H<sub>2</sub>O × 4.2 L/day = 1336 mOsm/day</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A standard diet contains 600–900 mOsm/day, which is then excreted by the kidneys to maintain homeostasis. When dietary intake exceeds this amount, water intake increases to maintain serum osmolality and facilitate excretion of excess solute. The combination of high solute and water intake result in a solute diuresis manifested by the clinical symptom of polyuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A solute diuresis can occur when the patient ingests, is administered, or endogenously produces excess solute. Common clinical scenarios include high-protein diets (including supplemental nutrition via gastrostomy tube or total parenteral nutrition), infusions of IV fluid (sodium and chloride or mannitol), resolution of AKI (numerous solutes), and uncontrolled diabetes or sodium-glucose cotransporter type 2 inhibition (glucose). However, this patient takes no medications and does not have diabetes or AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">To determine whether the excess solute load is generated by electrolytes or non-electrolyte sources, it is useful to calculate daily urine excretion of sodium, glucose, and urea. In this case, there is no urine glucose, and urine urea is not provided, but daily urine sodium excretion in this case is:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">124 mEq/L × 4.2 L/day = 521 mEq/day</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The recommended sodium intake (and excretion) is 2 g, or 88 mEq, per day. This patient’s dietary sodium intake is equivalent to 12 g/d and is consistent with his recent consumption of high-sodium fast food.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Protein restriction might be appropriate if a high urine urea were documented. Although urine urea is not measured in this case, it is clear that electrolytes (sodium, potassium, and accompanying anions) account for most of the osmolality of this patient’s urine. Fluid restriction is the treatment for polyuria due to a water diuresis but would not be appropriate management for a solute diuresis. Hydrochlorothiazide and desmopressin have been used to treat nephrogenic and central diabetes insipidus, respectively, but would not be appropriate in this case.</p>\n<p> </p>\n</div>",
        "references": []
    },
    "27": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 26-year-old man presents to clinic for management of X-linked hypophosphatemia (XLH). He was initially diagnosed at age 5 years and was prescribed oral phosphate supplementation and calcitriol. He has been inconsistently adherent to medications over\n    the years and has experienced multiple fractures and dental caries. He describes intermittent muscle weakness, fatigue, stiffness, and pain.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vital signs are normal. His height is at the 6th percentile for his age. Examination is notable for bowing of the legs and a waddling gait.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory studies are as follows:</span></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"60%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8.7 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>25-Hydroxyvitamin D</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>26 ng/mL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>30–60</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1,25-Dihydroxyvitamin D</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>4 pg/mL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>15–60</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>PTH intact</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>106 pg/mL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>10–65 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Burosumab"
            },
            {
                "label": "B.",
                "text": "Sodium phosphate IV"
            },
            {
                "label": "C.",
                "text": "Sodium phosphate PO and calcitriol"
            },
            {
                "label": "D.",
                "text": "No additional management"
            },
            {
                "label": "E.",
                "text": "Calcium carbonate PO and calcitriol"
            }
        ],
        "correct_answer": "Burosumab",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with XLH, hypocalcemia, and hypophosphatemia should receive burosumab, a monoclonal antibody against FGF-23.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">XLH is an X-linked dominant genetic disorder with an incidence of 1 in 20,000 live births. XLH is caused by a loss-of-function mutation in the <em>PHEX</em> (phosphate regulating endopeptidase homolog, X-linked) gene, which normally regulates FGF-23 production. Uncontrolled FGF-23 production, in turn, causes hypophosphatemia (1) by down-regulating sodium phosphate transporters in the proximal tubule and (2) by inhibiting 1α-hydroxylase and stimulating 24α-hydroxylase, thus decreasing 1,25-dihydroxyvitamin D production and consequent intestinal calcium and phosphate absorption. Clinical sequelae of this syndrome relate primarily to hypophosphatemia and include rickets, osteomalacia, bone fractures, and dental disease.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A recent 24-week study demonstrated that burosumab was effective at increasing serum phosphorus, tubular phosphate reabsorption, and 1,25-dihydroxyvitamin D levels; reducing musculoskeletal stiffness; improving physical functioning; and promoting healing of fractures in adults with XLH.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Treatment with sodium phosphate IV is not necessary, and potentially harmful, because administered phosphorus will be excreted, and increased phosphorus flux through the kidneys may dispose to nephrocalcinosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prior to the approval of burosumab, treatment with oral phosphorus and calcitriol was standard of care, but its efficacy was limited by adherence (phosphorus had to be taken up to 5 times per day) and concern for nephrocalcinosis, as noted above.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Withholding additional therapy with burosumab would be inappropriate, as this medication provides significant benefits for adult patients.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Oral calcium is not indicated in this patient, as he has no symptoms specific to hypocalcemia. Similar to treatment with phosphorus and calcitriol, treatment with calcium (especially when paired with calcitriol) increases the risk of nephrocalcinosis and worsening CKD.</p>\n</div>",
        "references": []
    },
    "28": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 63-year-old woman with ESRD due to glomerulonephritis receiving PD presents to the emergency department with diffuse abdominal pain and cloudy PD effluent. Her APD prescription is 4 × 2-L exchanges overnight using a combination of 2.5% and 4.25% dextrose, with a last fill of 1.5 L icodextrin. The patient is anuric.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A dialysate cell count with differential and culture are obtained. Cell count reveals 3294 WBC/μL with 76% neutrophils, and upon return of the cell count 6 hours later, intraperitoneal (IP) vancomycin and ceftazidime are administered.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Repeat effluent cell count after 3 days reveals 640 WBC/μL with 68% neutrophils. The PD culture remains negative, and ceftazidime is discontinued. A course of vancomycin, dose adjusted by concentration, is planned for 2 weeks, along with fluconazole prophylaxis. After 5 days, the patient is still experiencing abdominal pain, and the dialysate effluent remains cloudy. Effluent analysis now shows 965 WBC/μL with 65% neutrophils, and PD catheter removal is scheduled.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY cause of peritonitis treatment failure?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Culture-negative peritonitis"
            },
            {
                "label": "B.",
                "text": "Discontinuing ceftazidime"
            },
            {
                "label": "C.",
                "text": "Delayed antibiotic dosing"
            },
            {
                "label": "D.",
                "text": "No residual renal function"
            },
            {
                "label": "E.",
                "text": "Day 3 cell count >500 WBC/µL"
            }
        ],
        "correct_answer": "Delayed antibiotic dosing",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"> In this patient with persistent signs and symptoms of peritonitis requiring PD catheter removal, the most likely cause of treatment failure is delayed initiation of antibiotics.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Peritonitis treatment failure is loosely defined as failure of peritonitis to improve with appropriate or empiric antibiotic therapy, requiring catheter removal or resulting in death. Delay in the administration of antibiotics is the factor most closely associated with failure of therapy, risk of death, and PD catheter removal. A recent study found that each hour of delay in antibiotic administration from the time of presentation to a hospital facility increases the risk of PD technique failure or death by 6.8%. Although it is customary to base antibiotic therapy on the results of cell count and Gram stain, it may be prudent to initiate empiric antibiotics if these results cannot be obtained in a timely manner, as may be the case depending on when and where the patient presents with symptoms. Some programs provide patients with education and materials so that they can self-administer antibiotics immediately after collecting and saving (refrigerating) effluent for analysis and culture. Although IP antibiotic administration is preferred, IV antibiotics should be administered for initial treatment if IP administration would delay therapy significantly.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Culture-negative peritonitis, along with coagulase-negative staphylococci and streptococci, have a low risk of treatment failure, although data show that catheter removal is still required (as in this case) in 8.5-10% of cases. Moderate-risk (due to <em>Corynebacterium</em>, <em>Staphylococcus aureus</em>, <em>Enterococcus</em>, or non-<em>Pseudomonas</em> gram-negative bacteria) and high risk (due to <em>Pseudomonas</em> species, fungi, or polymicrobial) peritonitis have a 2.63- and 9.64-times risk, respectively, of not achieving antibiotic cure compared with low-risk infections.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Discontinuation of gram-negative antibiotic coverage in culture-negative infections is recommended by the International Society for Peritoneal Dialysis guidelines as long as there is evidence of resolving infection. In this case, improvement in effluent cell count on day 3 justified the withdrawal of gram-negative coverage.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Residual renal function (RRF) actually increases the risk of treatment failure and catheter removal. One study demonstrated that a residual eGFR of &gt;5 mL/min/1.73 m<sup>2</sup> was associated with a 6.8-fold increased risk of treatment failure in gram-positive peritonitis. A lesser degree of RRF (0–5 mL/min/1.73 m<sup>2</sup>) was associated with a 2.87-fold increased risk. The putative mechanism for this increased risk of treatment failure is inadequate antibiotic dosing.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A day 3 cell count threshold of &gt;1090/µL, higher than the 640/µL here, has a 74–75% sensitivity and specificity for predicting treatment failure.</p>\n</div>",
        "references": []
    },
    "29": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 47-year-old woman with stage 4 CKD due to lupus nephritis presents to the emergency department with a 1-day history of left lower quadrant abdominal pain, fever, and diarrhea. She notes no sick contacts. Current medications include mycophenolate mofetil, hydroxychloroquine, and prednisone. A stainless steel intrauterine device (IUD) is in place for contraception.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient’s BP is 100/64 mm Hg, heart rate 102/min, and temperature 38.6°C. On examination, she appears ill. Her lungs are clear, and heart examination reveals regular tachycardia.  Bowel sounds are normal and the abdomen is nondistended, but there is tenderness to palpation and percussion in the left lower quadrant with localized guarding.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                     \n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    WBC count\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    14,600/μL\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    4000–11,000\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    BUN\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    23 mg/dL\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    8–20\n                </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    Creatinine\n                </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    2.2 mg/dL (baseline, 2)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                    0.5–1.1\n                </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong style=\"font-size: 0.9375rem; font-style: normal;\">Which of the following is the NEXT MOST APPROPRIATE diagnostic study?</strong><br/></p>\n</div></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Flat and upright abdominal x-ray"
            },
            {
                "label": "B.",
                "text": "MRI of abdomen and pelvis with IV contrast"
            },
            {
                "label": "C.",
                "text": "CT scan of abdomen and pelvis with IV contrast"
            },
            {
                "label": "D.",
                "text": "MRI of abdomen and pelvis without IV contrast"
            },
            {
                "label": "E.",
                "text": "Abdominal ultrasound"
            }
        ],
        "correct_answer": "CT scan of abdomen and pelvis with IV contrast",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CT scan of the abdomen and pelvis with IV contrast is indicated in this immunocompromised patient presenting with signs and symptoms of a serious intrabdominal problem that may require intervention beyond antibiotic therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Historically, the fear of AKI resulting from exposure to IV contrast with diagnostic radiography has largely been based on uncontrolled observational data or extrapolated from literature describing the risk in patients receiving intra-arterial contrast in the setting of potentially life-threatening acute coronary syndromes. Although prospective randomized controlled trials do not exist, large retrospective studies using propensity score matching have failed to confirm an increased risk of AKI after IV contrast for CT scan. The available data are incomplete because these studies included relatively few numbers of patients with CKD stage 4 and 5. Nevertheless, it appears likely that the risk of contrast-associated AKI (CA-AKI) is lower than traditionally thought. In this case, the benefit of the information gained from a contrast-enhanced imaging study outweighs the uncertain risk of CA-AKI. Many practitioners might prefer to order CT scan of the abdomen and pelvis without IV contrast to avoid any risk for nephrotoxicity. There appears to be little difference in diagnostic accuracy between CT with and without IV contrast for adults undergoing evaluation for acute appendicitis, but accuracy and outcome data are lacking for other intra-abdominal diagnoses, and there are no data on the risk of delay in diagnosis or the harm of radiation exposure if additional imaging could have been avoided by first using IV contrast. The decision regarding use of IV contrast will likely be informed by local expertise, practice, and consultation with radiologic and surgical consultants.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Risk factors for developing CA-AKI include CKD, hypovolemia, and concurrent exposure to nephrotoxins. The strongest prophylactic measure appears to be volume expansion. Both the National Kidney Foundation and the American College of Radiology have recommended CA-AKI prophylaxis via volume expansion with isotonic saline in patients with eGFR &lt;45 mL/min/1.73 m<sup>2</sup>.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Stainless steel IUDs are contraindications to MRI, as they lead to image distortion and torque effects that can be harmful to the patient. Copper IUDs have fewer distortion and safety effects.  Flat and upright abdominal x-rays may be useful to demonstrate an obstructed pattern of bowel gas, a radio-opaque foreign body, or free intraperitoneal air, but are less sensitive than CT for localized abdominal or pelvic pathology. For these reasons, CT of the abdomen and pelvis is the preferred diagnostic study for this patient.</p>\n</div>",
        "references": []
    },
    "30": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 74-year-old woman with a 2-day history of progressive weakness is brought to the emergency department by her family. She has a history of hyperlipidemia, nephrolithiasis, and diarrhea-predominant irritable bowel syndrome. Medications include atorvastatin and loperamide. Review of systems is positive for diarrhea.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 112/64 mm Hg and heart rate 94/min. On physical examination, she has diffuse muscle weakness with hyporeflexia. The abdomen is nontender with sparse bowel sounds. The remainder of the examination is normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Laboratory data reveal the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 60%;\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px; width: 33.3%;\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px; width: 33.3%;\"><b>Result</b></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px; width: 33.3%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\"><span><strong>Serum</strong></span></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Sodium</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">135 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">136–145</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Potassium</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">1.8 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Chloride</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">112 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">98–106</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Total CO<sub>2</sub></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">13 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">23–28</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Creatinine</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">1.3 mg/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Calcium</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">11.9 mg/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">8.6–10.2</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Albumin</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">2.4 g/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Phosphorus</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">0.9 mg/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">3.0–4.5</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">PTH, intact</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">32 pg/mL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">10–65</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\"><span><strong>Urine, random</strong></span></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">pH</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">6.5</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">4.5–8.0</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Sodium</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">39 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">Varies with intake</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Potassium</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">43 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">Varies with intake</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Chloride</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">67 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">Varies with intake</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Creatinine</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">44.1 mg/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">Varies with intake</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 15px;\">Calcium</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">15.4 mg/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 1px 5px 1px 5px;\">Varies with intake</td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 20px;\">Kidney ultrasound reveals bilateral nephrocalcinosis without hydronephrosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><strong>Which of the following is the MOST LIKELY cause of her hypokalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Diarrhea"
            },
            {
                "label": "B.",
                "text": "Primary aldosteronism"
            },
            {
                "label": "C.",
                "text": "Sjögren syndrome"
            },
            {
                "label": "D.",
                "text": "Fanconi syndrome"
            },
            {
                "label": "E.",
                "text": "Primary hyperparathyroidism"
            }
        ],
        "correct_answer": "Primary hyperparathyroidism",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has hypokalemia mediated by renal K wasting, most likely caused by primary hyperparathyroidism (PHPT).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The evaluation of hypokalemia begins with an assessment of renal K handling, which may include measurement of spot or 24-hour urine K or determination of the urine K-to-creatinine ratio (expressed as mEq/g). The transtubular potassium gradient (TTKG) is no longer used because the assumptions underlying its use were found to be invalid. Although spot urine K concentrations may vary with urine volume, their measure is a convenient diagnostic strategy, and accuracy is improved when normalized to creatinine concentration.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, urine K-to-creatinine ratio is 98 mEq/g. In the presence of hypokalemia, a urine K-to-creatinine ratio &lt;15 mEq/g indicates appropriate K conservation. Thus, the cause of this patient’s hypokalemia is inappropriate K urinary potassium excretion. A spot urine K &gt;20–25 mEq/L or a daily K excretion &gt;25–30 mEq also suggests inappropriate renal K excretion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The combination of renal K wasting, non-anion gap metabolic acidosis, positive urine anion gap, and high urine pH is consistent with distal (type 1) renal tubular acidosis (RTA). Distal RTA in this case is most likely caused by hypercalciuria from PHPT, which may be diagnosed on the basis of hypercalcemia and hypophosphatemia with an inappropriately normal serum PTH. Most patients with PHPT have a PTH level that is either elevated or in the upper range of normal. However, occasional cases are reported in which the PTH is in the low-normal range. When hypercalcemia is unrelated to PTH, the serum PTH level is often suppressed below the normal range. Patients with distal RTA from PHPT frequently have a history of nephrolithiasis and nephrocalcinosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Diarrhea would not be the etiology of hypokalemia in this case, in which renal potassium conservation is impaired.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary aldosteronism is a frequent cause of hypokalemia but is characteristically accompanied by hypertension and metabolic alkalosis, which are not present in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sjögren syndrome is a cause of distal RTA but would not explain hypercalcemia and hypophosphatemia. Additionally, this patient has no clinical features to suggest Sjögren syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fanconi syndrome would cause proximal RTA with hypokalemia and hypophosphatemia, but urine pH would not be high, as distal acidification would be intact. Fanconi syndrome would not be expected to cause hypercalcemia unless it was a manifestation of multiple myeloma. Although this disease cannot be excluded by the data presented, a suppressed PTH concentration would be expected as discussed above.</p>\n</div>",
        "references": []
    },
    "31": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 34-year-old woman with a history of long-standing hematuria and non-nephrotic range proteinuria presents to the emergency department 2 days after a left-sided native kidney biopsy. The biopsy was uneventful, her post-procedure vital signs and hemoglobin were unchanged, and no gross hematuria was reported. On the day of presentation, when picking up her toddler from the ground, she experienced sudden, severe, left-sided flank pain that has persisted. She also reports a headache. Her urine has remained clear.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 180/104 mm Hg and heart rate 96/min. On examination, she appears uncomfortable. She has marked left flank tenderness with no bruising and no palpable mass. There is no edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Laboratory studies are notable for hemoglobin 12.1 g/dL (previously 12.6, reference range 12–16) and serum creatinine 1.0 mg/dL (previously 0.9, reference range 0.5–1.1). Platelet count and coagulation parameters are normal. A CT scan reveals a 6-cm subcapsular hematoma around the left kidney.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which ONE of the following is the MOST APPROPRIATE next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Percutaneous drainage of subcapsular hematoma"
            },
            {
                "label": "B.",
                "text": "Surgical capsulotomy and decortication"
            },
            {
                "label": "C.",
                "text": "Administer hydralazine"
            },
            {
                "label": "D.",
                "text": "Administer lisinopril"
            },
            {
                "label": "E.",
                "text": "Observation and repeat hemoglobin"
            }
        ],
        "correct_answer": "Administer lisinopril",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with Page kidney should be treated with lisinopril to manage hypertension.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Page kidney was first described in 1939 by Irving Page, who found that wrapping dog kidneys in cellophane induced acute hypertension. The hypertension is thought to result from microvascular ischemia due to extrarenal compression with subsequent activation of the renin-angiotensin-aldosterone system (RAAS). Some studies have demonstrated increased renin release in the affected kidney with an excellent response to RAAS inhibition, whereas others have suggested that hypertension is caused by acute interstitial nephritis. Because of the limited space between the kidney and the renal capsule, even a small hemorrhage can cause significant compression of the kidney parenchyma. In many cases, the onset of hypertension is gradual, and kidney function may not change if the contralateral kidney is unaffected.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Until the 1970s, most cases of Page kidney were noted in patients with traumatic kidney injury, but in the last several decades, the case mix has changed such that the majority of cases are reported as a consequence of kidney biopsies, particularly in kidney allografts. The largest single-center review of Page kidney reported 26 cases between 1960 and 2010 at the Mayo Clinic (transplant allografts were excluded). In that series, slightly more than 50% of patients presented with flank pain. Overall, 65% of patients required intervention, including nephrectomy (35%), hematoma evacuation (23%), or capsulectomy (15%). Fifty-eight percent of patients required long-term treatment with antihypertensive medications. Other cases series have also reported a relatively high rate of intervention in patients with Page kidney after an allograft biopsy, likely because of higher rates of AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with acute pain and hypertension with an unchanged creatinine and a slightly decreased hemoglobin. Lisinopril would be the best antihypertensive medication given the role of the RAAS in causing hypertension. There is no acute indication for percutaneous drainage or surgical intervention in this case, and the most appropriate treatment would be management of the hypertension and pain along with repeat imaging. Observation alone would be insufficient in this patient with acute, symptomatic hypertension. Because blockade of the RAAS is likely to specifically address the underlying pathophysiology of the hypertension, ACEI administration is preferred for acute management. Hydralazine, while often used to treat elevated BP in emergency departments or inpatient settings, would not be preferred, as its use can induce severe and prolonged hypotension and it does not address the underlying cause.</p>\n</div>",
        "references": []
    },
    "32": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A 54-year-old man with no significant past medical history presented to the emergency department 3 months ago with severe hypertension and hypokalemia. Evaluation for secondary causes of hypertension revealed an elevated ratio of serum aldosterone to plasma renin, and his aldosterone excretion was not suppressed after saline administration. A CT scan of the abdomen was consistent with bilateral adrenal hyperplasia. The patient was diagnosed with primary aldosteronism due to bilateral adrenal hyperplasia and prescribed spironolactone; the dose was gradually titrated to 100 mg daily with resolution of hypertension and hypokalemia.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Three months later, the patient returns to clinic describing bilateral painful gynecomastia. His BP is 126/72 mm Hg. Physical examination reveals bilateral, tender, enlarged breasts with no palpable masses or discharge. Laboratory data show potassium 4.5 mEq/L (reference range, 3.5–5.0), total CO<sub>2</sub> 25 mEq/L (reference range, 23–28), and creatinine 0.9 mg/dL (reference range, 0.7–1.3).</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP to manage gynecomastia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Change spironolactone to eplerenone"
            },
            {
                "label": "B.",
                "text": "Prescribe cabergoline"
            },
            {
                "label": "C.",
                "text": "Refer for surgical mastectomy"
            },
            {
                "label": "D.",
                "text": "Prescribe testosterone"
            },
            {
                "label": "E.",
                "text": "Change spironolactone to lisinopril"
            }
        ],
        "correct_answer": "Change spironolactone to eplerenone",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">The next best step in management for this patient with spironolactone-induced gynecomastia is to change spironolactone to eplerenone.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Spironolactone is a mineralocorticoid receptor antagonist that is used to treat patients with hyperaldosteronism and as an adjunct therapy for patients with heart failure, for whom it has been shown to reduce morbidity and mortality. The use of spironolactone may be limited by adverse effects, including gynecomastia, mastodynia, and decreased libido. At low doses (&lt;50 mg daily), gynecomastia is uncommon, occurring in approximately 10% of cases. However, in doses ≥150 mg daily, the prevalence of gynecomastia is as high as 52%. Note that male breast cancer, while uncommon, should be considered in the differential diagnosis of gynecomastia. However, the presentation is most commonly a painless, unilateral process with overlying skin changes. Bilateral disease accounts for &lt;1%. Thus, in this case of new-onset, bilateral, painful gynecomastia, breast cancer is exceedingly unlikely.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Spironolactone causes gynecomastia by decreasing the ratio of androgens to estrogens. Specifically, spironolactone decreases testosterone production and increases peripheral conversion of testosterone to estradiol, in part by displacing testosterone from steroid hormone-binding globulin. In addition, it binds competitively to androgen receptors, preventing the binding of testosterone and dihydrotestosterone. In contrast, the affinity of eplerenone for androgen receptors is 1/1000 that of spironolactone, so gynecomastia with eplerenone is unusual (0%, versus 12% with spironolactone). In fact, eplerenone has been found to reverse gynecomastia in patients with cirrhosis and hyperaldosteronism. Gynecomastia generally resolves within 3 months of discontinuing spironolactone.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Cabergoline, a prolactin inhibitor, would be inappropriate; the gynecomastia in this case is not caused by excess prolactin.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Surgical referral may be appropriate in patients whose gynecomastia does not resolve with spironolactone discontinuation but would not be the next step in management.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Testosterone supplementation would increase the androgen-to-estrogen ratio but is not the best treatment for spironolactone-induced gynecomastia.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Replacing spironolactone with lisinopril might remove the stimulus for gynecomastia but would not be optimal for a patient with secondary hypertension caused by hyperaldosteronism.</p>\n</div>",
        "references": []
    },
    "33": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 25-year-old man presented to the emergency department 5 days ago with fever, vomiting, and dyspnea. He was admitted to the ICU, and a right internal jugular (IJ) central venous catheter (CVC) was placed for administration of vasopressors.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP is currently 80/42 mm Hg, heart rate 112/min, respiratory rate 22/min, temperature 38.6°C, and body mass index (BMI) 24 kg/m<sup>2</sup>. On examination, he has bilateral, coarse crackles and generalized edema. The right IJ CVC is without erythema, drainage, or tenderness.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His 24-hour urine output was 30 mL of dark urine. A chest x-ray demonstrates bilateral pulmonary opacities and an appropriately positioned right IJ CVC</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory studies are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                93 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient consents to HD. Prior to dialysis access placement, bedside ultrasound of the right IJ vein reveals a catheter-associated thrombus.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the BEST approach to obtain dialysis access?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Place a temporary\ndialysis catheter in the left IJ vein"
            },
            {
                "label": "B.",
                "text": "Place a temporary\ndialysis catheter in the right femoral vein"
            },
            {
                "label": "C.",
                "text": "Exchange the CVC for a temporary dialysis catheter in the right IJ vein"
            },
            {
                "label": "D.",
                "text": "Refer for tunneled dialysis catheter placement in the left IJ vein"
            },
            {
                "label": "E.",
                "text": "Place a temporary\ndialysis catheter in the left subclavian vein"
            }
        ],
        "correct_answer": "Place a temporary\ndialysis catheter in the right femoral vein",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with indications for urgent renal replacement therapy and an existing right IJ CVC complicated by thrombosis should undergo placement of a femoral vein dialysis catheter.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The Cathedia study was a multicenter, randomized trial comparing dialysis access placement sites in 750 patients with AKI in an ICU. Contrary to prior dogma suggesting that femoral lines are associated with higher rates of infection, this study found that there was no difference in colonization rates between femoral and IJ catheters. However, a prespecified subgroup analysis found that patients in the highest BMI tertile (&gt;28.4 kg/m<sup>2</sup>) had a higher risk of infection with femoral versus IJ dialysis catheters. Interestingly, patients in the lowest BMI tertile (&lt;24.2 kg/m<sup>2</sup>) had a lower risk of infection with femoral catheters. A subsequent secondary analysis of this study found that there was a significantly higher rate of catheter malfunction and failure in patients with left IJ catheters (19.5%) compared with right IJ and femoral catheters (6.6% and 10.1%, respectively).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As a result of these and other studies, current KDIGO guidelines recommend the right IJ as the site of choice for non-tunneled dialysis catheters for renal replacement therapy in the ICU, followed by the femoral, left IJ, and subclavian veins. The subclavian veins are generally not used for dialysis access because of the risk of subclavian stenosis. This may decrease the likelihood of successful permanent dialysis access creation in the future. Furthermore, the subclavian vein is incompressible and confers an additional risk of hemorrhage.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A tunneled dialysis catheter would be inappropriate in this patient with AKI and suspected sepsis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Exchanging the implanted CVC for a temporary dialysis catheter in the right IJ vein would not be appropriate at this time because of the risk of clot embolization.</p>\n</div>",
        "references": []
    },
    "34": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 20px;\">A 35-year-old woman with no significant past medical history undergoes pelvic ultrasound as part of an infertility evaluation. Incidental note is made of 2 echogenic lesions in the right kidney. A follow-up MRI of her kidneys reveals the presence of 3\n    bilateral, fat-containing, solid renal masses consistent with angiomyolipomas. The largest lesion measures 3.8 × 3 cm in the upper pole of the right kidney.</p>\n<p dir=\"”ltr”\" style=\"margin-top: 20px; margin-bottom: 20px;\"><strong>Which of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Genetic testing forTSC3gene mutations"
            },
            {
                "label": "B.",
                "text": "Everolimus 5 mg daily to target trough 5–15 ng/mL"
            },
            {
                "label": "C.",
                "text": "Repeat ultrasound during pregnancy"
            },
            {
                "label": "D.",
                "text": "Surgical resection of the angiomyolipoma"
            }
        ],
        "correct_answer": "Surgical resection of the angiomyolipoma",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management is surgical resection of the angiomyolipoma (AML).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">AMLs are benign tumors composed of blood vessels, adipose tissue, and smooth muscle. The prevalence is approximately 2% in the general population, and they are 4 times more common in women. For unclear reasons, they are found more often on the right side. Most of these tumors are slow growing and do not require ablation, embolization, or surgical resection unless they are &gt;4 cm in diameter, are rapidly increasing in size, contain intralesional aneurysms &gt;5 mm in diameter, or are symptomatic (i.e., acute hemorrhage). However, almost all AMLs express estrogen receptors, and approximately 25% of renal AMLs also express progesterone and androgen receptors. Thus, AMLs may grow rapidly in response to exogenous hormonal therapy and during pregnancy. Acute flank pain due to hemorrhage occurs more commonly in pregnancy. Thus, in this case, the patient should be referred for potential excision of the largest lesion before she proceeds with fertility therapy and pregnancy. Alternatives to surgical resection include cryoablation, radiofrequency ablation, and arterial embolization. In general, nonsurgical approaches are reserved for smaller tumors and tumors close to the renal hilum. In this case, the largest lesion is near the size threshold and at high risk to grow during fertility treatment or pregnancy, so surgical resection is indicated. Whether other lesions should be addressed at the same time would depend on their location and size.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tuberous sclerosis complex (TSC) is characterized by the presence of benign tumors in multiple organs, including the brain, kidney, lungs, and liver. TSC results from pathogenic mutations in <em>TSC1</em> or <em>TSC2</em>. The presence of &gt;2 renal angiomyolipomas is one of the major criteria for the clinical diagnosis of TSC but is not sufficient to make a definitive diagnosis. Genetic testing for pathogenic <em>TSC1</em> or <em>TSC2</em> mutations would be reasonable to consider, but in the absence of other clinical criteria for tuberous sclerosis, genetic counseling should precede testing. <em>TSC3</em> is a gene encoding a serine palmitoyltransferase-regulating protein and is not implicated in the development of TSC.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mammalian target of rapamycin (mTOR) inhibitors have been shown to be useful in slowing tumor growth in patients with multiple or unresectable AMLs. However, everolimus both decreases fertility and may cause fetal harm if given during pregnancy, so should be avoided in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Surveillance of the AML with ultrasound during pregnancy would probably detect an enlarging lesion. However, the AML is likely to enlarge during pregnancy in any case, and definitive management would be further complicated during pregnancy. Waiting until the patient is pregnant to repeat imaging risks further growth and rupture of the AML in the meantime.</p>\n</div>",
        "references": []
    },
    "35": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-top: 15px;\">A 65-year-old woman with ESRD is evaluated for anemia. She has been receiving in-center HD thrice weekly for 4 hours per treatment for 6 months. She has a past medical history of type 2 diabetes mellitus, congestive heart failure, hypertension, and hyperlipidemia. Her oral medications include lisinopril, carvedilol, atorvastatin, glipizide, and B/C-complex vitamins. She generally feels well and reports a good appetite.</p>\n<p dir=\"ltr\" style=\"margin-top: 15px;\">Her hemoglobin has been 8–9 g/dL since initiating HD 6 months ago and has not improved despite 10 IV infusions of iron sucrose, for a total dose of 1000 mg, as well as an escalating dose of epoetin alfa IV. Her initial dose of epoetin alfa was 120 units/kg weekly, increasing to 450 units/kg weekly, with minimal change in hemoglobin. Fecal occult blood immunoassay was negative. Upper endoscopy and colonoscopy were unremarkable 3 months ago.</p>\n<p dir=\"ltr\" style=\"margin-top: 15px;\">BP during dialysis is 143/83 mm Hg and heart rate 68/min. Physical examination shows a well-functioning arteriovenous fistula and is otherwise unremarkable except for mild skin pallor. Kt/V is 1.3.</p>\n<p dir=\"ltr\" style=\"margin-top: 15px;\">Other current laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 70%;\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 50%;\"> </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 25%;\"><strong>Result</strong></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 25%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                Hemoglobin\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                8.5 g/dL\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                Mean corpuscular volume\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                75 fL\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                80–98\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                Transferrin saturation (TSAT)\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                36%\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                20–50\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                Ferritin\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                780 ng/mL\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                11–307\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                Folate\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                7.7 ng/mL\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                1.8–9.0\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                Vitamin B<sub>12</sub>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                506 pg/mL\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                200–800\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                Intact PTH\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                300 pg/mL\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                130–585 (dialysis patients)\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                C-reactive protein\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                3 mg/dL\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n                &lt;0.8\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 20px;\"><strong>Which one of the following is the NEXT BEST STEP in anemia management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discontinue lisinopril"
            },
            {
                "label": "B.",
                "text": "Administer epoetin alfa subcutaneously"
            },
            {
                "label": "C.",
                "text": "Prescribe nandrolone decanoate"
            },
            {
                "label": "D.",
                "text": "Increase dialysis time to achieve Kt/V ≥1.4"
            },
            {
                "label": "E.",
                "text": "Refer to hematology"
            }
        ],
        "correct_answer": "Refer to hematology",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p>This patient with erythropoiesis-stimulating agent (ESA) hyporesponsiveness should be referred to hematology and evaluated for other causes of anemia such as hemolysis and hemoglobinopathy, which could include measurement of lactate dehydrogenase and haptoglobin, reticulocyte count, hemoglobin electrophoresis, and examination of a peripheral blood smear. </p>\n<p>KDOQI defines ESA resistance or hyporesponsiveness as inability to achieve a target hemoglobin value in the presence of adequate iron stores with epoetin at a dose of 450 units/kg weekly IV or 300 units/kg weekly subcutaneously within 4–6 months. Causes of ESA resistance include iron deficiency, vitamin B<sub>12</sub> or folate deficiency, occult bleeding, hemolysis, chronic inflammation, inadequate dialysis, severe hyperparathyroidism, malignancy, bone marrow disorders, and hemoglobinopathies. In this case, investigation should continue with evaluation for hemolysis and hemoglobinopathy, which might be suggested by microcytosis in the absence of iron deficiency.</p>\n<p dir=\"ltr\" style=\"margin-top: 15px;\">ACEIs and ARBs may interfere with erythropoiesis by blocking angiotensin II-mediated stimulation of pericapillary fibroblasts and consequently reduce erythropoietin production. These agents have been used to treat mild to moderate cases of post-transplant erythrocytosis. There is no evidence that ACEIs or ARBs reduce the response to exogenous erythropoietin. Discontinuing lisinopril in this patient with elevated BP and a history of congestive heart failure would not be advisable.</p>\n<p dir=\"ltr\" style=\"margin-top: 15px;\">Changing ESA administration from IV to subcutaneous would be expected to result in a 30% lower dose of drug required to maintain a given hemoglobin level but would not treat ESA hyporesponsiveness.</p>\n<p dir=\"ltr\" style=\"margin-top: 15px;\">Androgens were commonly prescribed for anemia in patients with ESRD before the widespread availability of ESAs, but adverse effects such as acne, virilization, priapism, liver dysfunction, injection site pain, hepatocellular carcinoma, and peliosis hepatis (development of blood-filled cavities within the liver) have limited their use. Moreover, androgens have not been shown to reliably improve hemoglobin levels.</p>\n<p dir=\"ltr\" style=\"margin-top: 15px;\">Inadequate dialysis is a possible explanation for ESA resistance, but this patient’s Kt/V of 1.3 is adequate. Moreover, the patient feels well and does not demonstrate other signs or symptoms of inadequate dialysis. Although a higher Kt/V of ≥1.4 is desirable to avoid inadvertent underdosing of dialysis, there is no evidence that increasing the treatment time would improve ESA resistance.</p>\n</div>",
        "references": []
    },
    "36": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-top: 15px;\">A 58-year-old man with a history of diabetes and complete heart block status post pacemaker placement presents to the emergency department for evaluation of fevers and shortness of breath.</p>\n<p>His BP is 138/86 mm Hg and heart rate 102/min. Examination demonstrates elevated jugular venous pressure, crackles at both lung bases, and 2+ pitting lower extremity edema.</p>\n<p dir=\"ltr\" style=\"margin-top: 15px;\">Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 80%;\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding:  5px; width: 25%;\">\n<p><strong> </strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding:  5px; width: 25%;\">\n<p><strong>Admission</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding:  5px; width: 25%;\">\n<p><strong>Hospital Day 5</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding:  5px; width: 25%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>4.5 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>BUN</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>69 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>81</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>3.8 mg/dL (baseline 1.2)</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>5.4</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>C3</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>39 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>100–233</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>C4</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>23 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>14–48</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>ANA</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>Negative</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>≤1:40</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>ANCA</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>1:320</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>&lt;1:20</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>Urine protein-to-creatinine ratio</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>2.5 mg/mg</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px;\">\n<p>&lt;0.2</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 15px;\">The urine sediment is notable for acanthocytes, RBC casts, and granular casts. Blood cultures are positive for methicillin-resistant <em>Staphylococcus aureus</em>. Echocardiogram shows vegetations on the intracardiac pacemaker leads.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">On hospital day 5, a kidney biopsy (shown below) demonstrates crescentic and necrotizing glomerulonephritis with mesangial and endocapillary hypercellularity and C3 deposition. EM reveals subepithelial electron-dense deposits appearing\n    as humps.</p>\n<div style=\"margin-bottom: 15px; max-width: 960px; width: 75%;\">\n<figure style=\" display: inline-block; align: left; vertical-align: top;\">\n<figcaption><br/></figcaption><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q36-ksapv7m1-figa.png\" width=\"100%\"/>\n</figure>\n<figure style=\" display: inline-block; vertical-align: top;\">\n<figcaption><br/></figcaption><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q36-ksapv7m1-figb.png\" width=\"100%\"/>\n</figure>\n<figure style=\" display: inline-block; vertical-align: top;\">\n<figcaption><br/></figcaption><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q36-ksapv7m1-figc.png\" width=\"50%\"/>\n<p><em>Images courtesy of Clin J Am Soc Nephrol 15(4): 2020 and Mark Birkenbach, MD.</em> Light microscopy: periodic acid-Schiff staining; IF: C3 staining. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><strong>In addition to vancomycin IV, which of the following is the MOST APPROPRIATE treatment?</strong></p>\n</figure></div></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Methylprednisolone"
            },
            {
                "label": "B.",
                "text": "No additional therapy"
            },
            {
                "label": "C.",
                "text": "Cyclophosphamide"
            },
            {
                "label": "D.",
                "text": "Rituximab"
            },
            {
                "label": "E.",
                "text": "Plasma exchange"
            }
        ],
        "correct_answer": "No additional therapy",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with bacteremia and a kidney biopsy consistent with infection-related glomerulonephritis (IRGN), treatment of the infection alone is the preferred therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy is indicated in patients with decreased kidney function and an active urine sediment to identify the cause of glomerulonephritis, particularly those who will require immunosuppression. In IRGN, not only is immunosuppression not indicated, it could be harmful, allowing the infection to progress. There is no known role for plasma exchange in managing IRGN.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><em>Staphylococcus</em> remains the most frequent causative organism in IRGN in the developed world. It is up to 3 times more common in elderly patients, particularly those with cardiac devices such as pacemakers or prosthetic valves. Other risk factors include diabetes, malignancy, immunosuppression, and alcohol or IV drug use. Commonly, patients present with nephritic syndrome, heavy proteinuria that may reach the nephrotic range, and new-onset heart failure. Hypocomplementemia is common, with 35–80% of patients demonstrating low C3, low C4, or both. The most common biopsy finding is diffuse, necrotizing, crescentic glomerulonephritis with mesangial endocapillary hypercellularity and C3 immune complexes demonstrated by immunofluorescence.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ANCA positivity has been reported in up to 24% of patients with IRGN. Immunosuppressive therapy has not been found to benefit patients without ANCA positivity. Patients with IRGN and positive ANCA have a high rate of mortality (25%) and progressive CKD. Patients who, despite effective treatment of infection, demonstrate persistence or progression of kidney injury due to ongoing IRGN, may be candidates for immunosuppression. In this case, it would be premature to add immunosuppression before antibacterial therapy has had an opportunity to succeed.</p>\n</div>",
        "references": []
    },
    "37": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 65-year-old woman with a history of acute myeloid leukemia treated with cytarabine and daunorubicin, followed by an allogenic hematopoietic cell transplantation 1 month ago, presents with 4 days of gross hematuria, dysuria, and suprapubic\n    discomfort. She does not report changes in urine volume, fever, chills, flank pain, or diarrhea. She has no pets and has not traveled outside of the United States.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, her BP is 150/72 mm Hg, heart rate is 80/min, respiratory rate is 15/min, and she is afebrile. She appears well, with moist oral mucosa and no thrush. The lungs are clear, and there is no abdominal or flank tenderness and no peripheral\n    edema. She has no skin rashes, bruising, or petechiae.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">A non-contrast CT scan reveals no masses, stones, or hydronephrosis. Cystoscopy reveals diffuse oozing from the bladder mucosa without blood clots.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; 30%;\">\n<strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6500/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.1 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                145,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Prothrombin time\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 s\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11–13\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Partial thromboplastin time\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                33 s\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25–35\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                139 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                104 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                32 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">UA is notable for &gt;50 RBC/HPF. Urine microscopy shows numerous isomorphic RBCs, rare WBCs, and no casts. Urine culture is negative after 48 hours.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following diagnostic tests is MOST likely to reveal the cause of this patient’s hematuria?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Serum CMV DNA"
            },
            {
                "label": "B.",
                "text": "Serum C3 and C4"
            },
            {
                "label": "C.",
                "text": "Urine mycobacterial culture"
            },
            {
                "label": "D.",
                "text": "Serum BK virus DNA"
            },
            {
                "label": "E.",
                "text": "Urine schistosomiasis antigen"
            }
        ],
        "correct_answer": "Serum BK virus DNA",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hemorrhagic cystitis after stem cell transplantation most likely has BK virus infection.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hemorrhagic cystitis, an early complication after hematopoietic stem cell transplantation, is usually caused by viral infections or components of the stem cell conditioning regimen that are toxic to the bladder mucosa (e.g., cyclophosphamide). It typically manifests as gross hematuria, which can be severe, and may include symptoms of cystitis (dysuria, urinary frequency, urgency, and suprapubic discomfort). BK polyomavirus is the most common cause of hemorrhagic cystitis in hematopoietic stem cell recipients, and BK virus testing can be performed on either urine or serum. Higher serum BK viral loads are associated with increased severity of hemorrhagic cystitis as well as kidney outcomes. In addition to hemorrhagic cystitis, infection with BK polyomavirus may cause ureteral obstruction or BK virus nephropathy (BKVN), characterized by acute tubulointerstitial nephritis. BKVN is most commonly seen in kidney transplant recipients and is an important cause of kidney dysfunction and allograft loss.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A urine mycobacterial culture could be obtained if there is concern for a <em>Mycobacterium</em> <em>tuberculosis</em> genitourinary tract infection. This patient has a negative urine culture despite having symptoms of cystitis, which may prompt investigation for alternative causes of cystitis symptoms. However, this patient has no other signs of disseminated tuberculosis, such as hemoptysis, prolonged fever, night sweats, weight loss, or hepatosplenomegaly, and no known exposures, making this diagnosis much less likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CMV would be an unusual cause of hemorrhagic cystitis in a hematopoietic cell transplant recipient. More typical CMV-related syndromes in immunocompromised hosts include fever, cytopenia, pneumonitis, enteritis, retinitis, and interstitial nephritis. Hemorrhagic cystitis is much more likely to be caused by BK virus or adenovirus.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Testing serum complement levels and performing other serologic studies such as anti-GBM antibody and ANCA tests are important in the assessment of gross hematuria when glomerulonephritis is suspected. In this patient, the urine microscopy findings, as well as the oozing observed from the bladder mucosa, point to a nonrenal source of hematuria, decreasing the utility of such serologic testing.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Genitourinary schistosomiasis, caused by <em>Schistosoma haematobium,</em> often manifests with microscopic or gross hematuria. However, this patient has had no travel to areas in which <em>S. haematobium</em> is endemic, so schistosomiasis would be unlikely.</p>\n</div>",
        "references": []
    },
    "38": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 32-year-old woman is evaluated for potential kidney donation to her sister. She does not have any chronic medical conditions; her only medication is an over-the-counter multivitamin. Her physical examination is normal. Her BP is 120/78 mm Hg and heart rate 72/min, and she weighs 58 kg.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 40%;\"><br/></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                141 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                4.7 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                106 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                BUN</td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                10 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                0.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                0.5–1.1\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 20px;\"><strong>Which of the following is the BEST initial method for estimating her GFR?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Abbreviated Modification of Diet in Renal Disease (MDRD)"
            },
            {
                "label": "B.",
                "text": "Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI)"
            },
            {
                "label": "C.",
                "text": "Iothalamate I-125 GFR"
            },
            {
                "label": "D.",
                "text": "Cockcroft-Gault"
            }
        ],
        "correct_answer": "Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI)",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best initial method to estimate this patient’s GFR is the CKD-EPI formula.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The MDRD equation was developed in 1999 in patients with non-diabetic CKD and proteinuria who were part of a randomized study on the effects of dietary protein restriction and BP control on CKD progression. The original equation had six variables (age, sex, race, creatinine, albumin, and BUN) but was reduced to four variables in 2000. In 2006, the equation was revised for use with standardized creatinine measurements. The 2006 MDRD equation was found to be more accurate than the Cockcroft-Gault equation, with more patients’ eGFR within 30% of measured GFR by iothalamate clearance (83% versus 69%).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The CKD-EPI equation was derived in a more diverse population, including patients without CKD. Although the overall accuracy of CKD-EPI versus MDRD is similar, it performs better in people with higher GFR, particularly GFR ≥90 mL/min/1.73 m<sup>2</sup>. Conversely, in patients with GFR 15–29 mL/min/1.73 m<sup>2</sup>, MDRD may predict actual GFR better than CKD-EPI. In a meta-analysis of 12 studies including nearly 13,000 patients, the overall bias was smaller for the CKD-EPI creatinine equation than the MDRD equation in patients with a higher eGFR but larger at a lower eGFR. Both equations previously used race as a factor in the estimation equation, but a joint statement by the National Kidney Foundation and the American Society of Nephrology in 2022 recommended against the use of race in estimation equations. Many labs no longer report a race-based eGFR and race is no longer a required variable for web-based calculators. Lastly, the inclusion of cystatin C with creatinine to estimate eGFR has been demonstrated to increase accuracy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although measurement of GFR by methods such as iothalamate I-125 is the gold standard, this is an expensive, cumbersome technique not readily available at most centers. Therefore, it is not commonly used as the initial method for assessment of GFR. Rather, it is more often used when results of estimation equations are borderline or the prospective donor is of extreme age or size, or has other characteristics that might make the prediction equation less reliable.</p>\n</div>",
        "references": []
    },
    "39": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 63-year-old woman with ESRD due to diabetic kidney disease received a deceased donor kidney transplant 3 months ago and presents today for a routine post-transplant clinic visit. She received induction immunosuppression with alemtuzumab and is currently prescribed a maintenance regimen of tacrolimus, mycophenolate, and prednisone. Her hospital course was complicated by post-operative non-ST elevation myocardial infarction, for which she was prescribed atorvastatin, aspirin, and clopidogrel. Additional medications include amlodipine, trimethoprim-sulfamethoxazole, atorvastatin, valganciclovir, and supplemental magnesium.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, her BP is 128/74 mm Hg and heart rate 74/min. She has a well-healed right lower quadrant abdominal incision and no peripheral edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.3 mg/dL (post-transplant nadir, 1.1)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.0 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                PTH, intact\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                346 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–65\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP to manage this patient’s hypercalcemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Calcitriol"
            },
            {
                "label": "B.",
                "text": "Pamidronate"
            },
            {
                "label": "C.",
                "text": "Subtotal parathyroidectomy"
            },
            {
                "label": "D.",
                "text": "Cinacalcet"
            },
            {
                "label": "E.",
                "text": "Furosemide"
            }
        ],
        "correct_answer": "Cinacalcet",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step to manage this patient’s hypercalcemia attributed to persistent secondary hyperparathyroidism (SHPT) is cinacalcet.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cinacalcet, a calcimimetic that increases the sensitivity of the calcium-sensing receptor (CaSR) in the parathyroid chief cells, is the best initial treatment for patients with moderate asymptomatic hypercalcemia due to persistent hyperparathyroidism after kidney transplantation. Although a successful kidney transplant typically corrects metabolic abnormalities such as hyperphosphatemia that serve as the stimulus for excessive PTH secretion, SHPT often persists after transplantation, leading to hypercalcemia and hypophosphatemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cinacalcet is generally the first therapy for asymptomatic mild to moderate hypercalcemia caused by persistent SHPT. Treatment with cinacalcet effectively lowers serum calcium, raises serum phosphorus, and improves PTH in most cases. Because cinacalcet also activates the CaSR on the basolateral cell surface in the loop of Henle, causing calcium excretion, there has been a theoretical concern that the use of this agent in patients with near-normal kidney function can result in progressive calcium loss (i.e., from bone stores) and negative calcium balance. Conversely, by decreasing PTH secretion, cinacalcet may attenuate calcium excretion. Small studies have shown improved bone mineral density with cinacalcet in the post-transplant population.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Subtotal parathyroidectomy may be more effective in the correction of calcium and phosphorus caused by persistent SHPT or tertiary hyperparathyroidism. However, in most cases, surgical parathyroidectomy is reserved for patients with moderate to severe or symptomatic hypercalcemia, particularly if it is refractory to cinacalcet therapy or associated with allograft dysfunction. Moreover, surgery would carry an increased risk of bleeding in this patient who must continue taking aspirin and clopidogrel, and ideally would be delayed until these medications may be safely discontinued.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although calcitriol is commonly used to treat SHPT in patients with CKD or ESRD, it would not be appropriate for this patient with a functioning allograft and hypercalcemia; calcitriol would further increase gastrointestinal calcium absorption and increase the risk for hypercalcemia and kidney stones.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bisphosphonates such as pamidronate lower calcium levels but are not routinely given to transplant recipients when persistent hyperparathyroidism is the cause of their hypercalcemia. Although bisphosphonates would be expected to stabilize the bone and forestall further calcium mobilization, they would not address persistent renal calcium and phosphorus loss.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Loop diuretics such as furosemide can be used to lower serum calcium by enhancing urinary calcium excretion but would worsen total body calcium loss. In addition, loop diuretics would be expected to cause hypovolemia and worsening allograft function.</p>\n</div>",
        "references": []
    },
    "40": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 75-year-old woman with atrial fibrillation and colonic adenocarcinoma status post partial colectomy and colostomy is evaluated for AKI in nephrology clinic. She was recently admitted for AKI that improved with IV fluids. Her ostomy output has been copious;\n    she empties the colostomy bag 15–20 times per day despite taking loperamide 2 mg of twice daily.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 94/65 mm Hg and heart rate is 110/min. On physical examination, the patient is in no acute distress and has slightly dry mucous membranes. Abdominal exam shows a soft abdomen with normoactive bowel sounds and a right lower quadrant ostomy containing\n    watery brown liquid stool.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span><span style=\"\">Laboratory data are as follows: </span> </span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>4 Months Ago</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>1 Month Ago (Hospital Admission)</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Current Value</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>135 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>142</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>136</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>4.1 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>4.2</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>4.0</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>28 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>22</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>17</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>15 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>28</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>41</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>2.1</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.1</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Urine microscopy is shown below.</p>\n<figure><img alt=\"Urine Microscopy\" class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q40-ksapv7m1.png\" width=\"75%\"/><br/>\n<figcaption><em>40x magnification. Image courtesy of Kenneth Ralto, MD, University of Massachusetts Medical School.</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase loperamide dose and frequency"
            },
            {
                "label": "B.",
                "text": "Sodium bicarbonate 650 mg PO 4 times daily"
            },
            {
                "label": "C.",
                "text": "0.9% Saline IV"
            },
            {
                "label": "D.",
                "text": "0.45% Saline with 100 mEq/L of sodium bicarbonate IV"
            },
            {
                "label": "E.",
                "text": "Lactated Ringer's solution IV"
            }
        ],
        "correct_answer": "Lactated Ringer's solution IV",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with AKI attributed to acute tubular necrosis (ATN) from hypovolemia related to high output from her colostomy should be admitted to the hospital for IV fluid resuscitation with a balanced crystalloid solution and colorectal surgery consultation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">For patients who have undergone recent ileostomy creation, the 30-day readmission rate for hypovolemia and AKI is 17%. Ostomy output &gt;1.5 L/day may cause AKI, hyponatremia, hypomagnesemia, and metabolic acidosis. Approximately 16% of patients with small bowel stoma have high-output ostomies requiring medical management, and 27% of these patients eventually require parenteral saline administration or surgical revision. Patients who cannot maintain adequate hydration or electrolyte balance require hospitalization for IV fluid resuscitation. Most colostomies, except proximal excisions, are less prone than ileostomies to complications of high output.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Conservative management of high-output ostomies include antimotility agents (loperamide, diphenoxylate/atropine, tincture of opium) and bulking agents (psyllium fiber). Dietary changes such as increasing salt intake; ingesting small, frequent meals; and limiting sugar intake can also slow gut motility and decrease ostomy output. Ostomy creation in the proximal 100 cm of jejunum can produce output greater than is feasible to counteract via oral intake.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Starting loperamide or psyllium fiber with outpatient follow-up would not be appropriate, because this patient has recurrent AKI from ATN with a recent admission for the same problem. Adding sodium bicarbonate would be appropriate to correct her metabolic acidosis from losses of bicarbonate through her ostomy but would not address the AKI or high ostomy output. In addition, oral bicarbonate supplementation may be inadequate to correct the metabolic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The choice of resuscitation fluid remains an area of investigation, but increasingly, evidence points to the use of a balanced fluid such as lactated Ringer’s solution as a preferred option. Although not specifically studied in the case of excessive fluid loss from an ostomy, balanced solutions have been associated with lower rates of AKI and less metabolic acidosis when compared with isotonic saline. Half-isotonic saline with sodium bicarbonate 100 mEq/L is a hypertonic solution (154 mEq/L from 0.45% saline + 200 mEq/L from addition sodium and bicarbonate = 354 mEq/L) that has not been evaluated for safety or efficacy.</p>\n</div>",
        "references": []
    },
    "41": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 63-year-old man is evaluated in the outpatient clinic for CKD stage 4 due to diabetes and hypertension. He has no concerns except for an intermittent headache and occasional pruritis that is managed with topical medications. His home BP log shows readings of 140–150/85–95 mm Hg. Current medications include lisinopril, carvedilol, furosemide, amlodipine, and insulin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">His current BP is 154/88 mm Hg and heart rate 84/min. Recent laboratory data are significant for a creatinine of 3.95 mg/dL (reference range, 0.7–1.3) with an eGFR of 16 mL/min/1.73 m<sup>2</sup>. The patient is scheduled to have a brachiocephalic arteriovenous fistula (AVF) created this week.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following are the MOST LIKELY changes that will occur after AVF creation?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase in mean arterial pressure and decrease in systemic vascular resistance"
            },
            {
                "label": "B.",
                "text": "Decrease in mean arterial pressure and decrease in systemic vascular resistance"
            },
            {
                "label": "C.",
                "text": "Decrease in cardiac output and increase in systemic vascular resistance"
            },
            {
                "label": "D.",
                "text": "Decrease in cardiac output and decrease in systemic vascular resistance"
            }
        ],
        "correct_answer": "Decrease in mean arterial pressure and decrease in systemic vascular resistance",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p>Creation of an AVF will lead to a decrease in systemic vascular resistance (SVR) and mean arterial pressure (MAP).</p>\n<p>Creation of an AVF leads to several changes in hemodynamics. There is a drop in SVR due to the diversion of blood from the arterial system to the lower-resistance venous system. Additionally, the increased shear stress on the endothelium from high blood flow through the AVF leads to local release of vasodilators such as nitric oxide. This decrease in SVR leads to a compensatory increase in cardiac output due to increases in contractility and heart rate. Because of these changes, there is also increased venous return to the right side of the heart, which increases pulmonary artery pressure. The degree of these hemodynamic changes is related to the flow through the AVF, with upper arm AVFs (brachiocephalic and brachiobasilic) generally having higher flow rates and more significant hemodynamic changes than forearm AVFs (radiocephalic).</p>\n<p>Because of the decrease in overall SVR and release of vasodilators, the placement of an AVF usually leads to a decrease in MAP. A meta-analysis showed an average decrease in MAP of 6.6 mm Hg after AVF creation. Conversely, when an existing AVF was ligated, an increase in MAP of 3.7 mm Hg was observed.</p>\n</div>",
        "references": []
    },
    "42": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 33-year-old woman with granulomatosis with polyangiitis (GPA) involving her kidneys, upper respiratory tract, and sinuses is referred for treatment. Induction immunosuppression with rituximab and corticosteroids is planned.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p><table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aspartate aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                93 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B core antibody (total)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Positive\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B surface antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B surface antigen\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B DNA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following options is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Repeat hepatitis serologies"
            },
            {
                "label": "B.",
                "text": "Proceed with immunosuppression"
            },
            {
                "label": "C.",
                "text": "Hepatitis B immune globulin"
            },
            {
                "label": "D.",
                "text": "Prophylactic antiviral therapy"
            },
            {
                "label": "E.",
                "text": "Hepatitis B vaccination"
            }
        ],
        "correct_answer": "Prophylactic antiviral therapy",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient should receive prophylactic antiviral therapy directed against hepatitis B virus (HBV) prior to treatment with rituximab and high-dose corticosteroids.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The risk of HBV reactivation after the use of B-cell depleting agents or moderate- to high-dose prednisone for &gt;4 weeks is &gt;10% in patients positive for either hepatitis B surface antigen (HBsAg) or core antibody. High dose prednisone is generally considered to be &gt;20 mg/d. Prophylactic antiviral therapy for HBV is recommended prior to initiating immunosuppression with rituximab to prevent HBV reactivation, which can lead to severe or fatal liver disease. Entecavir, dose-adjusted for kidney function, is one possible choice. Anti-HBV prophylactic therapy should be continued for at least 12 months after the last dose of rituximab. A discussion with a hepatologist should be undertaken prior to discontinuation of prophylactic therapy. The use of anti-hepatitis B immunoglobulin and vaccination for hepatitis B are not established as effective methods for the prevention of HBV reactivation in this setting. Serum HBV DNA and liver function tests should be monitored at regular intervals after initiation of immunosuppression and HBV prophylaxis but repeating the serologic profile before therapy would not affect the approach to management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In contrast to rituximab and corticosteroids, antimetabolites such as azathioprine or methotrexate pose a lower risk of reactivation (&lt;1%) in patients with positive HBsAg or positive HBV core antibody.</p>\n</div>",
        "references": []
    },
    "43": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">\n    A 20-year-old woman was diagnosed with minimal change disease (MCD) 9 months ago after she presented with sudden onset of lower extremity swelling. She had no past medical history and took no medications. Her review of systems was negative except for swelling and foamy urine. Kidney biopsy showed preserved interstitium with 42 normal-appearing cortical and juxtamedullary glomeruli per section on light microscopy. IF was normal, and EM showed diffuse foot process effacement. She had disease remission within 3 weeks of starting prednisone at 1 mg/kg/day but relapsed with every attempt to taper her corticosteroid dose below 30 mg/day, requiring resumption of prednisone at that dose to maintain remission. Current symptoms include weight gain, facial acne eruptions, insomnia, and mood changes. Her medications are prednisone 30 mg daily, calcium carbonate 1200 mg daily, vitamin D3 1000 units daily, and trimethoprim-sulfamethoxazole double strength three times each week.</p>\n<p>Her BP is 136/84 mm Hg and weight 72 kg. Examination reveals a Cushingoid appearance. There is no edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory results include the following:</span></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"60%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>At Diagnosis</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>At Present</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>WBC count</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>6000/µL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>9000</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4000-11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Serum creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.7 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.8</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Serum albumin</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>2.0 g/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4.0</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Urine protein-to-creatinine ratio</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>10 mg/mg</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.2</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>&lt;0.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>ANA</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1:20</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1:40</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>≤1:40</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following options is the BEST NEXT step in management of this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Change prednisone to 60 mg every other day"
            },
            {
                "label": "B.",
                "text": "Repeat kidney biopsy"
            },
            {
                "label": "C.",
                "text": "Continue current prednisone dose"
            },
            {
                "label": "D.",
                "text": "Initiate tacrolimus"
            },
            {
                "label": "E.",
                "text": "Initiate cyclophosphamide"
            }
        ],
        "correct_answer": "Initiate tacrolimus",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tacrolimus is the most appropriate next step to manage this patient with steroid-dependent nephrotic syndrome (SDNS) due to MCD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nephrotic syndrome due to MCD is defined as steroid-sensitive if it remits with corticosteroid therapy. It can then be further defined as frequently relapsing nephrotic syndrome (FRNS) if there are 3 or more relapses over 1 year. SDNS is defined by relapses during the corticosteroid taper or within 2 weeks of completing a taper. A steroid-sparing approach is required for patients with either FRNS or SDNS who are at risk for or already experiencing significant steroid toxicity. A variety of immunosuppressive agents have been trialed in this setting, including calcineurin inhibitors (CNIs), cyclophosphamide, rituximab, mycophenolate mofetil, and others. Of these, CNIs and cyclophosphamide have the most reported experience.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cyclophosphamide is often effective in maintaining remission in FRNS or SDNS, but concerns about cumulative toxicity in a young patient, especially gonadal toxicity, make cyclophosphamide a less favorable choice.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Independent of immunosuppressive effects, CNIs such as tacrolimus or cyclosporine have direct antiproteinuric effects by stabilizing the actin cytoskeleton in podocytes. Either agent is typically given concurrently with a lower dose of prednisone that is subsequently very slowly tapered to a minimal maintenance dose. CNI therapy is usually tapered to the minimum dose that maintains remission and then continued for up to 2 years. Although CNI adverse effects can be significant, including CKD, the maintenance dose is generally low enough that adverse effects are tolerable.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although alternate-day prednisone may be associated with fewer adverse effects in children, this approach in adults has not resulted in either a better response or a reduction in adverse effects. Because this patient already experiences substantial glucocorticoid adverse effects, changing to every other day dosing or continuing the current dose of prednisone would not be the best approach.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A repeat kidney biopsy may have been indicated if there were no response to corticosteroid therapy or if the initial biopsy sampled few glomeruli, raising the possibility of unsampled focal segmental glomerulosclerosis. In this case, the biopsy sampled a large number of glomeruli, and the disease is clearly steroid-responsive. Other indications for repeat kidney biopsy might include an unexplained decline in kidney function or an active sediment.</p>\n</div>",
        "references": []
    },
    "44": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 68-year-old man with ESRD due to type 2 diabetes and hypertension presents to the outpatient clinic for management of CAPD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">He has been feeling well and performing PD without difficulty. He noticed that his exit site is erythematous and some drainage has been present on the dressing. He does not recall any trauma to the area. The PD effluent has remained clear. He applies mupirocin cream to the exit site daily.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, he appears healthy. His BP is 142/75 mm Hg, heart rate 78/min, and temperature 37°C. The abdomen is soft and nontender. The PD catheter exit site is erythematous, and some swelling and crusting around the catheter is observed (see image).\n    It is tender to palpation, and a purulent discharge can be easily expressed. There is no erythema or tenderness over the catheter tunnel.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">A swab of the exit site drainage is sent to the laboratory for Gram stain, culture, and sensitivity. Analysis of the PD effluent after a 2-hour dwell yields a cell count of 26/μL.</p>\n<figure><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q44-ksapv7m1.png\" width=\"90%\"/>\n<figcaption><em>Image courtesy of Adam Segal, MD, Lahey Hospital</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-top: 20px; margin-bottom: 15px;\"><b>Which of the following is the next best step in management?<b></b></b>\n</p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Apply silver nitrate topically"
            },
            {
                "label": "B.",
                "text": "Change mupirocin to gentamicin topically daily"
            },
            {
                "label": "C.",
                "text": "Prescribe clindamycin PO for 14 days"
            },
            {
                "label": "D.",
                "text": "Remove and reinsert PD catheter"
            },
            {
                "label": "E.",
                "text": "Prescribe cephalexin PO for 5 days"
            }
        ],
        "correct_answer": "Prescribe clindamycin PO for 14 days",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has a PD exit site infection (ESI) without evidence of peritonitis and should be treated with an antibiotic with coverage against <em>Staphylococcus aureus </em>for at least 2 weeks.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ESI is diagnosed by the presence of erythema, swelling, tenderness, and purulent drainage at the PD catheter exit site. Tunnel infection and peritonitis must be excluded, as was done in this case. Once ESI is diagnosed, the patient should receive at least 2 weeks of oral antibiotics with coverage against <em>Staphylococcus aureus</em>, such as trimethoprim-sulfamethoxazole, clindamycin, or cephalexin, although newer guidelines suggest that treatment can be shortened to 7–10 days if the infection has resolved at 1 week. Three weeks of treatment may be required if <em>Pseudomonas</em> infection is suspected or proven.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prophylaxis against ESI includes cleaning the exit site at least twice weekly and applying an antibiotic cream, such as mupirocin or gentamicin, to the site daily. Current guidelines do not recommend any one antibiotic over another for prophylaxis, and changing mupirocin to gentamicin would not appropriately treat the ESI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Silver nitrate has been used to treat granulation tissue around an exit site, although evidence for its use is anecdotal, but this therapy would not treat ESI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Removal and reinsertion of the PD catheter may be done in cases of refractory ESI but would not be indicated for this first instance of ESI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cephalexin would be an appropriate antibiotic choice, but 5 days would be insufficient for ESI treatment.</p>\n</div>",
        "references": []
    },
    "45": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 65-year-old woman with atrial fibrillation, congestive heart failure with an ejection fraction of 35%, and ESRD due to diabetic nephropathy has acute-onset dysarthria and headache 2 hours after starting her dialysis treatment. Her dialysis prescription includes treatment time of 4 hours, blood flow of 450 mL/min via a left upper arm arteriovenous fistula (AVF), 15-gauge fistula needles, 3 mEq/L potassium dialysate, target weight 70 kg, and a 2000-unit bolus of heparin followed by 500 units/h. Her dialysis treatment is terminated, and she is sent to the emergency department for further management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, her BP is 175/80 mm Hg, pulse 80/min, and respiratory rate 16/min. Lungs are clear to auscultation bilaterally. Cardiovascular examination reveals a 2/6 systolic murmur and an S3, which were present on a previous exam. Her AVF has a palpable thrill and audible bruit. Needle sites are covered with gauze and self-adherent elastic wrap, and there is no active bleeding. Neurologic exam shows slurred speech and right upper extremity weakness with 3/5 power proximally; there were no focal neurologic findings prior to dialysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pre-dialysis laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                60 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                International normalized ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.13\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Partial thromboplastin time\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 s\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25–35\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CT scan of the brain without contrast shows no signs of acute hemorrhage, midline shift, or mass effect. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">The time between onset of symptoms and the present is 2.5 hours.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is next BEST STEP in management?</strong></p>\n<p><br/></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Half-dose recombinant tissue-type plasminogen activator (tPA)"
            },
            {
                "label": "B.",
                "text": "Resume intermittent hemodialysis"
            },
            {
                "label": "C.",
                "text": "MRI of the brain without contrast"
            },
            {
                "label": "D.",
                "text": "Standard-dose recombinant tissue-type plasminogen activator"
            },
            {
                "label": "E.",
                "text": "Supportive care"
            }
        ],
        "correct_answer": "Standard-dose recombinant tissue-type plasminogen activator",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with signs and symptoms of an acute stroke and should be given standard dose recombinant tPA fibrinolytic therapy in the absence of absolute contraindications.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is controversy regarding the administration of tPA and bleeding risks among patients with ESRD presenting with symptoms of stroke, because of a suspected high bleeding risk. However, patients with ESRD and stroke appear to have a significantly higher mortality compared with those without ESRD (10% versus 4%). Despite IV heparin use with dialysis, this patient has normal coagulation parameters, is presenting within the accepted time “window” of 4.5 hours from symptom onset, and has no signs of acute intracranial hemorrhage, so she is a candidate to receive tPA. Although arterial puncture at a noncompressible site within 7 days is a contraindication to the use of tPA, recent access of a dialysis AVF does not preclude thrombolytic use.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Alternative tPA dosing regimens have not been studied among patients with advanced CKD or ESRD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MRI of the brain would be appropriate after the administration of tPA but delaying tPA for further imaging could compromise the effectiveness of thrombolysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Performing intermittent HD to normalize BP may affect cerebral perfusion pressure. At present, there are no urgent indications for HD in this patient who appears euvolemic. Continuous renal replacement therapy may be necessary in the future if signs of increased intracranial pressure occur.</p>\n</div>",
        "references": []
    },
    "46": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 48-year-old man with a diffuse large B-cell lymphoma (DLBCL) is evaluated for AKI. He initially presented with unintentional weight loss, dyspnea on exertion, and abdominal distention. CT of the abdomen and pelvis showed diffuse lymphadenopathy, pelvic masses, and infiltration of the adrenal glands. A biopsy confirmed DLBCL, and after volume expansion with 0.9% saline, combination chemotherapy was initiated with rituximab, dexamethasone, cytarabine, and cisplatin. Over the next 5 days, he experienced progressive oliguria, an 8-kg weight gain, and hypoxemia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient has no relevant past medical history and takes no regular medications. He does not smoke, rarely consumes alcohol, and does not use illicit drugs. He moved to the United States from Italy several years ago. His mother has been treated for cancer of unknown type.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On exam, his BP is 158/78 mm Hg, heart rate is 102/min, and oxygen saturation is 92% while receiving 3 L/min supplemental O<sub>2</sub> by nasal cannula. Bibasilar crackles and diminished breath sounds are identified, and there is 2+ bilateral leg edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"60%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>On Admission</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Current</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Sodium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>139 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>132</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4.6 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>5.5</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Chloride</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>98 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>95</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>23 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>18</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>BUN</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>11 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>34</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.7 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>2.2</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Calcium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>8.9 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>6.9</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Phosphorus</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.8 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>6.2</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Uric acid</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.4 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>14.2</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.0–7.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Lactate dehydrogenase</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>543 U/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>2374</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>80–225</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Measure glucose-6-phosphate dehydrogenase activity"
            },
            {
                "label": "B.",
                "text": "Prescribe rasburicase"
            },
            {
                "label": "C.",
                "text": "Infuse isotonic sodium bicarbonate"
            },
            {
                "label": "D.",
                "text": "Prescribe allopurinol"
            },
            {
                "label": "E.",
                "text": "Prescribe calcium acetate"
            }
        ],
        "correct_answer": "Measure glucose-6-phosphate dehydrogenase activity",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with clinical tumor lysis syndrome (TLS) should have glucose-6-phosphate dehydrogenase (G6PD) activity measured before rasburicase initiation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TLS is defined by laboratory criteria that include two or more of the following: potassium ≥6 mEq/L, calcium ≤7 mg/dL (or ionized calcium ≤1.12 mmol/L), phosphorus ≥4.5 mg/dL, uric acid ≥8 mg/dL, or at least a 25% change from baseline in any of these parameters. Clinical TLS additionally requires one or more of the following: AKI, cardiac complications of hyperkalemia, or symptomatic hypocalcemia. This patient fulfills both laboratory and clinical definitions of TLS, with hypocalcemia, hyperphosphatemia, and hyperuricemia as well as AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients at high risk for TLS include those with acute leukemias with WBC count ≥100,000/μL, metabolically active lymphomas (lymphoblastic, Burkitt, DLBCL, mantle cell, and T-cell) with significant tumor burden, and chronic lymphocytic leukemias treated with venetoclax. Additional risk factors include CKD, preexisting hyperuricemia or hyperphosphatemia, and inadequate pre-treatment volume infusion (“hydration”). Allopurinol is prescribed for patients at intermediate risk of TLS, because it may require 1 week for peak effect. Rasburicase acts within 4 hours and may prevent AKI in high-risk patients. Patients with established AKI due to acute urate nephropathy complicating TLS may also benefit from rasburicase. It is typically dosed at 0.2 mg/kg once daily for up to 7 days, with uric acid and lactate dehydrogenase measures repeated after 4 hours and then every 6–12 hours until parameters normalize. Because rasburicase retains enzymatic activity in blood sample tubes at room temperature, falsely low uric acid levels may be reported if specimens are not handled properly. This includes pre-chilling tubes and transporting them to the lab under refrigerated conditions.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Rasburicase is a recombinant urate oxidase that metabolizes uric acid into more soluble allantoin and is approved by the US FDA for prevention and treatment of TLS. Because this reaction produces hydrogen peroxide, patients with G6PD deficiency are susceptible to hemolysis and methemoglobinemia, so measuring enzyme levels is mandatory before administration. G6PD deficiency is X-linked, so it is more commonly expressed in men, and populations at highest risk include those of African, Asian, Middle Eastern, and Mediterranean descent. The package insert indicates that G6PD level should be measured in these populations. As G6PD deficiency has a worldwide prevalence of up to 6%, it is reasonable to consider measurement of G6PD status in all potential rasburicase recipients. Other adverse effects include anaphylaxis, which occurs in up to 6% of patients. Note that it would have been reasonable to measure G6PD activity as soon as chemotherapy was contemplated for this patient at high risk for TLS. In this case, rasburicase therapy must be delayed until the patient’s G6PD status is confirmed. HD is effective at removing uric acid and lowering serum urate levels, which can be associated with improvement in kidney function. If measurement of G6PD results in significant delay in treatment with rasburicase, dialysis should be considered. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prophylaxis against TLS includes volume expansion with isotonic saline rather than bicarbonate, because urinary alkalinization may cause calcium phosphate precipitation. In addition, this patient has developed an anion gap metabolic acidosis attributable to AKI with accumulation of urate and phosphate, and sodium bicarbonate administration is controversial in this setting. Lastly, additional IV fluid would not be advisable in this oliguric patient with hypoxemia and volume overload.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calcium acetate is a phosphate binder used to manage chronic hyperphosphatemia in patients with advanced CKD or ESRD. Although it may be used adjunctively to help manage hypocalcemia and hyperphosphatemia, it would not address the more pressing hyperuricemia.</p>\n</div>",
        "references": []
    },
    "47": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 23-year-old man presents to the outpatient clinic for management of CKD stage G5/A3. He underwent laparoscopic placement of a PD catheter 4 weeks ago and has returned to clinic weekly for routine flushes. He works as a roofer, with limited time to perform PD exchanges during the day. Since his last visit, he has developed anorexia, nausea, and fatigue. He continues to produce 400 mL/day of urine.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP is 148/86 mm Hg and heart rate 88/min, and he is afebrile. Abdominal exam reveals well-healed laparoscopic scars and a PD catheter that is clean and dry with no erythema at the exit site. There is 1+ peripheral edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">His most recent laboratory data are as follows:</p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>5.5 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5‒5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>19 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>23‒28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>101 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8‒20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>7.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.7‒1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>7.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8.6‒10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>6.1 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.0‒4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>2.8 g/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5‒5.5</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST APPROPRIATE dialysis prescription?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "CCPD with a mid-day exchange targeting Kt/V ≥1.7 (dialysis + renal)"
            },
            {
                "label": "B.",
                "text": "CCPD targeting weekly Kt/V ≥1.7 (dialysis + renal)"
            },
            {
                "label": "C.",
                "text": "CCPD targeting weekly Kt/V ≥1.7 (dialysis)"
            },
            {
                "label": "D.",
                "text": "CAPD with four exchanges daily targeting Kt/V ≥1.7 (dialysis + renal)"
            },
            {
                "label": "E.",
                "text": "Urgent-start PD with low-volume, supine exchanges"
            }
        ],
        "correct_answer": "CCPD targeting weekly Kt/V ≥1.7 (dialysis + renal)",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with CKD stage 5 and uremic symptoms, reasonable residual renal function, and inability to perform daytime exchanges should initiate CCPD or APD overnight to target a combined weekly Kt/V ≥1.7.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Incremental PD is characterized by an initial prescription that takes into account residual renal function and typically provides a lower duration, frequency, and total volume of exchanges than a standard prescription. A 2020 publication further clarified incremental PD as either of the following:</p>\n<ol start=\"1\" type=\"1\">\n<li>CAPD with fewer than four dwells daily, &lt;2 L dwell volume, or &lt;7 days/week</li>\n<li>APD with no day dwell, &lt;10 L total daily dose, or &lt;7 days/week </li>\n</ol>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the patient’s residual renal function, combined with incremental APD, should allow him to achieve solute clearance and ultrafiltration goals.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potential advantages to incremental PD include reduced exposure to hypertonic glucose, which may increase peritoneal solute transport rate and contribute to ultrafiltration failure. Moreover, a lower burden of exchanges may enhance PD adherence and reduce burnout. Incremental PD may also result in cost savings by requiring less dialysate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Neither CCPD with a mid-day exchange nor traditional CAPD with four exchanges daily is suitable for this patient whose job is not conducive to performing daytime exchanges.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Optimizing outcomes in patients with ESRD receiving PD seems to require achieving a total Kt/V, including both dialysis and residual renal Kt/V, of greater than 1.7. Most of the benefit of additional clearance appears to be related to residual renal function, so targeting Kt/V ≥1.7 with dialysis only is incorrect.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urgent start PD may be done for patients with newly placed PD catheters with the appropriate logistical and nursing resources. This technique requires that patients perform APD in the dialysis clinic every weekday while supine, which would not be feasible for this patient who works during the day. In addition, this patient’s catheter should be ready for home APD after 4 weeks, so urgent start PD in a supervised setting would not be required.</p>\n</div>",
        "references": []
    },
    "48": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 59-year-old man who had a kidney transplant 2 years ago because of diabetic kidney disease is admitted to the hospital for an acute rise in creatinine. He undergoes percutaneous ultrasound-guided transplant kidney biopsy without immediate complications. His biopsy demonstrates acute cellular rejection, and he is treated with high-dose methylprednisolone IV. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, he is alert and oriented in no apparent distress. He is afebrile with a BP of 146/88 mm Hg and heart rate 87/min, stable since before the biopsy. Abdominal exam demonstrates no tenderness or swelling at the allograft biopsy site. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data before and 6 hours after biopsy reveal the following:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong> </strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Pre-biopsy</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>6 Hours Post-Biopsy</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>12.3 g/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>11.3 </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Platelet counts</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>207,000/µL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>193,000</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4.4 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4.9 </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>21 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>20 </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>2.4 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>2.2 </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urinalysis is positive for protein, glucose, and 2+ blood, but there is no gross hematuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Six-hour post-biopsy Doppler ultrasound demonstrates a confetti-like pattern in the cortex (white line) and reduced systolic-diastolic flow difference (arrows), findings concerning for an arteriovenous malformation (AVM). </p>\n<p><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q48-ksapv7m1.png\" width=\"90%\"/></p>\n<figcaption><em>Image courtesy of Emily Chang M.D, University of North Carolina Kidney Center.</em></figcaption>\n<p dir=\"ltr\" style=\"margin-top: 20px; margin-bottom: 15px;\"><strong>Which one of the following is the most appropriate next step in management?</strong></p>\n</div></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Transfusion of packed RBCs"
            },
            {
                "label": "B.",
                "text": "Refer to interventional radiology"
            },
            {
                "label": "C.",
                "text": "Close monitoring"
            },
            {
                "label": "D.",
                "text": "Obtain further imaging with CT scan"
            },
            {
                "label": "E.",
                "text": "Refer to surgery"
            }
        ],
        "correct_answer": "Close monitoring",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient should be monitored closely for symptoms and signs of bleeding, worsening hypertension, allograft dysfunction, and gross hematuria. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As described, the post-biopsy spectral Doppler ultrasound shows a confetti-like pattern in the kidney parenchyma and reduced systolic-diastolic flow velocity difference, which reflects very low resistance arterial flow consistent with a traumatic AVM.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Traumatic AVMs are one potential complication of kidney biopsies. They occur at a rate of approximately 15% but often go undetected if post-biopsy ultrasound is not routinely obtained. Most cases are asymptomatic, spontaneously close, and do not require intervention. Those cases that require intervention exhibit clinical findings, including hemodynamic instability, hematuria, and decline in kidney function. Monitoring for these symptoms can guide further management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Despite the invasive nature of kidney biopsies, complication rates are relatively low. Most complications are related to hemorrhagic events, including hematoma formation, macroscopic hematuria, active bleeding requiring blood transfusion or intervention to control bleeding, and very rarely death. In a recent systemic review and meta-analysis, hematomas and macroscopic hematuria were the most frequent bleeding complications after native kidney biopsy with estimated occurrences of 11% and 3.5%, respectively. The need for blood transfusion due to bleeding was estimated to occur in 1.6% and interventions required to stop bleeding in 0.3%. Death was rare, estimated to occur in 0.06% of biopsies. Complication rates are lower in kidney transplant biopsies. Analysis of a large series of kidney allograft biopsies found that post-biopsy AVM formation had no relationship to needle size (18- versus 16-gauge), time from transplant, or indication (change in allograft function versus protocol). Allografts from non-living donors and older donor age were associated with an increased risk. Another series that included native and transplanted kidneys found no association among needle size (14- versus 16-gauge), hypertension, or immediate complication. Neither series reported specific biopsy location or needle depth.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient experienced a decrease in hemoglobin after biopsy, he is hemodynamically stable, so packed RBC transfusion is not necessary at this time. However, monitoring hemoglobin levels may be useful for detecting ongoing bleeding and lack of AVM closure. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Embolization by interventional radiology and surgical consultation are not indicated at this time in the absence of active bleeding, hemodynamic instability, or failure of AVM closure. The diagnosis is clear with Doppler ultrasound, so CT imaging is not needed and would expose the patient to unnecessary radiation and iodinated contrast. A small case series of four post-biopsy AVMs in transplant kidneys showed that contrast-enhanced ultrasound also detects the presence of AVMs. In equivocal cases, use of this modality may spare exposure to iodinated contrast.</p>\n</div>",
        "references": []
    },
    "49": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 50-year-old man with heart failure with reduced ejection fraction secondary to ischemic cardiomyopathy presents to the emergency department for worsening shortness of breath and edema. He has a history of coronary artery disease status post stenting. His outpatient medications include furosemide 60 mg twice daily, lisinopril 40 mg daily, carvedilol 12.5 mg twice daily, and aspirin 81 mg daily.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP is 140/80 mm Hg, pulse 60/min, respiratory rate 20/min, oxygen saturation 88% while breathing room air, and weight 100 kg (baseline, 90 kg). Physical examination is significant for elevated jugular venous pressure, bibasilar crackles on lung examination, and 3+ pitting edema to both knees. The patient receives furosemide 80 mg IV bolus followed by an infusion at a rate of 10 mg/h. His urine output is 2 L/day, with a net fluid balance of negative 0.5 L/day. On day 3, the patient continues to have 3+ pitting edema and elevated jugular venous pressure. Urine output subsequently decreases to 1.5 L/day..</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong> </strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Day 1 </strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Day 3 </strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4.2 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.8</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5‒5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>24 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>27</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>22‒28</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>BUN</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>15 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>20</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>8‒20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1.2 mg/dL (baseline, 1.0)</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1.6</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.7‒1.3</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Urinalysis is bland. Kidney ultrasound shows kidneys with no obstruction, normal echogenicity, and congested renal veins. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which ONE of the following is the most appropriate next step in the management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Decrease furosemide infusion rate to 5 mg/h"
            },
            {
                "label": "B.",
                "text": "Increase furosemide infusion rate to 20 mg/h"
            },
            {
                "label": "C.",
                "text": "Change furosemide to bumetanide 2 mg IV twice daily"
            },
            {
                "label": "D.",
                "text": "Discontinue furosemide and initiate isolated ultrafiltration"
            },
            {
                "label": "E.",
                "text": "Discontinue lisinopril"
            }
        ],
        "correct_answer": "Increase furosemide infusion rate to 20 mg/h",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with worsening kidney function and ongoing congestion should undergo augmented diuresis as therapy for cardiorenal syndrome (CRS) with AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">AKI is common in patients with CHF, with a rate of 25% among those undergoing diuresis for decongestion. The most likely diagnosis in this case is type 1 CRS, where AKI develops during an episode of acute decompensated heart failure (ADHF). The pathophysiology of this condition is complex and includes arterial underfilling, venous congestion, and neurohumoral activation. AKI during ADHF was previously attributed to excess diuresis or decreased cardiac output with arterial hypotension, but recent evidence suggests that renal venous congestion may play a dominant role. Studies have shown that modest increases in creatinine, variably termed worsening renal function (WRF), are not linked to worse outcomes if accompanied by successful diuresis. However, patients with WRF and persistent signs of congestion at the time of discharge have an increased risk of death and rehospitalization. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Achieving euvolemia is the main goal to improve patients’ symptoms and clinical outcomes, so diuresis with effective decongestion takes precedence over fluctuations in creatinine. It is important to rule out other causes of AKI. This patient has a modest increase in creatinine, persistent volume overload, imaging findings consistent with renal vein congestion, and decreased urine output. Urinalysis is bland, and kidney ultrasound does not reveal obstruction. Thus, intensifying the diuretic regimen to relieve congestion would be expected to improve kidney function. Addition of a thiazide-like diuretic would be another way to enhance diuresis in patients displaying diuretic resistance. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A protocol of stepped titration of IV diuretics has been studied in patients with CRS. The initial daily IV dose of loop diuretics should be ≥2.5 times the previous daily PO dose. The dose should be titrated to achieve a target urine output of 3‒5 L/day until euvolemia is achieved. For this patient, the furosemide dose should be increased to 20 mg/h.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Continuous infusions have been shown to be equivalent to bolus doses of IV loop diuretics. Bumetanide 1 mg IV is equipotent to furosemide 40 mg IV, so the proposed change would be an effective decrease in diuretic dose. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The role of isolated ultrafiltration to manage ADHF remains controversial, as it has not been shown to be more effective than IV diuresis and can be accompanied by more complications. It is not preferred for first-line management of CRS.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ACEIs and ARBs should generally be continued in patients admitted for ADHF unless hypotension, hypovolemia, hyperkalemia, or severe AKI occur.</p>\n</div>",
        "references": []
    },
    "50": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 19-year-old woman presents to the emergency department for evaluation of headache, nausea, and vomiting. The patient’s roommate states that the patient took part in a water-drinking contest at a college fraternity party that evening. Each “contestant” was instructed to drink as much water as they could in 1 hour without urinating. It is not known how much the patient consumed, but since completing the contest, she has been nauseated and confused and was observed to vomit during transit to the emergency department. She was not observed to consume drugs or alcohol at the party. There is no known past medical history, and she does not take any medications on a regular basis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 120/80 mm Hg, heart rate 88/min, temperature 37°C, and body mass index 21 kg/m<sup>2</sup>. On examination, the patient is lethargic and unable to engage in conversation. Pupils are equal and reactive to light. The patient can move all extremities and has no neck rigidity, and the rest of the examination is normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Sodium </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>119 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.3 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>26 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Chloride </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>83 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Glucose</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>90 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Plasma osmolality</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>250 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>275–295</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Urine specific gravity is 1.002.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which is one of the following is the most appropriate next step in the management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "3% Saline bolus"
            },
            {
                "label": "B.",
                "text": "3% Saline infusion"
            },
            {
                "label": "C.",
                "text": "0.9% Saline bolus"
            },
            {
                "label": "D.",
                "text": "Tolvaptan"
            },
            {
                "label": "E.",
                "text": "No additional management"
            }
        ],
        "correct_answer": "3% Saline bolus",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with acute symptomatic hyponatremia should be treated with a bolus of hypertonic (3%) saline to quickly increase the serum sodium by 4–6 mEq/L.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyponatremia is acute if the onset is less than 48 hours prior to presentation. Acute hyponatremia due to water ingestion is commonly encountered in patients with psychogenic polydipsia, endurance exercise with water intoxication, or use of drugs such as ecstasy. Although rare, deaths have been reported from acute water intoxication in water-drinking contests and hazing at college fraternity parties or similar events. Normal adults can excrete about 20 L of water per day, but the maximum urine flow rate in adults rarely exceeds 800‒1000 mL/h, so consuming large amounts of water in a relatively short time can result in hyponatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has severe hyponatremia, as her serum sodium is &lt;120 mEq/L with moderate to severe symptoms. Nonspecific symptoms, such as nausea, vomiting, or confusion, suggest cerebral edema and, if unchecked, can quickly progress to seizures, respiratory arrest, brain herniation, coma, and death. In patients with suspected or confirmed severe hyponatremia, bolus infusions of 3% saline 100 mL should be given, and doses should be repeated if necessary to increase the serum sodium level by 4‒6 mEq/L within 6 hours to reverse cerebral edema. Once the patient’s neurological symptoms abate, she should be monitored and sodium allowed to correct to normal levels. Patients with hyponatremia due to polydipsia will self-correct rapidly once water intake abates, but this rapid correction is not associated with osmotic demyelination if the hyponatremia is acute. Chronic hyponatremia must be controlled to a correction rate not greater than approximately 6 mEq/L per day. Tolvaptan, furosemide, and 0.9% saline are not recommended in the acute management of severe, symptomatic hyponatremia because their onset of action is delayed compared with that of hypertonic saline, and the change in sodium concentration is unpredictable and might not reach target. Similarly, it would be inappropriate to withhold acute therapy even if the urine is dilute and the patient will self-correct because of the risk of immediate complications as discussed above. An infusion of 3% saline would effectively increase the sodium concentration but not as rapidly as a bolus, so would not be not preferred in this setting. </p>\n</div>",
        "references": []
    },
    "51": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 75-year-old man with chronic lymphocytic leukemia (CLL) is admitted to the hospital for hyperkalemia. Diagnosed 2 years ago, his CLL has followed an indolent course and has been managed with observation only. The patient’s medical history includes hypertension, diabetes, atrial fibrillation, and coronary artery disease. Home medications include rivaroxaban, atenolol, rosuvastatin, clopidogrel, lisinopril, and metformin. He describes no recent fever, chills, night sweats, abdominal pain, or changes in urine output, and he currently feels well.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, BP is 116/65 mm Hg, heart rate 59/min, respiratory rate 17/min, temperature 37.2°C, and oxygen saturation 96% while breathing room air. Heart, lung, and abdominal examinations are normal, and there is no peripheral edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>WBC count</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>225,000/μL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>7.0 g/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Platelet count</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>220,000/μL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Plasma</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>6.8 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Total CO<sub>2</sub></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>22 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1.2 mg/dL (baseline)</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Glucose</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>104 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>70–99, (fasting)</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Calcium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>9.1 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Phosphorus</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.9 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Uric acid</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>7.7 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.0–7.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Lactate dehydrogenase</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>184 U/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>80–225</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">EKG reveals normal sinus rhythm with no ST or T wave abnormalities.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe rasburicase"
            },
            {
                "label": "B.",
                "text": "Measure serum potassium"
            },
            {
                "label": "C.",
                "text": "Prescribe insulin and dextrose"
            },
            {
                "label": "D.",
                "text": "Discontinue lisinopril"
            },
            {
                "label": "E.",
                "text": "Prescribe sodium zirconium cyclosilicate"
            }
        ],
        "correct_answer": "Measure serum potassium",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with reverse pseudohyperkalemia should have serum potassium measured to confirm the diagnosis. Measuring whole-blood potassium would also be appropriate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyperkalemia may be life-threatening and requires prompt diagnosis and treatment. Even if a diagnosis of spuriously high potassium is considered, the first step in evaluation is obtaining an EKG, which in this case did not reveal any cardiac abnormalities.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potassium is typically measured from a sample of plasma or serum. A plasma sample is collected in a tube that contains heparin and clotting factors, whereas a serum sample does not contain heparin and clotting factors have precipitated. During the clotting process, platelets aggregate and release potassium. Thus, patients with thrombocytosis may demonstrate pseudohyperkalemia, in which the serum K will be spuriously higher than the plasma K. Conversely, patients with hematologic malignancies such as CLL, in which fragile WBCs are vulnerable to heparin-mediated cell membrane damage, may demonstrate reverse pseudohyperkalemia, in which the plasma K will be spuriously higher than the serum K. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tumor lysis syndrome (TLS) is defined by laboratory criteria that include two or more of the following: potassium ≥6 mEq/L, calcium ≤7 mg/dL (or ionized calcium ≤1.12 mmol/L), phosphorus ≥4.5 mg/dL, uric acid ≥8 mg/dL, or at least a 25% change from baseline in any of the above parameters. Clinical TLS additionally requires one or more of the following: AKI, cardiac complications of hyperkalemia, or symptomatic hypocalcemia. This patient does not meet the criteria for TLS, so he would not be a candidate for rasburicase.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">It would be inappropriate to discontinue lisinopril or prescribe immediate-acting therapy, including insulin and dextrose, for a patient with spurious hyperkalemia. Sodium zirconium cyclosilicate is a novel potassium binder that would also be inappropriate in the setting of reverse pseudohyperkalemia; moreover, it has not been approved for acute management of hyperkalemia.</p>\n</div>",
        "references": []
    },
    "52": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 55-year-old man with CKD stage 4 attributed to type 2 diabetes and hypertension presents for follow-up.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient reports feeling well. He is adherent to his medication regimen, which includes lisinopril, glipizide, and atorvastatin. At his last visit 6 months ago, the patient was reluctant to add any new medications but was agreeable to dietary changes. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP is 125/75 mm Hg, and he has no peripheral edema. The remainder of the physical exam is normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span> Laboratory data include the following: </span></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\"><br/></td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>6 Months Ago</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Current</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4.2 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>5.0</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>16 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>19</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>2.10 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>2.0</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>BUN</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>14 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>15</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Phosphorus</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.3</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Hemoglobin A<sub>1c</sub></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>7.5%</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>7.2</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4.0–5.6</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Increased dietary intake of which of the following MOST LIKELY accounts for the observed changes?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Fish"
            },
            {
                "label": "B.",
                "text": "Whole grains"
            },
            {
                "label": "C.",
                "text": "Dairy"
            },
            {
                "label": "D.",
                "text": "Fruits and vegetables"
            },
            {
                "label": "E.",
                "text": "Legumes"
            }
        ],
        "correct_answer": "Fruits and vegetables",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p>This patient’s most likely dietary change is an increase in his consumption of fruits and vegetables.</p>\n<p>Metabolic acidosis is a common complication of CKD, and alkali therapy is often prescribed to correct this acidosis. Various studies have examined dietary modifications in patients with CKD; plant-based diets are being investigated for improving CKD outcomes. In one study, increased consumption of fruits and vegetables significantly improved serum bicarbonate levels, though to a lesser degree than sodium bicarbonate supplementation. Of note, sodium bicarbonate supplementation to improve serum bicarbonate has been shown to delay the progression of CKD. Fruits and vegetables are often high in potassium, so monitoring for hyperkalemia is imperative, particularly in patients taking ACEIs. The increase in serum bicarbonate and potassium suggest that the patient has increased his intake of fruits and vegetables.</p>\n<p>Grains, dairy, legumes, and animal protein (such as fish) are all associated with an acid load. In addition, these foods are relatively rich in protein and phosphorus, which would be expected to result in increased BUN and phosphorus concentrations. Increased intake of these foods would be unlikely to cause the improved total CO<sub>2</sub> and stable BUN and phosphorus levels observed in this case.</p>\n</div>",
        "references": []
    },
    "53": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 35-year-old woman with ADPKD presents for routine follow-up. She experienced a kidney cyst rupture 1 year ago that resulted in acute pain, and she has since developed persistent back pain. She localizes the pain to her lower back bilaterally, and it\n    is exacerbated by prolonged standing. She reports no fever, chills, nausea, vomiting, diarrhea, constipation, weakness, numbness, or urinary symptoms. She has been taking acetaminophen with incomplete relief. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her physical examination is notable for a protuberant abdomen with palpable kidneys, but there are no focal areas of tenderness. The spine and back are nontender. Her neurologic examination is normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">UA and urine culture are negative for infection. Her eGFR is stable at 35 mL/min/1.73 m<sup>2</sup>. A CT scan with IV contrast (representative image below) shows enlarged kidneys with innumerable cysts bilaterally. </p>\n<figure><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q53-ksapv7m1.png\" width=\"90%\"/>\n<figcaption><em>Image courtesy of <span>Clin J Am Soc Nephrol</span> 1(4): 754–760, 2006</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Ibuprofen"
            },
            {
                "label": "B.",
                "text": "Oxycodone"
            },
            {
                "label": "C.",
                "text": "Physical therapy"
            },
            {
                "label": "D.",
                "text": "Catheter-based renal denervation"
            },
            {
                "label": "E.",
                "text": "Cyst aspiration"
            }
        ],
        "correct_answer": "Physical therapy",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best choice for this patient with ADPKD presenting with chronic low back pain is physical therapy (PT). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Low back pain, abdominal pain, and flank pain are common in patients with ADPKD, and it can be challenging to establish a specific diagnosis. Acute pain or a change in chronic pain should prompt an evaluation for cyst rupture, hemorrhage, infection, or nephrolithiasis. Even with cross-sectional imaging, it can be difficult to identify a precise anatomic cause of pain. Dystrophic calcification can be difficult to differentiate from a stone. Because cysts may not communicate with the urine, UA and urine culture may fail to disclose infection. In the absence of constitutional symptoms, laboratory evidence of infection or inflammation, or definitive findings on imaging, it is reasonable to consider a musculoskeletal etiology of pain, for which PT is indicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Management of chronic pain should first include a noninvasive approach. PT is recommended for improving mobility, particularly because patients with ADPKD are prone to postural difficulties due to enlarged kidneys. Exercises that improve core tone may be effective. Compression of the affected side may also be used in the case of cyst rupture with no other complications.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">NSAIDs such as ibuprofen generally should be avoided by patients with CKD, although short courses may be helpful for patients with preserved eGFR. Narcotics can be considered to treat acute, severe pain but should be a last resort to treat chronic pain.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Catheter-based renal denervation has shown promise in several case reports of patients with pain refractory to narcotics. However, this technique needs greater study and would not be an appropriate initial intervention. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cyst aspiration may be considered to treat acute pain if a large or dominant cyst is identified as the likely culprit, but this technique is usually ineffective, as fluid will reaccumulate. Cyst decortication and nephrectomy may be considered in cases of severe, refractory pain.</p>\n</div>",
        "references": []
    },
    "54": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">An 84-year-old woman is admitted to the hospital for evaluation and management of severe AKI. She has a past medical history of hypertension and long-standing mild anemia and thrombocytopenia, the etiology of which is unknown. Two weeks ago, she presented to her primary care physician’s office with blood-tinged urine and was prescribed a 5-day course of trimethoprim/sulfamethoxazole (TMP/SMX) for presumed cystitis, but hematuria failed to improve. Medications include amlodipine and a multivitamin. She lives alone with a kitten and does not smoke, drink, or use recreational drugs. Review of systems is positive for fatigue and 3 months of intermittent, non-bloody diarrhea, but negative for fever, chills, weight loss, arthralgias, rash, or urinary symptoms.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 142/67 mm Hg, heart rate 84/min, and temperature 37°C. On examination, she appears tired. A few linear abrasions are present on her hands and arms that she attributes to her kitten. The oropharynx is normal and there is no lymphadenopathy. The\n    heart, lungs, and abdomen are normal, and there is no edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9500/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.3 g/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                97,000/µL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.3 mg/dL (baseline, 0.8)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Total protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.5–9.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  C3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                104 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  C4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                17 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  ANA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1:40\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤1:40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  ANCA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Not detected\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Not detected\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Anti-proteinase 3 (PR3) antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                29.3 U\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Anti-myeloperoxidase antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.4 U\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤1.0\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">UA demonstrates moderate blood and +2 protein, and microscopy shows frequent acanthocytes and occasional coarse granular casts. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Blood and urine cultures are negative at 48 hours.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy demonstrates necrotizing glomerulonephritis with crescents and mesangial immunoglobulin G (IgG) and C3 deposits in a granular, peripheral distribution. IF, including staining for κ and λ light chains, is unremarkable. EM shows segmental GBM duplication with subepithelial electron-dense deposits (arrow).</p>\n<figure><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q54-ksapv7m1.png\" width=\"90%\"/>\n<figcaption><em>Image courtesy of Jason Pettus, MD, Dartmouth Hitchcock Medical Center</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Drug-induced AKI"
            },
            {
                "label": "B.",
                "text": "Hemolytic-uremic syndrome"
            },
            {
                "label": "C.",
                "text": "ANCA-associated vasculitis"
            },
            {
                "label": "D.",
                "text": "Monoclonal gammopathy"
            },
            {
                "label": "E.",
                "text": "Infection-associated glomerulonephritis"
            }
        ],
        "correct_answer": "Infection-associated glomerulonephritis",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The findings demonstrated in the biopsy are most consistent with infection-associated glomerulonephritis (IAGN), as demonstrated by granular IgG and C3 deposits and subepithelial electron-dense deposits in a classic “hump” shape. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Subepithelial immune deposits are a stimulus for the influx of inflammatory cells, leading to a hypercellular glomerulonephritis (GN) that can be necrotizing and crescentic in its most severe form. C3, C4, or both may be low, but in this case, they are at the low end of their reference ranges. The terminology for this condition has evolved from “post-infectious” to “infection-associated” or “infection-related” because GN is sometimes concurrent with infection. Subepithelial humps tend to be most characteristic of <em>Streptococcus</em> infection, whereas <em>Staphylococcus</em> IAGN often resembles IgA nephropathy. Neither pharyngitis nor positive blood cultures are required for diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In cases of unexplained AKI, especially in the presence of abnormal urine sediment, kidney biopsy is indicated. In this case, further evaluation demonstrated a <em>Bartonella</em> IgG titer of 1:1024 (reference, &lt;1:128), probably associated with cat exposure. <em>Bartonella</em> IAGN is most commonly seen in the setting of infective endocarditis, and anti-PR3 antibodies may be present, raising the possibility of a pauci-immune GN. However, the observed immune complex deposition and subepithelial humps in this case are inconsistent with the pauci-immune GN expected with ANCA vasculitis.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HUS is often considered in the setting of AKI, diarrhea, anemia, and thrombocytopenia. However, HUS typically presents with worsening anemia and thrombocytopenia, and biopsy would show thrombotic microangiopathy. The GBM may demonstrate double contours with variable hypercellularity and fibrin deposition, but immune complex deposition is not expected.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TMP/SMX has been associated with AKI and can have features of acute tubular necrosis and acute interstitial nephritis, typically caused by SMX, whereas the crescentic, immune-complex glomerulonephritis identified would be unexpected. TMP may also inhibit proximal tubular creatinine secretion and cause a small increase in serum creatinine.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A variety of glomerular injury patterns related to monoclonal gammopathy have been described, including MPGN, C3 GN, and pauci-immune necrotizing and crescentic GN. However, there is no evidence of monoclonality on IF microscopy, and subepithelial humps have only rarely been noted in MPGN from monoclonal gammopathy. Although a search for an underlying paraproteinemia would not be unreasonable, especially considering chronic anemia and thrombocytopenia, in this case, IAGN is a more likely explanation.</p>\n</div>",
        "references": []
    },
    "55": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 50-year-old woman with ESRD secondary to hypertension is referred for evaluation of anemia. She has undergone thrice-weekly HD for the past 6 years, with a stable dose of erythropoietin (EPO) 4000 units IV with each treatment. Over the past 4 months, she has required increasing doses of EPO, currently 12,000 units IV with each treatment, to achieve Hb &gt;10 g/dL (reference range, 12–16; target for treatment, 10–12). There have been no intercurrent illnesses, and gastrointestinal bleeding was not identified on several immunoassays for occult blood. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Physical examination is unremarkable.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>1 Year Ago</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>6 Months Ago</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Current</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>11.8 g/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>10.8</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>10.1</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Iron saturation</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>38%</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>33</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>41</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>20–50</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Ferritin</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>485</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>602</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>513</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>11–307</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Further review revealed that this patient’s HD unit was expanded from 10 to 20 stations 8 months ago, at which time more membranes were added to the reverse osmosis (RO) system. Over 80% of the patients in this unit have required increased EPO dosing over the past 6 months.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which is the following is the MOST LIKELY cause of anemia refractory to increased EPO dosing?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Fluoride toxicity"
            },
            {
                "label": "B.",
                "text": "Hard water syndrome"
            },
            {
                "label": "C.",
                "text": "Aluminum toxicity"
            },
            {
                "label": "D.",
                "text": "Endotoxin contamination"
            },
            {
                "label": "E.",
                "text": "Lead toxicity"
            }
        ],
        "correct_answer": "Aluminum toxicity",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with anemia resistant to increased EPO dosing, or erythropoiesis-stimulating agent (ESA) hyporesponsiveness, most likely has aluminum toxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Aluminum toxicity was more common when aluminum-based phosphate binders were widely used. These agents are rarely used in current practice because of toxicity, which may manifest as anemia, osteomalacia, and dementia. Aluminum toxicity in the modern era usually results from dialysate contamination from the municipal water supply or from dialysis unit purification or distribution problems. Acute aluminum intoxication may cause seizures or encephalopathy, whereas chronic toxicity may present with bone or muscle pain or weakness, fractures, hypercalcemia, microcytic anemia without iron deficiency, and progressive dementia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the refractory anemia among numerous patients associated with expansion of the dialysis unit suggests dialysate water contamination. Municipal water supplies contain high concentrations of aluminum, and adding more membranes to the RO system without upgrading other components of the water purification and delivery system can overwhelm the purification apparatus, resulting in delivery of aluminum-rich dialysate to patients. This scenario appears to be the most frequent cause of aluminum toxicity in HD centers today. Aluminum may also be introduced from the inappropriate use of aluminum-rich metal alloys during expansion of the water delivery system. Heavy metal screening should be done after alterations to the water treatment system. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fluoride toxicity may worsen bone disease, but anemia would be unexpected. Fluoride toxicity has been described in the setting of exhausted deionization units.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hard water syndrome is a constellation of findings that occurs when dialysate is contaminated with high levels of iron, calcium, and magnesium, and presents with nausea, vomiting, headache, muscle weakness, and hypertension. Hard water syndrome occurs with failure of water softeners.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Contamination of dialysate water with endotoxin or other bacterial breakdown products may cause ESA hyporesponsiveness but more commonly presents as fever and hypotension during HD. Endotoxin contamination may occur with malfunctioning RO systems.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Lead toxicity manifests as abdominal pain, muscle weakness, and peripheral neuropathy. Anemia can also occur but would be unlikely to be the only manifestation. Lead can leach from plumbing components in the presence of chloramine, which is present in the municipal water supply and is usually removed by activated charcoal during dialysate water purification.</p>\n</div>",
        "references": []
    },
    "56": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 64-year-old woman with ESRD attributed to type 2 and hypertension is evaluated for hyperphosphatemia. She has a chronic, non-healing, sacral decubitus ulcer that developed after a prolonged hospitalization for pneumonia. The ulcer is associated with chronic osteomyelitis, for which she takes suppressive doxycycline. The patient receives nutritional supplements from her HD center, and her most recent Kt/V was 1.52. The dietitian reports that the patient avoids processed food and most dairy products, but eats a serving of protein at each meal, such as eggs, fish, chicken, or beef.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her medications include insulin, lisinopril, carvedilol, aspirin, atorvastatin, a B/C-complex vitamin, and doxycycline.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, her BP is 100/50 mm Hg, heart rate 92/min, and BMI 17 kg/m<sup>2</sup>. There is 1+ lower extremity edema to the knees bilaterally. Notes from the home wound care nurse describe the ulcer as stage 4 without drainage or foul odor.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span style=\"font-size: 0.9375rem;\">Laboratory data include the following:</span><br/></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>9.0 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8.5–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>6.7 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>2.1 g/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>PTH, intact</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>480 pg/mL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>130–585</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST STEP in management?</strong></p>\n</div></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Decrease phosphorus intake to <800 mg/day"
            },
            {
                "label": "B.",
                "text": "Prescribe sevelamer"
            },
            {
                "label": "C.",
                "text": "Place a peripherally inserted central catheter for total parenteral nutrition"
            },
            {
                "label": "D.",
                "text": "Prescribe calcium acetate"
            },
            {
                "label": "E.",
                "text": "Place a gastrostomy tube for tube feedings"
            }
        ],
        "correct_answer": "Prescribe sevelamer",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management for this patient with hyperphosphatemia and severe protein-calorie malnutrition with a sacral ulcer is to start a phosphate binder to control hyperphosphatemia while continuing oral protein intake to maintain nutrition. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Guidelines call for a serum phosphorus target of 3.5–5.5 mg/dL in patients receiving dialysis. This target is an opinion based on observations that high and low phosphorus levels are associated with adverse outcomes. Although treatment with binders\n        has been shown to be effective in achieving phosphorus control, a Cochrane review found little evidence that treatment with binders improves clinical outcomes. They did find a possible advantage to sevelamer compared with calcium-containing binders.\n        In this patient, whose calcium concentration corrected for hypoalbuminemia is 10.5 mg/dL, sevelamer would be preferred to avoid exacerbation of hypercalcemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyperphosphatemia may be addressed by dietary phosphate restriction to 800–1200 mg/day and phosphate binders. These approaches are often used concurrently, with substitution of less bioavailable plant phosphate (inositol hexakisphosphate, phytate) for\n        animal phosphate when possible. Specifically, patients should typically avoid consuming dairy and processed food, which frequently contain phosphoric acid and other derivatives as preservatives.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nutritional supplementation is a priority for this severely malnourished patient with a sacral ulcer, so dietary phosphate restriction would likely adversely affect nutritional status, although as mentioned, plant sources may be substituted for animal\n        sources of protein.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tube feedings or total parenteral nutrition are unnecessary in a patient who is able to eat and take other protein supplements by mouth. </p>\n</div>",
        "references": []
    },
    "57": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 44-year-old woman with uncontrolled diabetes is admitted to the ICU with <em>Escherichia coli</em> bacteremia and septic shock requiring vasopressors. She develops AKI with progressive oliguria over the next 3 days. Because of worsening metabolic acidosis and volume overload, a temporary dialysis catheter is placed in her right internal jugular (RIJ) vein, and CVVH is initiated with heparin anticoagulation, blood flow 150 mL/min, post-filter replacement fluid rate 2 L/h, and net ultrafiltration rate 50 mL/h.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">The next day, the CVVH machine alarms because of persistently high venous pressure, recorded as 330 mm Hg. Inspection of the blood circuit reveals no kinks. Arterial, hemofilter, and effluent line pressures are normal. Chest x-ray demonstrates appropriate position of the RIJ dialysis catheter, with the catheter tip located at the junction of the superior vena cava and the right atrium.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Replace CVVH hemofilter"
            },
            {
                "label": "B.",
                "text": "Decrease effluent flow rate"
            },
            {
                "label": "C.",
                "text": "Administer replacement fluid pre-filter"
            },
            {
                "label": "D.",
                "text": "Increase blood flow rate to 200 mL/min"
            },
            {
                "label": "E.",
                "text": "Instill tissue plasminogen activator (tPA) into the catheter"
            }
        ],
        "correct_answer": "Instill tissue plasminogen activator (tPA) into the catheter",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management is instilling the thrombolytic agent tPA into the dialysis catheter.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In CRRT, the return pressure is the positive pressure in the venous return circuit generated by the blood pump that pushes blood back into the patient. An elevated return pressure (&gt;250 mm Hg) may be observed if there are kinks in the return circuit, a thrombus in or around the venous port of the catheter, or stenosis in the central vein that accommodates the dialysis catheter. If a thrombus has developed, instilling tPA and allowing it to dwell for up to 2 hours may help dissolve the clot and restore catheter patency and function. If this intervention fails, a catheter exchange over a guidewire or catheter replacement should be considered. The KDIGO 2012 AKI guidelines recommend a non-tunneled catheter for renal replacement therapy in the following order of preference: RIJ vein, femoral vein, left internal jugular vein, dominant-side subclavian vein, and non–dominant-side subclavian vein. The RIJ and femoral veins typically allow for higher blood flow than necessary for effective CRRT.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Filter thrombosis usually manifests as elevated filter and transmembrane pressures, as well as reduced solute clearance, rather than elevated venous pressure. Replacement of the hemofilter is indicated if these features are present.</p>Decreasing effluent flow rates, administering replacement fluid pre-filter rather than post-filter, and increasing blood flow rate are strategies to reduce the likelihood of filter thrombosis. These interventions would not address elevated return pressures due to catheter malfunction. \n</div>",
        "references": []
    },
    "58": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 69-year-old man undergoing treatment for relapsed chronic lymphocytic leukemia (CLL) is referred for evaluation of worsening kidney function. Over 2 months while he has been receiving ibrutinib, his creatinine has increased from a baseline\n    of 1.1 mg/dL to 2.0 mg/dL (reference range, 0.7–1.3). Concurrently, the patient developed abscesses associated with bulky cervical lymphadenopathy and received several courses of antibiotics. Review of systems is positive for an acneiform rash on his face,\n    attributed to ibrutinib by his dermatologist. Current medications are ibrutinib, levofloxacin, pantoprazole, and allopurinol.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, the patient is normotensive and euvolemic. Weight is 57 kg. Bulky cervical lymphadenopathy and an acneiform rash on his face are the only significant findings.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Sodium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>143 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>136‒145</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>5.1 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5‒5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>27 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>23‒28</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>BUN</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>26 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>8‒20</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>2.0 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.7‒1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>C3</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>65 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>100‒233</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>C4</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>32 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>14‒48</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>CH50</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>151 units/mL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>110‒190</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">UA shows 2+ albumin with no cells or casts on microscopy. Blood cultures are negative. Kidney ultrasound reveals bilateral 14-cm kidneys without hydronephrosis (right kidney image shown).</p>\n<figure><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q58-ksapv7m1.png\" width=\"90%\"/>\n<figcaption>\n<p>Kidney biopsy demonstrates a widespread lymphocytic infiltrate (image).</p>\n</figcaption>\n</figure>\n<figure><img height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q58figb-ksapv7m1.png\" width=\"90%\"/>\n<figcaption>Hematoxylin and eosin, 400x magnification.\n        <figcaption>Images courtesy of Surya V. Seshan, MBBS, Cornell University.</figcaption>\n</figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-top: 20px; margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acute interstitial nephritis (AIN)"
            },
            {
                "label": "B.",
                "text": "Rapidly progressive glomerulonephritis (RPGN)"
            },
            {
                "label": "C.",
                "text": "Leukemic infiltration"
            },
            {
                "label": "D.",
                "text": "Acute pyelonephritis"
            }
        ],
        "correct_answer": "Leukemic infiltration",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis for this patient’s worsening kidney function, based on the ultrasound and biopsy findings, is leukemic infiltration of the kidney. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CLL is the most commonly diagnosed adult leukemia in the United States. The most common causes of kidney disease attributable to CLL include prerenal AKI, acute tubular necrosis, and tumor lysis syndrome; leukemic infiltration is a rare cause of AKI or CKD among patients with leukemia and has been linked to more aggressive or advanced malignancy. The mechanism of AKI is thought to involve tubular or microvascular compression by the infiltrate as well as inflammation and cytokine release, which could account for the hypocomplementemia occasionally observed. No additional treatment beyond chemotherapy for the underlying CLL is recommended. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The leukemic infiltrate, as in this instance, is generally composed of monomorphic and atypical lymphoid cells. In contrast, reactive lymphocytes, macrophages, eosinophils, and occasionally even neutrophils are expected in cases of AIN and paraneoplastic glomerular diseases. Acute pyelonephritis would be characterized by a predominantly neutrophilic infiltrate. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s kidney ultrasound shows moderately enlarged kidneys without obstruction, which is also typical of leukemic infiltration, although the sensitivity and specificity of this finding are unknown. Of note, autopsy studies suggest that many patients with leukemia have cellular infiltration of the renal parenchyma that remains clinically silent during life, with no change in kidney function. None of the other options listed would be expected to cause nephromegaly.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The findings on UA do not support the diagnosis of RPGN or acute pyelonephritis and would be somewhat atypical for AIN, which often has some degree of pyuria or hematuria.</p>\n</div>",
        "references": []
    },
    "59": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 68-year-old man presents to the emergency department with an inability to swallow any solid food over several weeks. He has been consuming only sips of broth and has lost 20 kg.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, his BP is 96/52 mm Hg, heart rate 104/min, weight 60 kg, and body mass index 13.5kg/m<sup>2</sup>. He appears cachectic, and inspection of his oropharynx reveals a large mass.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">He is admitted to the hospital. A percutaneous gastrostomy tube is placed on the second hospital day, and standard-dose tube feeding with free water flushes is initiated. On the fifth hospital day, the patient is found lethargic, tachypneic, and tachycardic. He has had two loose stools over the past day.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows: </span></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" width=\"30%\">\n<p><strong> </strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Admission</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Day 5</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" width=\"30%\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>130 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>130</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>136‒145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" width=\"30%\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>2.4</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5‒5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" width=\"30%\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>97 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>95</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>98‒106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" width=\"30%\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>18 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>25</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>23‒28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" width=\"30%\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>11</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8‒20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" width=\"30%\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.1 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.2</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.7‒1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" width=\"30%\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>2.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.9</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.0‒4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" width=\"30%\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>2.8 g/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5‒5.5</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY cause of this patient’s hypokalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Primary aldosteronism"
            },
            {
                "label": "B.",
                "text": "Refeeding syndrome"
            },
            {
                "label": "C.",
                "text": "Hypokalemic periodic paralysis"
            },
            {
                "label": "D.",
                "text": "Diarrhea"
            },
            {
                "label": "E.",
                "text": "Osmotic diuresis"
            }
        ],
        "correct_answer": "Refeeding syndrome",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has developed refeeding syndrome, suggested by concomitant hypokalemia and hypophosphatemia after receiving nutrition following a prolonged period of malnutrition. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Refeeding syndrome can be anticipated and managed by supplementing potassium, magnesium, and phosphorus before deficiency occurs. Thiamine and other vitamins should be supplemented before the delivery of nutrition. For high-risk patients, feeding can be initiated at a rate below goal and then gradually advanced to reduce the risk of refeeding syndrome. Patients at high risk for refeeding syndrome include those with &gt;10% weight loss, little or no intake for &gt;5 days, and use or misuse of ethanol, insulin, diuretics, antacids, or chemotherapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">During periods of prolonged starvation or inadequate nutrition, the body shifts to a catabolic state in which glucagon production is stimulated and insulin production inhibited. This change in the glucagon-insulin ratio results in a catabolic state with major changes in metabolism: reduction in glycogen stores leading to more gluconeogenesis and glucose production from glycolysis. Eventually, fatty acid oxidation becomes the primary energy source for the body.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On initiation of nutrition, relative hyperglycemia is sensed, and insulin is again secreted. This leads to a cascade of anabolic processes, including insulin-mediated activation of the Na-K-ATPase pump, shifting potassium into cells. Insulin also triggers shift of phosphate intracellularly, via mechanisms that remain poorly elucidated, so that ATP can be generated. These actions, compounded by total body electrolyte depletion related to poor electrolyte intake prior to refeeding, cause a marked decrease in serum potassium, phosphate, and magnesium. Clinical features of refeeding syndrome include acute decompensated heart failure due to cardiac atrophy and thiamine deficiency, respiratory failure due to diaphragmatic weakness, and rhabdomyolysis and seizures from phosphate depletion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The other causes of hypokalemia listed do not have concomitant hypophosphatemia as a prominent feature.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with primary aldosteronism develop hypokalemia via excess urinary loss of potassium. Aldosterone results in increased activity of the epithelial sodium channel for sodium reabsorption and potassium channels for potassium excretion in the distal nephron. Thus, patients present with hypertension with hypokalemia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with hypokalemic periodic paralysis present in childhood or adolescence with intermittent episodes of sudden, generalized weakness with marked hypokalemia after consuming high-carbohydrate meals, periods of fasting, or intense exercise.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Gastrointestinal losses of potassium, such as what occurs with diarrhea, are associated with bicarbonate losses. Thus, a non-anion gap metabolic acidosis is typically seen. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although an osmotic diuresis can occur in the setting of hyperalimentation, leading to urinary water loss in greater proportion to sodium and potassium loss, this patient has no clear history of polyuria, and his serum sodium value is stable from admission.</p>\n</div>",
        "references": []
    },
    "60": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 48-year-old man with a history of ESRD secondary to immunoglobulin A (IgA) nephropathy who received a deceased donor kidney transplant 1 year ago presents with inadequately controlled hypertension for the past 4 months. His BP remains elevated despite treatment with nifedipine 60 mg twice daily, clonidine 0.1 mg thrice daily, furosemide 20 mg twice daily, and carvedilol 25 mg twice daily. He adheres to a low-sodium diet. His immunosuppression consists of tacrolimus, mycophenolate mofetil, and prednisone. Tacrolimus trough levels have been 6–8 ng/dL.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP in the office today is 158/86 mm Hg. Examination demonstrates a well-healed left lower abdominal surgical scar with a bruit heard over the lower portion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>138 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.9 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.9 mg/dL (baseline, 1.0)</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Tacrolimus, whole blood trough</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8 ng/mL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>5.0–10.0 &gt;3 months post-transplant</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Test results for CMV IgG are positive and EBV IgG negative.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">UA is normal. Ultrasound shows that the allograft is 10.5-cm long and without hydronephrosis; the transplant renal artery is widely patent. Resistive indices are &lt;0.6 in all segments.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which one of the following is the BEST next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "CT angiography of iliac artery"
            },
            {
                "label": "B.",
                "text": "Captopril renography"
            },
            {
                "label": "C.",
                "text": "Kidney allograft biopsy"
            },
            {
                "label": "D.",
                "text": "Switch tacrolimus to belatacept"
            },
            {
                "label": "E.",
                "text": "Repeat ultrasound in 6 months"
            }
        ],
        "correct_answer": "CT angiography of iliac artery",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Additional investigation for transplant renal artery stenosis (TRAS) or iliac stenosis proximal to the transplant renal artery should be performed in this patient with worsening kidney function and refractory hypertension.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TRAS or native iliac artery stenosis occurs in 1–23% of kidney transplant recipients. It usually manifests within the first few months through a year and a half after transplant. TRAS can cause refractory hypertension with or without allograft dysfunction. TRAS is more common in deceased donor transplants and allografts with prolonged ischemia time. CMV infection, delayed graft function, hypertriglyceridemia, obesity, and advanced recipient age also predispose to TRAS. It can be caused by new stenosis at the site of the surgical anastomosis. A bruit over the allograft may be auscultated but is nonspecific, because some patients will demonstrate a bruit without stenosis. The first step in evaluation is obtaining a renal artery duplex ultrasound to identify high pressures or high velocity in the donor renal artery or the native iliac artery. Low resistive indices may also be present (([peak systolic flow – peak diastolic flow]/peak systolic flow). In contrast, allograft dysfunction due to rejection, calcineurin inhibitor toxicity, or acute tubular necrosis usually produces elevated resistive indices. If ultrasound is inconclusive, an MRI, CT angiogram, or conventional arteriography may be obtained. CO<sub>2</sub> contrast can substitute for iodinated contrast if there are strong concerns for contrast-associated AKI in the setting of AKI or advanced CKD. Patients with elevated serum creatinine or uncontrolled hypertension due to TRAS or iliac stenosis should undergo vascular intervention (angioplasty with or without stenting), which has high success rates in observational studies. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Conservative management of BP may be indicated in patients with stable kidney function. In this case, there is already significant graft dysfunction and uncontrolled hypertension, so repeating the ultrasound in 6 months would not be the preferred approach. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calcineurin inhibitors, especially cyclosporine, can cause elevated BPs after kidney transplantation. This patient has had acceptable tacrolimus trough levels, but some patients will experience toxicity at therapeutic levels that can warrant a change in therapy. However, belatacept is contraindicated in this patient, as he is negative for EBV IgG. Belatacept in EBV-naive patients substantially increases the risk of post-transplant lymphoproliferative disease.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">If a vascular, hemodynamic explanation for the decline in graft function is not identified, biopsy would be a reasonable next step to exclude rejection or interstitial nephritis. Recurrent glomerulonephritis is unlikely with bland sediment. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Captopril renography was in common use to diagnose allograft dysfunction in prior decades, but results can be nonspecific, and this technique has largely been supplanted by anatomic studies such as ultrasound and CT. </p>\n</div>",
        "references": []
    },
    "61": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 75-year-old woman with a history of diabetes, hypertension, and coronary artery disease presents to the emergency department with 5 days of episodic, upper abdominal pain. She undergoes CT of the abdomen and pelvis with IV contrast, which is negative for acute abdominal pathology and shows normal-size kidneys without obstruction. Ketorolac 60 mg and hydralazine 50 mg are administered IV for pain and BP control, respectively.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">She is admitted to the hospital and continued on her home medications of furosemide 40 mg twice daily and hydralazine 50 mg every 8 hours. On the fourth day of hospitalization, her abdominal pain becomes constant and severe, and abdominal angiography is done to rule out mesenteric ischemia. On the fifth day, she becomes hypotensive and is transferred to the ICU. Norepinephrine is initiated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Currently, the patient’s BP is 92/50 mm Hg and heart rate 120/min. Examination reveals regular tachycardia with scattered crackles in the lung bases. The abdomen is mildly tender in the mid-epigastrium. Extremities reveal 1+ edema, a mottled rash on the thighs, and dusky discoloration of the left great toe.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data include the following:</span></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong> </strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Presentation</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Day 4</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Day 5</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Day 7</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Blood</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>4200/µL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8100</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>4000‒11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>   Neutrophils</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>70%</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>73</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>50‒70</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>   Lymphocytes</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>32%</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>34</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>30‒45</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>   Eosinophils</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.9%</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>6.5</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0‒3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>11.5 g/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>10.3</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>12‒16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.8 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.9</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>4.5</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>5.3</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5‒5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>25 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>23</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>22</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>20</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>23‒28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>15 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>16</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>28</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>35</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8‒20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.8</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.6</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.9</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.5‒1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Protein</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1+</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1+</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Blood</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Large</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>RBCs</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>20/HPF</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0‒2</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY cause of AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "IV contrast"
            },
            {
                "label": "B.",
                "text": "Ketorolac"
            },
            {
                "label": "C.",
                "text": "Hypovolemia"
            },
            {
                "label": "D.",
                "text": "Acute tubular necrosis"
            },
            {
                "label": "E.",
                "text": "Atheroembolism"
            }
        ],
        "correct_answer": "Atheroembolism",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute atheroembolic disease is the most likely cause of AKI in this patient with atherosclerosis who recently underwent abdominal angiography.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with diabetes, hypertension, and coronary artery disease likely has atherosclerosis affecting other vascular beds, including the abdominal arteries. Review of the laboratory data shows that AKI developed after arteriography, which is a common trigger for cholesterol embolization to the renal arterial bed. Cholesterol crystals do not occlude the arterioles but impair flow and induce an inflammatory response by attracting neutrophils and eosinophils, which release proteolytic enzymes in an attempt to phagocytose the crystals. Clinical manifestations include livedo reticularis (a lacy, mottled, or dusky rash, frequently in dependent areas of the lower extremities), digital arterial embolization (manifested as a blue tip of a finger or toe), central scotoma from retinal arterial embolization (blurry or absent vision in the center of the visual field), eosinophilia, and C3 hypocomplementemia. Pancreatitis and gastrointestinal bleeding can also be observed. Subacute manifestations may include constitutional symptoms (fever, anorexia, weight loss). The prognosis for atheroembolic kidney disease is poor, and although statins are recommended, treatment is mainly supportive.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Both IV iodinated contrast and ketorolac have been associated with AKI. Ketorolac is an NSAID that may impair renal perfusion, especially in elderly patients with underlying CKD. Contrast administration has been associated with AKI, and although the causality of this association has been called into question, kidney function typically worsens within 2‒3 days and improves by 7‒10 days. In this case, neither of these drugs was temporally associated with the development of AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypovolemia (prerenal AKI) and acute tubular necrosis are important components of the differential diagnosis but would not explain the livedo reticularis or the eosinophilia.</p>\n</div>",
        "references": []
    },
    "62": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 35-year-old man of Ghanian descent is referred to nephrology clinic to evaluate AKI. He has a history of HIV, diagnosed 8 years ago, as well as hepatitis C and sickle trait. His baseline creatinine is 1.5 mg/dL, last checked 4 months ago. He traveled to Mexico 1 month ago, after which he developed diarrhea; he continues to produce 3–4 loose stools daily. Medications include tenofovir disoproxil fumarate, emtricitabine, dolutegravir, and trimethoprim-sulfamethoxazole prophylaxis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient’s BP is 115/75 mm Hg, heart rate 75/min, respiratory rate 14/min, and temperature 37.2°C. There is no postural change in BP or heart rate. He appears mildly ill, but examination is otherwise normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data are as follows:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><span><strong>Serum</strong></span></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>132 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>2.8 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Chloride</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>106 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>18 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>32 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Creatinine </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Calcium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>7.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Phosphorus</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>2.7 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Glucose</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>85 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Aspartate aminotransferase</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>90 U/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Alanine aminotransferase</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>45 U/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Alkaline phosphatase</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>120 U/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>30–120</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><span><strong>Urine</strong></span></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Protein-to-creatinine ratio</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.2 mg/mg</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>&lt;0.2</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">UA reveals specific gravity 1.010, pH 6, albumin 1+, blood negative, and glucose 2+, and microscopy is unremarkable. Kidney ultrasound shows kidneys of 10.5–11 cm in length without hydronephrosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which one of the following is the MOST LIKELY cause of the elevated creatinine concentration?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Tenofovir toxicity"
            },
            {
                "label": "B.",
                "text": "HIV-associated nephropathy"
            },
            {
                "label": "C.",
                "text": "Hepatitis C-associated MPGN"
            },
            {
                "label": "D.",
                "text": "Trimethoprim-sulfamethoxazole toxicity"
            },
            {
                "label": "E.",
                "text": "Hypovolemia"
            }
        ],
        "correct_answer": "Tenofovir toxicity",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has AKI due to tenofovir toxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tenofovir disoproxil fumarate (TDF) is a commonly used nucleotide analog component of HIV antiretroviral therapy. TDF enters proximal tubule cells via organic cation transporter-1 and subsequently depletes mitochondrial DNA, leading to proximal tubulopathy characterized by Fanconi syndrome and acute tubular necrosis. This patient has evidence of Fanconi syndrome with hypokalemia, metabolic acidosis, hypocalcemia, hypophosphatemia, and euglycemic glycosuria. TDF can also cause acute interstitial nephritis (AIN) resulting in AKI in addition to tubular dysfunction, which may require kidney biopsy to establish the diagnosis, depending on the clinical circumstance. In this case, there is substantial evidence for TDF toxicity resulting in proximal tubulopathy and interstitial nephritis. Tenofovir alafenamide is a prodrug formulation that does not seem to confer the same risk for nephrotoxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HIV-associated nephropathy (HIVAN) is an uncommon cause of AKI for those with access to antiretroviral medications. In previous decades, and currently in developing countries, HIVAN was a common cause of AKI in patients of African ancestry, most commonly in those with low CD4 T-cell counts. HIVAN is characterized by nephrotic-range proteinuria and rapidly progressive AKI, neither of which is present in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hepatitis C-associated MPGN is an immune complex glomerulonephritis characterized by nephritic sediment, hypocomplementemia, moderate proteinuria, and AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Trimethoprim-sulfamethoxazole can cause AKI attributed to AIN or intratubular obstruction from sulfamethoxazole crystals, as well as hyperkalemia and increased creatinine from trimethoprim-mediated inhibition of the epithelial sodium channel in the collecting duct and the organic cation transporter in the proximal tubule, respectively. Although these possibilities should be included in the differential diagnosis for AKI, TDF toxicity is more likely given the spectrum of electrolyte abnormalities and evidence of proximal tubulopathy present in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypovolemia is suggested by the history, but this diagnosis is not supported by the findings of a normal BP and heart rate without a postural change in vital signs. The relatively low BUN-to-creatinine ratio also argues against hypovolemia as the cause of AKI.</p>\n</div>",
        "references": []
    },
    "63": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 27-year-old woman is evaluated in clinic. She is currently at 17 weeks of gestation with her first pregnancy and has had no complications. She takes only a prenatal vitamin and feels well.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, her BP is 148/96 mm Hg, heart rate 75/min, and respiratory rate 18/min. Heart examination reveals a soft, systolic ejection murmur in the pulmonic area. Lungs are clear and the abdomen is gravid, appropriate for gestational age. There is trace lower extremity edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">A comprehensive metabolic panel and UA are normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Obtain renal artery duplex ultrasound"
            },
            {
                "label": "B.",
                "text": "Obtain echocardiogram"
            },
            {
                "label": "C.",
                "text": "Prescribe hydrochlorothiazide"
            },
            {
                "label": "D.",
                "text": "Prescribe nifedipine"
            },
            {
                "label": "E.",
                "text": "Repeat evaluation in 2 days"
            }
        ],
        "correct_answer": "Repeat evaluation in 2 days",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management is to repeat the evaluation, including BP measurement, in 2‒3 days.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The diagnosis and differential diagnosis of hypertension in pregnancy is challenging and relies on history of hypertension, gestational age, and evidence of end-organ damage. Hypertension cannot yet be diagnosed in this woman at 17 weeks of gestation with a single elevated BP and no symptoms or evidence of hypertensive damage. The diagnosis of gestational hypertension requires two BP measurements at least four hours apart after 20 weeks of gestation, whereas the diagnosis of preeclampsia requires meeting these criteria as well as proteinuria. Patients under 20 weeks of gestation with BP ≥140/90 mm Hg are diagnosed with chronic hypertension. Before making any of these diagnoses or changing management, BP measurement should be repeated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Either hydrochlorothiazide or nifedipine would treat hypertension once diagnosed, although diuretics are usually avoided during pregnancy for fear of causing hypovolemia and adversely affecting placental function. Systolic murmurs and trace edema are common during pregnancy, and in the absence of chest pain, dyspnea on exertion, or lightheadedness, there is no indication for either echocardiography or hospital admission currently. The level of hypertension at which pharmacologic therapy in pregnancy should be initiated is controversial, but based on the results of the Chronic Hypertension and Pregnancy Study, improved outcomes were observed at a treatment threshold of 140/90 mm Hg, which is now endorsed by the American College of Obstetrics and Gynecology. Individualized evaluation and close follow-up are mandatory. Symptomatic patients or those with evidence of organ dysfunction should be treated sooner.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Renal artery stenosis due to fibromuscular dysplasia may present with onset of hypertension during pregnancy, but it would be premature to investigate for this condition before a diagnosis of hypertension has been established.</p>\n</div>",
        "references": []
    },
    "64": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 45-year-old woman presents to the emergency department with severe headaches and blurry vision for 4 days. Past medical history includes hypertension, diabetes, asthma, and chronic knee pain. She reports a 20-pack-year history of smoking and occasional cocaine use. Medications include hydrochlorothiazide, glipizide, metformin, albuterol, and ibuprofen as needed for pain. The patient notes that she has not been taking medications as prescribed because they “get stuck in the chest,” and she has avoided grocery shopping because her fingers become painful when exposed to the cold. Two weeks ago, her primary care physician prescribed a 5-day prednisone taper for asthma exacerbation. Routine chemistry panel was normal 1 month ago.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Physical examination reveals a BP of 230/124 mm Hg, heart rate 95/min, and normal temperature. Heart, lung, and abdominal examinations are normal. Skin examination reveals dilated, small blood vessels around the mouth and hard deposits beneath the tips of several fingers.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data reveal the following:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>WBC count</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4500/µL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4000‒11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>10.5 g/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>12‒16</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Platelet count</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>96,000/µL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>150,000‒450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Sodium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>143 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>136‒145</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4.5 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5‒5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Chloride</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>105 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>98‒106</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Total CO<sub>2</sub></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>20 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>23‒28</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  BUN</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>35 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>8‒20</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Creatinine </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1.6 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.5‒1.1</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">UA reveals pH 5.5, specific gravity 1.015, and 1+ protein and blood. Microscopy reveals 1‒2 RBC/HPF and 1–2 WBC/HPF. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which one of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Labetalol"
            },
            {
                "label": "B.",
                "text": "Captopril"
            },
            {
                "label": "C.",
                "text": "Nicardipine"
            },
            {
                "label": "D.",
                "text": "Therapeutic plasma exchange"
            },
            {
                "label": "E.",
                "text": "Methylprednisolone"
            }
        ],
        "correct_answer": "Captopril",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of AKI in this patient is scleroderma renal crisis, and the preferred therapy is captopril.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The history and physical examination identify several features of CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias) syndrome or limited systemic sclerosis. Scleroderma renal crisis (SRC) occurs in up to 15% of patients with systemic sclerosis, more commonly in those with diffuse than limited forms, and usually within the first few years of diagnosis. Rarely, SRC can be the presenting manifestation. Up to half of cases are accompanied by thrombotic microangiopathy (TMA), evidenced by low hemoglobin and platelets, as seen in this case. Rapid progression of sclerosis and antibodies to RNA polymerase III are among the risk factors. The recent steroid prescription may also be a precipitating factor in this case, although the association with corticosteroid use and SRC has been questioned. The pathophysiology of SRC is thought to involve fibrinoid necrosis of the renal and other arteries, with renal ischemia causing increased production of renin, angiotensin, and aldosterone. The associated hypertensive emergency requires immediate treatment, classically with ACEIs. There is more experience with captopril, but other ACEIs and ARBs have also been used. Calcium channel blockers can be used as add-on therapy but not as primary treatment. The choice of oral or IV therapy should be made on the basis of the patient’s clinical condition, ability to take oral medications, and available formulations. Of note, captopril given by the sublingual route demonstrates a slightly faster onset of action.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cocaine is a frequent cause of hypertensive urgency. α-Adrenergic blockade, or the use of labetalol, which has a combined α-and β-adrenergic blocking action, is historically the preferred approach, but there is growing evidence for the safety and effectiveness of β-blockers. Although cocaine-related hypertensive emergency must be considered based on the  history, it would not explain the features of CREST syndrome in this patient.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Therapeutic plasma exchange is the mainstay of treatment of thrombotic thrombocytopenia purpura (TTP), a TMA that is defined by low ADAMTS13 activity. Although it would be reasonable to measure ADAMTS13, TTP would not account for the clinical presentation with CREST syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Methylprednisolone, usually given as a series of large IV doses (“pulse steroids”), is a mainstay of treatment for many causes of rapidly progressive glomerulonephritis (RPGN). In this case, the urine findings do not suggest RPGN.</p>\n</div>",
        "references": []
    },
    "65": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 30-year-old man with a history of ulcerative colitis (UC) is referred to the outpatient clinic for evaluation of AKI. UC was diagnosed 1 year ago. He describes having 5–6 watery bowel movements daily with crampy abdominal pain. He does not have a rash, sinus congestion, cough, or specific joint pain. There is no history of nephrolithiasis. Medications include budesonide and mesalamine.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient’s BP is 90/40 mm Hg, heart rate 100/min, and temperature 37°C. Physical examination reveals no oral ulcers, nasal crusting, rash, skin nodules, costovertebral angle tenderness, or edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data are as follows:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong> </strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>WBC count</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>12,200/μL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>11.0 g/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Platelet counts</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>450,000/μL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>2.5 mg/dL (baseline 1 month ago, 0.8)</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>C3</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>120 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>100–233</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>C4</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>24 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>14–48</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>ANA</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1:80</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>≤1:40</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>ANCA, perinuclear (p-ANCA)</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Positive</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>ANCA, cytoplasmic (c-ANCA)</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Negative</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Urine protein-to-creatinine ratio</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1.2 mg/mg</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>&lt;0.2</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urine microscopy reveals numerous granular casts, 2–3 WBC/HPF, and 2–3 isomorphic RBC/HPF.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Chest x-ray is normal. Non-contrast CT of the abdomen and pelvis shows normal-size kidneys without hydronephrosis and a 3-mm calcification in the left lower pole consistent with a kidney stone.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>In addition to a more detailed serologic analysis, which of the following is the next BEST STEP in diagnosis and management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Fluid resuscitation"
            },
            {
                "label": "B.",
                "text": "Discontinue mesalamine"
            },
            {
                "label": "C.",
                "text": "Stress-dose corticosteroids"
            },
            {
                "label": "D.",
                "text": "Kidney biopsy"
            },
            {
                "label": "E.",
                "text": "24-Hour urine chemistry and stone analysis"
            }
        ],
        "correct_answer": "Fluid resuscitation",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hypotension, hypovolemia from chronic diarrhea, and granular casts on urine sediment analysis most likely has acute tubular necrosis (ATN), and initial management would be volume resuscitation to euvolemia to avoid progressive kidney injury.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ATN from prolonged hypovolemia is managed conservatively, by optimizing volume status and avoiding additional insults, such as NSAID-mediated vasoconstriction. ATN may be accompanied by subnephrotic, tubular proteinuria and granular or muddy brown casts on urine microscopy. Normalization of kidney function with volume resuscitation would also be evidence against an alternative diagnosis such as glomerulonephritis or interstitial nephritis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mesalamine has been associated with acute interstitial nephritis and minimal change disease. The rapidity of AKI and absence of nephrotic-range proteinuria make these conditions less likely than hypovolemia-associated ATN. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The positive p-ANCA in this patient, without information regarding antimyeloperoxidase (anti-MPO) or anti-proteinase 3 (anti-PR3) antibodies, is difficult to interpret. In patients with signs and symptoms consistent with ANCA-associated vasculitis, serological testing combining both indirect immunofluorescence (IIF) and ELISA provides the highest specificity for disease process. IIF is performed on ethanol-fixed neutrophils; ELISA uses purified antigens. The specific antigens MPO and PR3 are both located within azurophilic granules in the cytoplasm of neutrophils. IIF produces three different staining patterns: cytoplasmic staining (c-ANCA), associated with an antibody against PR3; perinuclear staining (p-ANCA), associated with an antibody against MPO; and atypical staining (a-ANCA), a combination of these. The perinuclear pattern is an artifactual relocation of cationic MPO from the cytoplasm to the negatively charged nucleus during ethanol fixation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A positive ANCA test, either by IIF or ELISA, in a patient with no clinical evidence of vasculitis, suggests either (1) the presence of a non-pathogenic antibody against PR3 or MPO or (2) the presence of an antibody against other neutrophil antigens, such as elastase, lactoferrin, bactericidal increasing protein, and enolase. A common scenario is positive p-ANCA on IIF and negative ELISA, reflecting anti-elastase antibody vasculitis in patients who abuse cocaine adulterated with levamisole. Positive p-ANCA or a-ANCA results on IIF and negative ELISA are encountered in up to 50% of patients with UC, as well as those with chronic liver disease, rheumatoid arthritis, and cystic fibrosis with <em>Pseudomonas</em> infection. Likewise, a nonspecific, positive ANA is also often present in patients with UC. Patients with clinical features of rapidly progressive glomerulonephritis should undergo kidney biopsy or empiric immunosuppression, depending on the clinical circumstances. In this patient, the positive p-ANCA and low titer ANA likely reflect UC. The extremely rapid tempo of AKI, absence of active urine sediment, and negative ANCA ELISA make ANCA-associated vasculitis less likely than ATN. Therefore, although it would be reasonable to obtain more specific serologic data, including ELISA studies, performing a kidney biopsy would not be indicated at this time.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"> </p>\n<p>Patients with inflammatory bowel disease are often hypovolemic and may have malabsorption, placing them at higher risk for calcium oxalate and uric acid nephrolithiasis, but AKI would be unlikely in the absence of bilateral ureteral obstruction if baseline kidney function is normal, as in this case. Acute nephrolithiasis is often accompanied by severe flank or costovertebral angle pain that radiates to the groin, with many RBCs and WBCs on urinalysis. Sodium, oxalate, uric acid, citrate, magnesium, phosphorus, and creatinine may be measured via 24-hour urine collection to assess risk factors for stone formation, but such testing should wait at least 3 months from the last stone to allow urine stabilization. Stone analysis would require passage and collection of a stone to be sent to the laboratory to determine chemical composition.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">An inadequate adrenal response due to suppression of the hypothalamic-pituitary-adrenal (HPA) axis should be considered in patients receiving chronic corticosteroids who present with compatible symptoms and signs such as hypotension. Budesonide, oral or rectal, acts topically on the intestinal mucosa, has limited systemic bioavailability, and therefore is unlikely to suppress the HPA axis. </p>\n</div>",
        "references": []
    },
    "66": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 30-year-old woman with no significant past medical history is referred for asymptomatic proteinuria detected during an insurance physical examination. Review of systems is negative for photosensitivity, rash, arthralgias, oral ulcers, or alopecia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 142/92 mm Hg and heart rate 72/min. Heart, lung, and abdominal examinations are unremarkable, and there is no edema. There is no pain to joint palpation and no rash on skin examination. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory tests yield the following:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>WBC count</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>5000/μL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>12.0 g/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Platelet count</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>200,000/μL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.8 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Albumin</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.8 g/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>C3</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>106 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>100–233</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>C4</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>20 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>14–48</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>ANA</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1:640</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>≤1:40</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Antibodies to double-stranded DNA</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>36 IU/mL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0–7</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Urine protein-to-creatinine ratio</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.86 mg/mg</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>&lt;0.2</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urine sediment reveals 3–5 dysmorphic RBC/HPF.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient undergoes kidney biopsy. Light microscopy shows increased mesangial matrix expansion and increased cellularity without crescents, fibrinoid necrosis, or interstitial inflammation (see photomicrograph below). IF shows granular, immunoglobulin G (IgG)-dominant “full house” staining of the capillary loops and tubular basement membrane. EM shows mesangial deposits with tubuloreticular inclusions in some endothelial cells. There are no subepithelial or subendothelial deposits. She is diagnosed with class II lupus nephritis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Lisinopril is initiated, and the patient is counseled on pregnancy prevention.</p>\n<figure><img src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/q66-ksapv7m1.png\" style=\"width: 70%; height: auto;\"/>\n<figcaption><em> Image courtesy of <span>J Am Soc Nephrol</span> 15(2): 241–250, 2004</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-top: 20px; margin-bottom: 15px;\"><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prednisone"
            },
            {
                "label": "B.",
                "text": "Prednisone and mycophenolate"
            },
            {
                "label": "C.",
                "text": "Tacrolimus"
            },
            {
                "label": "D.",
                "text": "No additional therapy"
            },
            {
                "label": "E.",
                "text": "Hydroxychloroquine"
            }
        ],
        "correct_answer": "Hydroxychloroquine",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with class II lupus nephritis (LN), normal kidney function, and low-grade proteinuria should receive an ACEI or ARB plus hydroxychloroquine (HCQ) to decrease the risk of disease progression.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Non-proliferative LN (class I, II, and V with low-grade proteinuria) without extrarenal manifestations does not require immunosuppressive therapy. Rather, it is managed conservatively with medications to decrease proteinuria and control BP. In addition, anti-malarial drugs such as HCQ, which block Toll-like receptor signaling and downregulate pro-inflammatory cytokines, have been found to delay progression of kidney disease. Therefore, the combination of HCQ and an ACEI or ARB is the preferred approach. Because ACEIs and ARBs are contraindicated in pregnancy, it would be necessary to counsel this patient regarding contraception, or to choose an alternative approach if pregnancy is anticipated. Some practitioners would treat non-proliferative LN with immunosuppression if there is persistent or progressive proteinuria, but blockade of the renin-angiotensin-aldosterone system and HCQ are the first steps.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Proliferative LN (class III and IV) and membranous LN (class V) with nephrotic-range proteinuria should be managed by combining HCQ and an ACEI or ARB with immunosuppression. Choices of medications include corticosteroids and mycophenolate, cyclophosphamide, or calcineurin inhibitors, potentially in combination. Immunosuppression may also be considered for patients with extrarenal manifestations of lupus and those with rapidly deteriorating kidney function irrespective of histologic classification.</p>\n</div>",
        "references": []
    },
    "67": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 62-year-old man with a past medical history of osteoarthritis presents to his primary care provider for his annual healthcare visit. He reports no acute complaints. His only medication is acetaminophen as needed. He drinks one or two bottles of beer every night and up to four bottles on weekends.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, his BP is 122/82 mm Hg, heart rate 76/min, temperature 37.2°C, and weight 74 kg. Heart, lung, and abdominal examinations are normal. There is no edema. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Review of records shows that his serum sodium has been 131–134 mEq/L over the past 6 years.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data are as follows:</span></p><div style=\"margin-bottom: 15px;\"><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>132 mEq/L </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>11 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Glucose</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>89 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>70–99, (fasting)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Albumin</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.9 g/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Osmolality</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>271 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>275–295</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>62 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>  Osmolality</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>356 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>38–1400</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">A water loading test is performed with oral ingestion of 1 L of water. Four hours after ingestion, his urine output is 860 mL.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY etiology of hyponatremia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Syndrome of inappropriate antidiuretic hormone (SIADH)"
            },
            {
                "label": "B.",
                "text": "Reset osmostat"
            },
            {
                "label": "C.",
                "text": "Hypoperfusion"
            },
            {
                "label": "D.",
                "text": "Pseudohyponatremia"
            },
            {
                "label": "E.",
                "text": "Beer potomania"
            }
        ],
        "correct_answer": "Reset osmostat",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely etiology of this patient’s hyponatremia is a reset osmostat.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Reset osmostat is a hypo-osmolar, hypotonic hyponatremia due to an aberrant plasma tonicity setpoint. In the general population, when plasma tonicity is below a threshold of 280 mOsm/kg H<sub>2</sub>O, vasopressin release and thirst are suppressed, resulting in excretion of a dilute urine and normalization of the plasma tonicity. In individuals with reset osmostat, this suppression does not occur until the tonicity is lower.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Historical clues to reset osmostat include mild, chronic hyponatremia with urine that is intermittently concentrated and intermittently dilute. Reset osmostat is a benign condition, and no pharmacotherapy, dietary changes, or fluid restriction is warranted. Reset osmostat can be transient if secondary to acute illness.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">When suspected, reset osmostat can be diagnosed using a water loading test, in which an oral water load of 10–15 mL/kg is administered to suppress vasopressin secretion. In a patient with reset osmostat, 80% of the water load will be excreted within 4 hours. Furthermore, the urine will become dilute, with osmolality &lt;100 mOsm/kg H<sub>2</sub>O. In a patient with SIADH, vasopressin will not be suppressed and the water load will not be excreted, resulting in worsened hypotonicity and persistently concentrated urine. The use of a water loading test should be limited to patients with mild hyponatremia, because patients with SIADH will have worsened hypotonicity from the water load.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypoperfusion is unlikely in the absence of history or examination findings consistent with hypovolemia, normal BUN-to-creatinine ratio, and urine sodium &gt;20 mEq/L. Pseudohyponatremia is excluded because the serum osmolality is depressed to a similar extent as the serum sodium. Beer potomania occurs when patients with alcohol use disorder consume large quantities of dilute fluid (i.e., beer), but do consume sufficient solute to allow excretion of the water load despite a maximally dilute urine. The pathophysiology of this condition is similar to that of hyponatremia associated with a “tea and toast” diet.</p>\n</div>",
        "references": []
    },
    "68": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 30-year-old woman with CKD stage G3a/A2 seeks preconception counseling in the outpatient setting. She anticipates pregnancy within 4 to 6 months. She has a 15-year history of type 1 diabetes and a 3-year history of hypertension. Medications include insulin, lisinopril, and hydrochlorothiazide. She currently feels well.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vital signs include BP 128/74 mm Hg and heart rate 72/min. Physical examination is normal. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Laboratory studies show a serum creatinine of 1.1 mg/dL (reference range, 0.5‒1.1) and urine albumin-to-creatinine ratio 45 mg/g (reference range, &lt;30).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Lisinopril is discontinued.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discontinue hydrochlorothiazide"
            },
            {
                "label": "B.",
                "text": "Prescribe losartan"
            },
            {
                "label": "C.",
                "text": "Prescribe nifedipine"
            },
            {
                "label": "D.",
                "text": "Prescribe atenolol"
            },
            {
                "label": "E.",
                "text": "Prescribe spironolactone"
            }
        ],
        "correct_answer": "Prescribe nifedipine",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">To reduce the risk of teratogenicity and maintain BP control, this patient’s lisinopril should be changed to nifedipine before proceeding with pregnancy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypertension is the most common medical disorder during pregnancy and complicates up to 15% of pregnancies. Although classified as pregnancy category C (risk cannot be ruled out), based on long experience and observation, nifedipine, labetalol, and α-methyldopa are considered safe, first-line medications for hypertension during pregnancy. Adverse effects of long-acting nifedipine include palpitations, peripheral edema, headaches, and facial flushing. Labetalol has both α- and β-adrenergic blocking activity and preserves uteroplacental blood flow to a greater extent than traditional β-blockers. α-Methyldopa has a slow onset of action (3‒6 hours) and blocks central α-2 receptors; adverse effects include impaired alertness and salivation, xerostomia, and elevated liver enzymes.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Antihypertensive medications contraindicated during pregnancy include renin-angiotensin system inhibitors and atenolol (pregnancy category D, evidence of risk). Lisinopril and losartan are traditionally avoided because of the increased risk of fetal kidney, heart, and central nervous system malformations. This risk is well established for exposure to these drugs in the second and third trimesters, but some studies have questioned this association in the first trimester. Nevertheless, these drugs should be avoided in pregnancy. Patients taking ACEIs or ARBs who become pregnant should discontinue them as soon as possible. Spironolactone, category D, also has fetal anti-androgenic effects. Atenolol, also category D, is contraindicated for use in pregnancy because of the risk of fetal intrauterine growth restriction. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thiazide diuretics may be continued through pregnancy by women who are taking them prior to conception. Diuretics affect the plasma volume expansion of normal pregnancy but are otherwise not associated with adverse fetal outcomes. Discontinuing the drug with no substitution would risk worsening hypertension. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although not offered as an option in this case, some clinicians would simply discontinue lisinopril and observe the BP before adding an alternative agent.</p>\n</div>",
        "references": []
    },
    "69": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 32-year-old woman presents for preconception counseling. She has ESRD due to immunoglobulin A (IgA) nephropathy. She received a kidney transplant from her husband 3 years ago. She had an episode of acute rejection 18 months ago that was successfully treated with glucocorticoids, and kidney function has subsequently been stable. Her current immunosuppressive medications are mycophenolate, tacrolimus, and prednisone. She feels well and reports no symptoms.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vital signs include a BP of 114/68 mm Hg and pulse 76/min. Physical examination is normal. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Laboratory data are significant for a creatinine of 1.2 mg/dL (reference range, 0.5‒1.1).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which one of the following is the MOST APPROPRIATE recommendation regarding pregnancy planning?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Pregnancy is contraindicated"
            },
            {
                "label": "B.",
                "text": "Change tacrolimus to cyclosporine"
            },
            {
                "label": "C.",
                "text": "No change in management"
            },
            {
                "label": "D.",
                "text": "Change mycophenolate to azathioprine"
            },
            {
                "label": "E.",
                "text": "Delay pregnancy for one year"
            }
        ],
        "correct_answer": "Change mycophenolate to azathioprine",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate recommendation for this patient with ESRD status post kidney transplantation with good kidney function is to change mycophenolate to azathioprine before proceeding with pregnancy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Managing immunosuppression in kidney transplant recipients is important because of concerns about teratogenic risk. Mycophenolate mofetil is a category D drug for pregnancy and has been associated with fetal limb and facial congenital anomalies, including microtia, hypoplastic nails, shortened fifth finger, and cleft lip and palate; congenital diaphragmatic hernia; congenital heart defects; and increased risk of spontaneous abortion. Azathioprine, low-dose corticosteroids (prednisone &lt;20 mg/day or equivalent), and calcineurin inhibitors (CNIs) are considered relatively safe during pregnancy. Medications that are teratogenic should be changed or stopped in kidney transplant recipients at least 6 weeks before conception. Typically, mycophenolate is changed to azathioprine, and sirolimus is changed to a CNI. Counseling about childbearing and risk of teratogenicity with immunosuppression should start at the pre-transplant evaluation and should be continued during post-transplant visits. Women of childbearing potential should follow a risk evaluation and mitigation strategy (REMS) and should be advised to use contraception while taking mycophenolate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Changing tacrolimus to cyclosporine would be unnecessary because both are CNIs and would not be expected to alter pregnancy outcomes. Conversely, changing mycophenolate to sirolimus would substitute one teratogenic medication for another. Pregnancy is not absolutely contraindicated, but maternal and fetal complications occur with greater frequency in transplant recipients, and careful counseling and close management are required. Most transplant programs ask patients to delay pregnancy for at least one year after surgery. A 2019 meta-analysis found that complications were fewer in the cohort who became pregnant 3 years or longer after surgery, but there did not appear to be an advantage to a longer delay.  </p>\n</div>",
        "references": []
    },
    "70": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 56-year-old man presents for follow-up of CKD stage G4. His past medical history includes hypertension, type 2 diabetes, gastroesophageal reflux, and ulcerative colitis. He feels well but reports transient lightheadedness on standing. Current medications include furosemide, levothyroxine, amlodipine, omeprazole, magnesium oxide, glipizide, and a multivitamin. During his last visit 2 months ago, his potassium was 5.4 mEq/L, and he was seen by a dietitian and educated about a low-potassium diet, to which he has adhered strictly. Furosemide was also increased at that time because of lower extremity edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient’s BP is 118/66 mm Hg, pulse 88/min, and respirations 15/min. When he is upright, there are no changes in BP, but his heart rate increases to 100/min. Heart, lung, and abdominal exams are normal. No lower extremity edema is appreciated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data are as follows:</span></p>\n<div style=\"margin-bottom: 15px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>141 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>5.9 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>104 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>27 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>2.4 mg/dL (baseline)</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Glucose</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>135 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>70–99, (fasting)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>9.2 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Magnesium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.2 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>1.6–2.6</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>4.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>Urine albumin-to-creatinine ratio</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>86 mg/g</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\">\n<p>&lt;30</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">An EKG reveals normal sinus rhythm with no ST or T wave changes.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST STEP to manage hyperkalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe sodium zirconium cyclosilicate"
            },
            {
                "label": "B.",
                "text": "Prescribe patiromer"
            },
            {
                "label": "C.",
                "text": "Prescribe sodium polystyrene sulfonate"
            },
            {
                "label": "D.",
                "text": "Prescribe sodium bicarbonate"
            },
            {
                "label": "E.",
                "text": "Increase furosemide"
            }
        ],
        "correct_answer": "Prescribe sodium zirconium cyclosilicate",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with CKD stage 4, probable hypovolemia, and hyperkalemia refractory to dietary modification may benefit from a sodium-containing potassium binder such as sodium zirconium cyclosilicate (SZC).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">SZC exchanges sodium and hydrogen ions for potassium in the gastrointestinal tract. This medication has been shown to reduce potassium levels in persistently hyperkalemic patients with CKD, diabetes, or heart failure, including those receiving renin-angiotensin-aldosterone blockers. In the HARMONIZE trial, normokalemia was achieved with SZC in 84% of patients within 24 hours and maintained at 4 weeks of therapy. SZC contains a significant amount of sodium, which could potentially contribute to volume overload in patients who are predisposed. SZC must be administered 2 hours before or after other medications to avoid impairing absorption. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patiromer exchanges potassium with calcium in the colon. The AMETHYST-DN and OPAL-HK studies demonstrated the ability of this drug to lower potassium levels in patients with CKD and chronic hyperkalemia, with or without diabetes. Like ZS-9, patiromer may interfere with absorption of other medications in the gut, including levothyroxine, and a 3-hour drug separation is recommended. In addition, calcium-magnesium exchange may cause or worsen hypomagnesemia. In this patient with preexisting hypomagnesemia, patiromer would not be preferred.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although there are no direct comparisons between the available potassium binders, sodium polystyrene sulfonate (SPS) was initially approved based on small clinical trials with heterogeneous populations, and its effectiveness has been questioned. In addition, SPS or the sorbitol with which it has been co-formulated have been linked to gastrointestinal ulcers and perforation and intestinal ischemia and thrombosis, especially among patients with a history of gastrointestinal pathology, such as this patient with ulcerative colitis. For these reasons, SPS would not be the best choice.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sodium bicarbonate may be effective in managing hyperkalemia associated with a non-anion gap acidosis (i.e., normal anion gap), but not the more commonly encountered organic acidosis associated with CKD or lactic acidosis. In addition, sodium bicarbonate therapy to improve the serum bicarbonate may delay the progression of CKD. In this case, his serum bicarbonate is already high at 27 mEq/L, so supplemental sodium bicarbonate would not be expected to provide additional benefit.</p>Increasing the furosemide dose would not be indicated at this time given this patient’s hypovolemia. \n</div>",
        "references": []
    },
    "71": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 54-year-old woman presents to the outpatient clinic with anorexia, lethargy, and a 5-kg weight loss. Past medical history includes hypertension and a recently diagnosed rectal adenoma, for which she underwent partial colectomy and diverting loop ileostomy 6 weeks ago. Her medications include extended-release propranolol and vitamin D; lisinopril was discontinued 3 weeks ago.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, her BP is 88/56 mm Hg and heart rate 56/min. Upright BP was not obtained. She has dry mucous membranes and decreased skin turgor. Heart examination is normal except for bradycardia. Abdominal examination reveals a well-healed surgical incision and ileostomy with a clean bag.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data are as follows: </span></p>\n<div style=\"margin-bottom: 20px;\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\" width=\"75%\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Sodium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>132 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.8 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Chloride</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>102 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Total CO<sub>2</sub></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>18 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  BUN</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>28 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>1.2 mg/dL (baseline, 0.7)</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Cortisol</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>46 μg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>5–25 (8 a.m.)</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Aldosterone</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>68 ng/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>≤10 ng/dL (seated)</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Renin activity</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>20 ng/mL per hour</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>0.3–2.5 (upright)</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Sodium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>12 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Potassium</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>9 mEq/L</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>  Creatinine</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>75 mg/dL</p>\n</td>\n<td style=\"vertical-align: top; border: 1px solid rgb(0, 0, 0);\">\n<p>Varies</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY explanation for normal serum potassium despite high serum aldosterone?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Loss of\nfunction of the mineralocorticoid receptor"
            },
            {
                "label": "B.",
                "text": "Upregulation of Na-Cl cotransporter"
            },
            {
                "label": "C.",
                "text": "Inhibition of renal outer medullary potassium channel"
            },
            {
                "label": "D.",
                "text": "Aldosterone breakthrough"
            },
            {
                "label": "E.",
                "text": "Pressure natriuresis"
            }
        ],
        "correct_answer": "Inhibition of renal outer medullary potassium channel",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s normal serum potassium in the setting of high serum aldosterone is consistent with renal outer medullary K (ROMK) channel inhibition. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The ability of aldosterone to stimulate Na reabsorption without K excretion during hypovolemia and to stimulate K excretion without Na retention during hyperkalemia is referred to as the aldosterone paradox. Normally, Na reabsorption in the distal nephron generates a negatively charged lumen that favors K excretion through the ROMK channel. Hypovolemia stimulates an appropriate increase in renin, angiotensin II (AT II), and aldosterone, as seen in this case. AT II stimulates the WNK4 (protein kinase “with no lysine” 4) pathway, which inhibits ROMK and allows aldosterone-mediated Na reabsorption without K excretion. In this case, renal K retention is confirmed by the low urine K-to-creatinine ratio of 12 mEq/g, which is less than the threshold value of 15 mEq/g for appropriate renal response to hypokalemia.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pseudohypoaldosteronism type 1 (PHA I) is a rare hereditary condition, that mimics hypoaldosteronism, characterized by variably severe salt wasting and hyperkalemia despite elevated renin and aldosterone levels. PHA I is due to mineralocorticoid receptor resistance. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pseudohypoaldosteronism type 2 (PHA II, Gordon syndrome) is a rare genetic disorder resulting from mutations in <em>WNK1</em> and <em>WNK4</em>. The WNK4 enzyme negatively regulates the Na-Cl co-transporter, so genetic mutations in <em>WNK4</em> lead to unregulated Na-Cl reabsorption, hypertension, hyperkalemia, and metabolic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Aldosterone breakthrough occurs when treatment with renin-angiotensin-aldosterone blockers initially reduce serum aldosterone levels, but levels later reach or exceed pre-treatment values via alternative biochemical pathways.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Aldosterone escape is a physiologic phenomenon observed in primary aldosteronism. Hyperaldosteronism causes Na retention, which leads to hypertension without causing edema. Edema is absent because Na retention is mitigated due to pressure natriuresis and decreased proximal tubule Na reabsorption.</p>\n</div>",
        "references": []
    },
    "72": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">An 82-year-old man presented to the emergency department reporting weakness and confusion for the past 3 days. Two weeks ago, he sustained a knee injury and began taking ibuprofen 400 mg three times daily. For the past week, he has also had abdominal pain, but he continued to take ibuprofen. Past medical history includes CKD stage 3 attributed to type 2 diabetes and hypertension. He has smoked 2 packs of cigarettes per day for the past 60 years. Medications include irbesartan, chlorthalidone, amlodipine, glipizide, and aspirin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient’s vital signs are BP 114/58 mm Hg, heart rate 96/min, and respiratory rate 23/min. On examination, he is confused and lethargic. There is mild tenderness to mid-epigastric abdominal palpation and decreased tissue turgor.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">An indwelling urinary catheter is placed, and the patient receives a total of 3 L of IV isotonic saline, after which urine output is only 100 mL. HD is initiated via a temporary catheter with the following prescription: high-flux, 1.8 m<sup>2 </sup>dialyzer, treatment time 3.5 h, blood flow 400 mL/min, dialysate flow 500 mL/min, dialysate sodium 138 mEq/L, potassium 2 mEq/L, bicarbonate 40 mEq/L, and glucose 100 mg/dL. Ultrafiltration of 1.5 L is performed with stable hemodynamic parameters. HD is uneventful, but 6 hours after treatment, the patient complains of headache. He becomes more confused, and myoclonic jerks are observed. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 70%;\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 25%;\"><strong> </strong></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 25%;\"><strong>On Presentation</strong></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 25%;\"><strong>6 Hours Post-HD</strong></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 25%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">Sodium</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">147 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">139</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">136–145</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">Potassium</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">5.2 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">3.4</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">Chloride</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">113 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">104</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">98–106</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">Total CO<sub>2</sub></td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">15 mEq/L</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">24</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">23–28</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">BUN</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">196 mg/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">46</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">8–20</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">Creatinine</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">11 mg/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">4.8</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">Glucose</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">74 mg/dL</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">87</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">70–99 (fasting)</td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Urine sediment reveals numerous, muddy brown casts. CT scan of the brain reveals changes compatible with mild cerebral edema without herniation.</p>\n<p dir=\"ltr\" style=\"margin-top: 15px; margin-bottom: 20px;\"><strong>Which of the following changes in management would have been MOST LIKELY to prevent the observed post-dialysis complications?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Decrease blood flow (Qb) to 200 mL/min"
            },
            {
                "label": "B.",
                "text": "Increase dialysate sodium concentration to 144 mEq/L"
            },
            {
                "label": "C.",
                "text": "Decrease dialysate bicarbonate concentration to 30 mEq/L"
            },
            {
                "label": "D.",
                "text": "Decrease treatment time to 2 hours"
            },
            {
                "label": "E.",
                "text": "Infuse mannitol IV prior to dialysis"
            }
        ],
        "correct_answer": "Decrease treatment time to 2 hours",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has developed dialysis disequilibrium syndrome, which most likely would have been avoided by shortening the duration of the initial dialysis session. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dialysis disequilibrium was first described in the 1960s with the introduction of dialysis. It was more commonly reported during the early years of dialysis, when it was typical for BUN levels to climb very high prior to initiation of renal replacement therapy. Urea is removed more slowly from the intracellular compartment and cerebrospinal fluid than from blood, and this gradient results in the development of cerebral edema when BUN decreases rapidly. The same physiology would apply to rapid normalization of the sodium concentration. Symptoms of disequilibrium syndrome may be mild, such as headache and restlessness; moderate, such as nausea, vomiting, and hypertension; or severe, such as seizures and coma.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most common strategy to prevent dialysis disequilibrium includes limiting the urea removal during the first treatment by prescribing a lower blood flow rate and shorter duration of treatment. Although it varies between dialyzers and with dialysate flow rate (Qd), the reduction in urea clearance at a Qb of 200 mL/min compared with 400 mL/min is about 25%. Although nonlinear, reducing the time of treatment will have a larger impact, reducing urea removal by much more than 25%. Therefore, if only one intervention were made, shortening treatment time would have the greatest impact. Note that a reduction in Qd parallel to a reduction in Qb is often prescribed as well. Many practitioners will prescribe a short treatment time, low Qb, and low Qd for the initial dialysis and then incrementally increase each parameter with subsequent treatments, gradually working toward a standard prescription.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing the dialysate sodium concentration to approximate that of the patient’s, or using a sodium modeling program, is also a reasonable approach to reduce the likelihood of disequilibrium. However, implementing only a modest change in dialysate sodium from 138 mEq/L to 144 mEq/L is unlikely to prevent disequilibrium in this severely azotemic patient. Adding glucose to the dialysate or administering IV mannitol during dialysis to reduce the osmotic gradient between the extracellular and intracellular compartments has been used to prevent disequilibrium, but these measures would not be taken prior to dialysis and are not widely practiced. Reducing the dialysate bicarbonate concentration might blunt the correction of metabolic acidosis but is not known to affect the development of disequilibrium syndrome. In the absence of concern for metabolic alkalosis or potassium shift, this approach would not be needed.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">For patients vulnerable to developing cerebral edema, CRRT should also be considered.</p>\n</div>",
        "references": []
    },
    "73": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 56-year-old man is evaluated following elective open cholecystectomy. Past medical history includes cholelithiasis, hypertension, type 2 diabetes, and CKD stage G3/A2. Outpatient medications include amlodipine, lisinopril, hydrochlorothiazide (HCTZ), and glipizide, but all medications were discontinued on admission because of a pre-operative NPO requirement. Surgery proceeded uneventfully, and the patient was able to tolerate clear liquids on the second post-operative day.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, his BP is 178/110 mm Hg and heart rate 78/min. Heart, lung, and abdominal examinations are unremarkable, with mild tenderness to palpation around the surgical incision in the right upper quadrant. Bowel sounds are present. There is no edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>Laboratory data include the following:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 30;\">\n<strong>Value</strong>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width: 30;\">\n<strong>Reference Range </strong>\n</td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px; width:30%;\">\n                Sodium \n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                138 mEq/L\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                Potassium\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                4.4 mEq/L\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                23 mEq/L\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                Creatinine \n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                1.4 mg/dL (stable)\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                Urine albumin-to-creatinine ratio \n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                75 mg/g\n            </td>\n<td style=\"vertical-align: top; border: 1px solid black; padding: 5px 5px 5px 5px;\">\n                &lt;30 \n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 20px;\"><strong>Which of the following is the next BEST STEP in managing this patient’s hypertension?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Resume amlodipine, lisinopril, and HCTZ"
            },
            {
                "label": "B.",
                "text": "Resume amlodipine"
            },
            {
                "label": "C.",
                "text": "Prescribe hydralazine IV"
            },
            {
                "label": "D.",
                "text": "Prescribe topical clonidine"
            },
            {
                "label": "E.",
                "text": "Prescribe labetalol IV"
            }
        ],
        "correct_answer": "Resume amlodipine, lisinopril, and HCTZ",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with asymptomatic stage 2 hypertension and stable CKD should resume taking his home medication regimen of amlodipine, lisinopril, and HCTZ.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In the absence of acute end-organ damage, asymptomatic hypertension in the hospitalized setting does not require rapid BP lowering. Although IV medications are commonly used in the hospital setting to treat asymptomatic BP elevation, there is no evidence that such an approach confers benefit in reducing major adverse cardiovascular events, short-term mortality, or length of hospitalization. Conversely, there might be harm due to the hypoperfusion and medication adverse effects, such as tachycardia with IV hydralazine or nitroprusside. Although topical administration of clonidine would be useful if there were concerns about enteral absorption or the safety of taking oral medications, this patient is tolerating a liquid diet and the physical examination is reassuring. Therefore, after addressing or excluding causes of reactive hypertension such as pain, anxiety, and urinary retention, the correct course of action is to resume home oral medications. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In the absence of hyperkalemia, prerenal AKI, or other intolerance, there is no reason to stop lisinopril and HCTZ. Guidelines generally call for withholding ACEIs, ARBs, and diuretics on the day of surgery and continuing other antihypertensive agents. In fact, there are no robust data supporting the common practice of withholding ACEIs or ARBs peri-operatively, and there is some suggestion of potential harm.   </p>\n</div>",
        "references": []
    },
    "74": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A 45-year-old woman with a history of type 2 diabetes, obesity, and metastatic breast cancer is hospitalized for neutropenic fever. Her metastatic breast cancer has been managed with gemcitabine and paclitaxel, most recently administered 3 days before\n    admission.</p>\n<p>On admission, the patient’s BP is 90/52 mm Hg, temperature 38.5°C, and weight 110 kg. She is prescribed vancomycin 20 mg/kg IV followed by 15 mg/kg twice daily, as well as piperacillin-tazobactam 3.375 g every 6 hours. After 48 hours, she is afebrile and normotensive.\n    Nephrology consultation is requested on day 4 for oliguric AKI.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Admission</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Day 4</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range </strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                900/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1,600\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.3 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                89,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                92,000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Potassium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5‒5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                17\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23‒28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                32 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                42\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8‒20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.2 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5‒1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Vancomycin, trough\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mg/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15–20, target\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">UA reveals specific gravity 1.020, 1+ protein, 1+ blood, 4‒5 WBC/HPF, 3–5 RBC/HPF, and occasional granular casts.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the most appropriate NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Initiate hemodialysis"
            },
            {
                "label": "B.",
                "text": "Discontinue piperacillin-tazobactam"
            },
            {
                "label": "C.",
                "text": "Obtain kidney biopsy"
            },
            {
                "label": "D.",
                "text": "Discontinue vancomycin"
            },
            {
                "label": "E.",
                "text": "Discontinue gemcitabine"
            }
        ],
        "correct_answer": "Discontinue vancomycin",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has AKI secondary to vancomycin nephrotoxicity, so vancomycin should be discontinued.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vancomycin, a glycopeptide antibiotic, is widely used in the setting of resistant gram-positive bacterial infection or as empiric therapy for sepsis. It is predominantly cleared by glomerular filtration. Typically, trough levels are monitored, and higher levels are associated with nephrotoxicity, although it remains controversial whether this is a cause or effect of the decline in GFR. Risk factors for vancomycin nephrotoxicity include a higher severity of illness, including need for ICU admission, preexisting CKD, higher dosing regimens (10‒20 mg/kg or &gt;4 g/day total dose), higher vancomycin trough levels (&gt;15 mg/L), longer duration of vancomycin administration (&gt;7 days), and concomitant use of other nephrotoxic medications, such as aminoglycosides and piperacillin-tazobactam. The exact mechanisms of vancomycin nephrotoxicity are incompletely understood, but vancomycin has been demonstrated to cause oxidative stress as well as inflammatory damage to proximal tubular cells, leading to acute tubulointerstitial injury. Intratubular obstructive casts, consisting of vancomycin and uromodulin, have also been demonstrated in patients with AKI in the setting of vancomycin administration. The reported incidence of vancomycin-associated AKI varies from 5–35% depending on the definition used, but many studies report an incidence of 10% that increases to 20% when combined with piperacillin-tazobactam.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vancomycin is moderately dialyzable with widely used high-flux dialyzers because of its modest plasma protein binding (about 50%), relatively low volume of distribution (0.5‒1 L/kg), and low molecular weight (1449 Da). However, in the absence of standard indications, HD is only required when serum vancomycin levels are severely elevated, with concomitant oliguria and lack of improvement with drug withdrawal. A precise level at which to dialyze has not been established, but some case reports have described the use of dialysis until vancomycin levels decrease to below 50 mg/L.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy might aid in establishing an accurate diagnosis if kidney function does not recover within days of discontinuing vancomycin but would not be the next best step in management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although it has little intrinsic nephrotoxicity, piperacillin-tazobactam potentiates the nephrotoxicity of vancomycin. It would be important to adjust the dose of this antibiotic for kidney function but it would not be necessary to discontinue treatment.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Both gemcitabine and paclitaxel can cause AKI due to thrombotic microangiopathy and ATN, respectively, but this patient’s clinical course is more consistent with vancomycin-induced nephrotoxicity.</p>\n</div>",
        "references": []
    },
    "75": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 37-year-old man with ESRD attributed to primary hyperoxaluria presents to discuss options for transplantation. He has received HD for the past 12 months. Past medical history includes recurrent calcium oxalate nephrocalcinosis. Previous evaluation included a 24-hour urine collection showing urine oxalate 107 mg/day (reference range, &lt;45) and plasma oxalate 31.7 µmol/L (reference range, &lt;1.9). A kidney biopsy demonstrated nephrocalcinosis, acute tubular injury, and extensive deposition of calcium oxalate in cortical and medullary tubules. Additional testing identified a mutation in the <em>AGXT</em> gene, which encodes alanine glyoxylate aminotransferase (AGT), consistent with primary hyperoxaluria type 1. The patient has also developed several extrarenal complications of oxalate deposition, including peripheral vascular disease, arthritis, and impaired vision.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, his BP is 132/72 mm Hg and heart rate 74/min, and he is afebrile. He has a left arm arteriovenous fistula with a palpable thrill. Visual acuity is 20/200 bilaterally, and extremity examination is significant for decreased range of motion and diminished peripheral pulses.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Current laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                48 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aspartate aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alanine aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                74 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n</tbody>\n</table><strong>Which ONE of the following is the most appropriate strategy to manage this patient’s ESRD?</strong><p></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Kidney transplant alone"
            },
            {
                "label": "B.",
                "text": "Liver transplant alone"
            },
            {
                "label": "C.",
                "text": "Stem cell transplant followed by kidney transplant"
            },
            {
                "label": "D.",
                "text": "Transplant contraindicated; continue dialysis"
            },
            {
                "label": "E.",
                "text": "Liver and kidney transplant"
            }
        ],
        "correct_answer": "Liver and kidney transplant",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with ESRD due to primary hyperoxaluria type 1 should undergo combined liver-kidney transplantation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary hyperoxaluria type 1 is an autosomal recessive disease caused by an <em>AGXT</em> gene mutation resulting in the deficiency or absence of AGT, an enzyme involved in glyoxylate metabolism. Deficiency of this enzyme causes excessive endogenous production of oxalate, which manifests as recurrent nephrolithiasis, nephrocalcinosis, and ESRD caused by excessive calcium oxalate deposition.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Combined liver-kidney transplantation (simultaneous or sequential) is the treatment of choice for most patients with ESRD secondary to primary hyperoxaluria type 1. Only liver transplantation can replace the underlying AGT enzyme deficiency. Therefore, liver transplantation in conjunction with kidney transplantation allows for the correction of the underlying abnormality as well as replacement of kidney function.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Performing kidney transplantation alone in this patient would not correct the underlying enzyme deficiency. Without correction of the underlying problem, the patient would be at risk of recurrent oxalate deposition in the allograft, with a high risk of early kidney allograft failure.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Isolated liver transplantation has been proposed as an option for some patients with rapidly progressive CKD. When considered, liver transplant alone is typically reserved for patients with eGFR &gt;40 mL/min/1.73 m<sup>2</sup>. Isolated liver transplantation is not appropriate for this patient, who is already receiving HD, because liver transplant alone would not address ESRD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is no role for stem cell transplantation for the treatment of primary hyperoxaluria, as enzyme production is corrected with liver transplantation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Transplantation is not contraindicated in patients with primary hyperoxaluria type 1 and would be preferred to continuing HD indefinitely.</p>\n</div>",
        "references": []
    }
}